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Abstract 
Bacterial polyprenyl transferases transfer polyprenyl groups onto molecular 
acceptors, such as proteins and small molecules, and they are very important functional 
entities that are involved in bacterial cell wall biosynthesis, biofilm formation, virulence 
formation and natural product formation. Structurally, bacterial polyprenyl transferases 
can be categorized into eight groups: αcyclase, α, αβ, αβγ, βγ, ε, ζ and TIM barrel fold 
proteins. Six bacterial polyprenyl transferases were investigated in the current research, 
including Streptomyces ghanaensis MoeO5 and Bacillus subtilis/Staphylococcus aureus 
PcrB (TIM barrel fold), Bacillus subtilis YisP (ε fold), Bradyrhizobium japonicum 
Kaurene synthase (αcyclase fold), Mycobacterium tuberculosis Rv3378c and DPPS (ζ fold 
The function, mechanism of action, structure, inhibition and functional engineering of 
these six polyprenyl transferases were studied by X-ray crystallography, mutagenesis, 
activity assays, thermal dynamics measurements etc. Besides that, a multi-target drug 
discovery approach was also proposed as an attempt to combat drug resistance in anti-
infective drug discovery campaigns, both based on structural homology of 
Mycobacterium tuberculosis Rv3378c and DPPS (ζ fold), and the multi-target effect of 
SQ-109 and its analogs. 
MoeO5 catalyzes the first step biosynthesis of Moenomycin A, which is a 
phosphoglycolipid antibiotic. We determined the first crystal structure of MoeO5 and 
studied the binding mode of bound substrates. We also assayed its activity with different 
substrates and compared MoeO5 with its homolog PcrB, which led to a proposal of 
MoeO5 reaction mechanism. 
  iii 
YisP is essential in biofilm formation in Bacillus subtilis and is predicted to produce 
C30 isoprenoids. We determined the structure of YisP, and proved that YisP acts as a 
phosphatase. Using DSC, we confirmed that farnesol shift and broaden the gel-to-liquid 
crystal transition of lipids. 
The X-ray structure of the bacterial diterpene cyclase ent-kaur-16-ene synthase from 
the soil bacterium Bradyrhizobium japonicum was determined in apo-, substrate and 
inhibitor-bound forms. The catalytic activity of the cyclase was studied by site-directed 
mutagenesis and inhibition of the enzyme was also investigated.  
Structures of tuberculosinol/iso-tuberculosinol synthase (Rv3378c) and cis-
decaprenyl diphosphate synthase (DPPS) from M. tuberculosis were determined. They 
are targets for anti-infective therapies that block virulence factor formation and for cell 
wall biosynthesis, respectively. Given the similarity in local and global structure between 
these two proteins, the possibility exists that it may be possible to develop inhibitors that 
target not only virulence, but also cell wall biosynthesis. 
SQ-109, one new anti-tuberculosis ethylenediamine drug, was found to be active 
against other bacteria and yeasts. Based on the SAR study and biochemistry assay results 
with eleven SQ-109 analogs, we found that it might be an example of multi-target drug 
candidate that inhibits isoprenoid/quinone biosynthesis and/or respiration. 
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Chapter 1: Introduction to Bacterial Polyprenyl Transferases and Drug Discovery 
for Tuberculosis 
 
1.1 Bacterial Polyprenyl Transferases 
Polyprenyl transferases refer to proteins that transfer polyprenyl groups from prenyl 
donors to prenyl acceptors. As shown in Figure 1.1, the prenyl donors are usually 
polyisoprenyl diphosphates that donate their allylic polyisoprenyl groups to prenyl 
acceptors, such as other proteins (protein prenylation), small molecules (small molecule 
prenylation), polyisoprenyl diphosphates (polyprenyl diphosphate synthesis) or 
themselves (cyclization).  
Protein prenylation is a type of post-translational modification of proteins, in which 
farnesyl (15-carbon) or more commonly geranylgeranyl (20-carbon) isoprenoids are 
added via thioether linkages to cysteine residues at or near the C terminus of intracellular 
proteins.1 Protein prenylation is an important process to mediate protein-protein 
interactions and protein-membrane interactions, as the attached lipid is required for 
proper function of the modified protein, either as a mediator of membrane association or 
a determinant for specific protein-protein interactions. Three distinct protein 
prenyltransferases can be classified in two functional classes1: the CAAX 
prenyltransferases, identified by their lipid substrate and termed protein 
farnesyltransferase (FTase) and protein geranylgeranyltransferase type I (GGTase-I); and 
the Rab geranylgeranyltransferase or protein geranylgeranyltransferase type II (GGTase-
II). 
Small molecule prenylation  is very common in lipid formation and natural product 
formation in all organisms. For example, Archaeoglobus fulgidus geranylgeranylglyceryl 
phosphate synthase (AfGGGPS)2 catalyzes the reaction between geranylgeranyl 
diphosphate (GGPP) and glycerol-1-phosphate (G1P) to form geranylgeranylglyceryl 
phosphate (GGGP), a precursor of the (perhydro)geranylgeranyl-based phospholipids 
found in Archaea3. Also, In Streptomyces ghanaensis, the enzyme MoeO5, encoded by 
the moe gene cluster 1 catalyzes the initial step of moenomycin production in which the 
C15-hydrocarbon moiety of farnesyl pyrophosphate (FPP) is transferred to the 2-hydroxyl 
group of 3-phosphoglycerate (3PG), forming an ether bond. The phosphoglycolipid 
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antibiotic moenomycin directly blocks bacterial cell wall biosynthesis by inhibiting 
peptidoglycan glycosytransferases.4 
Polyprenyl diphosphate synthesis and cyclization polyprenyl diphosphate belong to a 
broader class of reactions termed terpene biosynthesis. Terpenes (or terpenoids) represent 
the largest class of small molecules on the planet5 and most are synthesized by enzymes 
that contain one or more of six main types of fold: , , , ,  and 6 (Figure 1.2). 
Functionally, they can be classified into the following groups: head-to-tail trans prenyl 
transferases (- and -domain structures), head-to-tail cis prenyl transferases (-
domain structures), head-to-head prenyl transferases (-domain structures), diterpene 
cyclases (-fold structures). 
Bacterial polyprenyl transferases are very important functional entities that are 
involved in bacterial cell wall biosynthesis, biofilm formation, virulence formation and 
natural product formation.6-7 Six bacterial polyprenyl transferases were investigated in 
the current research (Scheme 1.1), including Streptomyces ghanaensis MoeO58 and 
Bacillus subtilis/Staphylococcus aureus PcrB9 (TIM barrel fold), Bacillus subtilis YisP10 
(ε fold), Bradyrhizobium japonicum Kaurene synthase11 (αcyclase fold), Mycobacterium 
tuberculosis Rv3378c and DPPS12 (ζ fold) (Figure 1.3), on their functions, mechanisms 
of action, structures, inhibition and functional engineering studied by X-ray 
crystallography, mutagenesis, activity assay, thermal dynamic measurement etc. 
 
1.2 Streptomyces ghanaensis MoeO5 and Bacillus subtilis/Staphylococcus aureus PcrB 
Recently, several new structures of PTs that contain a TIM barrel fold 
(geranylgeranylglyceryl phosphate synthase (GGGPS), MoeO5 and PcrB) have been 
discovered2, 8, 13, and there is considerable interest in their mechanisms of action8, 13b.  The 
reactions catalyzed by these three proteins are shown in Scheme 1.2.  
MoeO5 catalyzes the initial step of moenomycin production in which the C15-
hydrocarbon moiety of farnesyl pyrophosphate (FPP) is transferred to the 2-hydroxyl 
group of 3-phosphoglycerate (3PG), forming an ether bond. As showed in Scheme 1.2, 
the reaction is similar to that of GGGPS for synthesizing Archaea-type phospholipids.2 
However, unlike GGGPS whose product retains the all-trans configuration of the 
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isoprenyl chain, the farnesyl group transferred by MoeO5 undergoes a trans-to-cis 
isomerization at the C2-C3 double bond.13b  
Then enzyme PcrB catalyzes a very similar reaction as that of GGGPS, but in this 
case the prenyl donor is heptaprenyl diphosphate (HepPP)14. The PcrB product, 
heptaprenylglyceryl phosphate (HepGP), is then dephosphorylated to heptaprenylglycerol, 
then acetylated, Scheme 1.114. The function of this ester product is unknown. However, 
PcrB forms part of an operon with PcrA, an essential DNA helicase15, and a ∆pcrB 
mutant (in Bacillus subtilis) has a deranged, “cloggy” pattern of growth14, so it seems 
likely that PcrB is important for growth (or perhaps, virulence) in other Bacilli, such as 
the pathogen Staphylococcus aureus, and may be of interest as a drug target. 
The crystal structures of GGGPS and the bacterial homologue PcrB reveal a triose 
phosphate isomerase (TIM)-barrel fold, which had not been observed previously in 
prenyltransferases (PTs).2, 13a, 14 The sequences of GGGPS and PcrB share 35% amino 
acid identity, but MoeO5 shows only 10% identity to both enzymes. We thus investigated 
the structures and mechanisms of action of MoeO5 and PcrB, in comparison of those of 
GGGPS. 
 
1.3 Bacillus subtilis YisP 
There is currently considerable interest in the structures, functions and inhibition of 
the enzymes catalyze the “head-to-head” condensation of isoprenoid diphosphates to 
form tri- terpenes such as squalene and dehydrosqualene, such as squalene synthase (SQS) 
and dehydrosqualene synthase (CrtM) (Scheme 1.3a).  Squalene synthase inhibition 
represents new mechanisms of action to develop cholesterol-lowering drugs16 and 
antiparasitics targeting ergosterol biosynthesis17. CrtM from Staphylococcus aureus is 
involved in formation of staphyloxanthin18, a virulence factor for the organism providing 
resistance to killing from host reactive oxygen species.19 Thus, CrtM is of interest as a 
target in anti-virulence therapy. 
The CrtM gene (or a close analog) is also present in Bacillus subtilis (yisP) and it was 
recently reported20 that YisP was involved in biofilm and pigment formation and had 
squalene synthase activity which was blocked by zaragozic acid (Scheme 1.3b), a known 
SQS/CrtM inhibitor.21 Zaragozic acid was also reported to block biofilm formation in S. 
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aureus, but had no effect on cell growth in either organism. Moreover, one of the two 
conserved active site motifs in SQS/CrtM family is missing in YisP. We thus investigated 
the structure, function and mechanism of action of YisP with X-ray crystallography and 
activity assay. 
 
1.4 Bradyrhizobium japonicum Kaurene synthase 
Diterpenes have been found in bacteria22, and these compounds are of interest since 
some have activity as anti-infective and anti-cancer drug leads, virulence factors, as well 
as plant growth hormones. There are two different classes of terpene cyclases, Class I and 
Class II, defined by the amino acid motifs that are essential for catalysis23. Class I 
cyclases contain two conserved motifs, DDXXD, and (N,D)DXX(S,T,G)XXX(E,D) 
(hereafter referred to as NTE), in which the boldface residues generally bind to the three 
Mg2+ that facilitate ionization of an isoprenoid diphosphate group, generating a reactive 
carbocation intermediate. In contrast, Class II cyclases typically contain only a DXDD 
motif in which the boldface aspartic acid protonates an isoprenoid double bond or an 
oxirane to, once again, generate a reactive carbocation intermediate. In some cases, both 
Class I as well as Class II motifs are present and these molecules are bi-functional or in 
one reported case, tri-functional24.  For example, abietadiene synthase from Abies grandis 
(AgABS) is bi-functional and converts geranylgeranyl diphosphate (GGPP) to copalyl 
diphosphate (CPP) in a Class II reaction and then CPP is converted to abietadiene in a 
Class I reaction, Scheme 1.4a. Similarly, the moss Physcomitrella patens utilizes a 
trifunctional CPPS/KS (PpCPPS/KS) to convert GGPP to ent-CPP in a Class II reaction 
and then to ent-kaur-16-ene (20%) and 16-hydroxy-ent-kaurane (80%) via a Class I 
reaction with, in the case of kauranol, carbocation quenching25, Scheme 1.4b.     
Here, we report the first structure of a bacterial diterpene cyclase, ent-kaurene 
synthase from the soil bacterium Bradyrhizobium japonicum (BjKS; gene # blr2150)22b. 
BjKS catalyzes the cyclization of ent-CPP which is produced by ent-copalyl diphosphate 
synthase (ent-CPPS; blr2149) from GGPP (Scheme 1.4c), and one possible mechanism of 
action 26 for the ent-kaurene synthase reactions is shown in Scheme 1.4c. The ent-KS 
reactions proceed via initial diphosphate loss from ent-CPP (catalyzed by Mg2+) and 
cyclization to form the 8-carbonium ion, the pimaren-8-yl cation, which then undergoes 
5 
 
secondary cyclization with Wagner-Meerwein migration of C-12 to C-16 to form the ent-
kauran-16-yl cation. This cation can then loose a proton to form ent-kaur-16-ene, or in P. 
patens the ent-kauranyl cation can also be quenched by a water molecule to form 16--
hydroxy-ent-kaurane, Scheme 1.4b25.  
Structurally, Class I proteins contain a catalytic  domain while Class II proteins 
contain two domains, , and with bi-functional species such as abietadiene synthase, all 
three domains () are present27. In previous work7b it was proposed that these  
domain proteins might have arisen by the fusion of the genes of + proteins in 
ancestral, perhaps soil dwelling, bacteria, so determining the structures of bacterial  
(and ) cyclases is of interest not only from a mechanism of action perspective, but also 
from an evolutionary one. Is, for example, the structure of BjKS (a predicted7b  domain 
protein) most similar to that of the  domains seen in modern plant terpene cyclases? To 
investigate this and other questions we determined the structure of BjKS in the presence 
of its ent-CPP substrate, as well as apo- and inhibitor-bound structures, and we used site-
directed mutagenesis to probe its catalytic activity. In addition, we compared the BjKS 
structure with the structures of diverse other terpene cyclases, and synthases. 
 
1.5 Mycobacterium tuberculosis Rv3378c and decaprenyl diphosphate synthase 
Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, is a major source 
of morbidity and mortality worldwide with almost two million deaths annually, and the 
rise in multi-drug resistant and extensively drug resistant strains is of great concern28. 
There is thus considerable interest in the development of new drugs and new leads such 
as SQ109 and TMC-20729, which target cell wall biosynthesis and ATP formation, 
respectively, and also in the development of new therapeutic approaches that target 
virulence factor (VF) formation. VFs are by definition not essential for bacterial growth 
outside of host cells, but are involved in processes such as invasion, persistence, lysis, 
and evasion of innate immune system responses, as found for example with 
staphyloxanthin in Staphylococcus aureus30. This carotenoid VF provides resistance to 
host-based reactive oxygen species-based killing, and inhibiting staphyloxanthin 
biosynthesis is a novel route to anti-infective therapy30b. In M. tuberculosis, one class of 
VFs are the tuberculosinols31: tuberculosinol (TOH) and the (±) iso-tuberculosinols (iso-
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TOH), Scheme 1.5. The latter were first isolated from a marine sponge from the Nosy Be 
island, Madagascar, and are thus also known as (±) nosyberkols32 (Scheme 1.5). The 
original structures proposed31-32 have been confirmed by total synthesis33. The 
biosynthesis of the tuberculosinols is catalyzed by two enzymes: Rv3377c, tuberculosinyl 
(halama-5,13-dien-15-yl) diphosphate synthase, and Rv3378c, tuberculosinol/(±)iso-
tuberculosinol synthase (Scheme 1.5). Both proteins are essential for bacterial survival 
inside macrophages34 with the tuberculosinols inhibiting phagolysosome maturation, as 
well as macrophage phagocytosis31b, c, 35. The three-dimensional structures of both 
Rv3377c and Rv3378c are thus of considerable interest since they are thought to 
represent novel anti-virulence therapeutic targets for tuberculosis36. Rv3377c is a 
diterpene cyclase that converts geranylgeranyl diphosphate (GGPP) into tuberculosinyl 
diphosphate (TPP), while Rv3378c converts TPP into TOH and the iso-TOHs, acting as a 
phosphatase/isomerase, as shown in Scheme 1.5. Here, we report the structure of 
Rv3378c both in its apo form as well as bound to its TPP substrate, and to a 
bisphosphonate inhibitor, BPH-629 (Scheme 1.5). We also report the structure of the M. 
tuberculosis cis-decaprenyl diphosphate synthase (Rv2361c) with another 
bisphosphonate inhibitor, BPH-640 (Scheme 1.5) which has a similar structure and 
inhibitor-binding mode as found with Rv3378c-the phosphatase. 
 
1.6 Drug Discovery for Tuberculosis 
Antibiotic resistance is a public health problem that, arguably, has the potential to 
destroy the efficacy of all antibiotics in the next 10-20 years37. There is, therefore, an 
urgent need for new drugs-especially ones that might be more “resistance-resistant”. In 
this work, we consider the mechanism(s) of action of the new anti-tuberculosis drug 
SQ109 (1) (Chart 1.1), currently in Phase II clinical trials43. This drug candidate appeared 
of interest since it contains a C10 isoprenoid  (geranyl) side-chain together with a strongly 
basic (ethylenediamine) fragment-a likely cationic center-suggesting that it might act as a 
carbocation isostere for a transition state/reactive intermediate in isoprenoid 
biosynthesis44 and, as with other inhibitors of isoprenoid biosynthesis, it might be 
involved in multi-targeting. 1 was developed in a synthesis/screening program45 in which 
~64,000 ethylenediamine analogs of the anti-tuberculosis drug ethambutol (2) were 
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synthesized. 1 was ~ 4x more active than any of the other leads developed, having a 
minimum inhibitory concentration (MIC) of ~0.7-1.56 µM against M. tuberculosis 
(H37Rv, Erdman and drug-resistant strains) and insights into its mode of action recently 
became available when the target of SQ109 was proposed46 to be MmpL3, a trehalose 
monomycolate (TMM) transporter, an essential membrane protein that transports TMM 
into the cell envelope. This conclusion was based on the observation that several M. 
tuberculosis mutants produced via serial passage with several 1-like inhibitors had 
mutations in the mmpL3 gene and cross-resistance to 1, although these latter effects were 
rather small46. More intriguingly, no spontaneous resistant mutants were obtained when 
using 1, suggesting the possibility of multiple targets46-47. That idea is supported by the 
observation that 1 also has activity against other bacteria, e.g. Helicobacter pylori48 as 
well as against the yeast Candida albicans49, neither of which possess the mmpL3 gene, 
suggesting again that other 1 targets are harbored by these organisms, and potentially, by 
M. tuberculosis.   
 In this work, we synthesized a series of analogs of 1 in which we varied the 
adamantane head-group and the ethylenediamine linker (varying the possible charge 
centers), Chart 1.1. All compounds were screened against a panel of bacteria (M. 
tuberculosis, M. smegmatis, Escherichia coli, Staphylococcus aureus and Bacillus 
subtilis), two yeasts (Saccharomyces cerevisiae and Candida albicans), a malaria parasite 
(Plasmodium falciparum) and a human cell line (MCF-7), to establish anti-bacterial, anti-
fungal and anti-malarial structure-activity relationships and to assess mammalian cell 
toxicity. In addition, we investigated a subset of compounds for activity against a series 
of putative targets, isoprenoid biosynthesis enzymes, while also investigating the effects 
of these compounds on respiration, ATP synthesis, and the proton motive force (PMF).  
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1.7 Schemes, Charts, Tables and Figures 
Scheme 1.1 Reactions catalyzed by the six bacterial polyprenyl transferases investigated. 
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Scheme 1.2 Structures of molecules and reactions of interest. a) Reactions catalyzed by 
PcrB (n=5) or GGGPS (n=2) b) Reaction catalyzed by MoeO5. 
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Scheme 1.3 Structures of compounds of interest. a) Biosynthesis of virulence factors, 
sterols and farnesol. b)  A biofilm inhibitor and some B. subtilis pigments. 
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Scheme 1.4 Reactions catalyzed by AgABS, PpCPPS/KS and BjKS, and proposed 
catalytic mechanism for the BjKS reaction. (a) Abietadiene is formed from GGPP by a 
bifunctional terpene cyclase abietadiene synthase, in Abies grandis.  (b) Formation of ent-
CPP, ent-kaurene and kauranol from GGPP catalyzed by Physcomitrella patens 
CPPS/KS. (c) Two proteins are used to produce ent-kaurene in the soil bacterium, 
Bradyrhizodium japonicum. Proposed carbocation intermediates are shown. 
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Scheme 1.5 Biosynthesis of Mycobacterium tuberculosis virulence factors 
(tuberculosinols) and decaprenyl diphosphate, which is essential for cell wall 
biosynthesis. 
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Chart 1.1 Structures of compounds investigated. 
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Figure 1.1 Overview of bacterial polyprenyl transferases. 
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Figure 1.2 Structural phylogenetic tree from bacterial prenyl transferases. 
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Figure 1.3 Structures of the six bacterial polyprenyl transferases investigated. 
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Chapter 2: Insights into the Mechanism of the Antibiotic-Synthesizing Enzyme 
MoeO5 from Crystal Structures of Different Complexes 
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2.2 Introduction 
The phosphoglycolipid antibiotic moenomycin directly blocks bacterial cell wall 
biosynthesis by inhibiting peptidoglycan glycosytransferases.[1] The enzyme MoeO5, 
encoded by the moe gene cluster 1 in Streptomyces ghanaensis, catalyzes the initial step 
of moenomycin production in which the C15-hydrocarbon moiety of farnesyl 
pyrophosphate (FPP) is transferred to the 2-hydroxyl group of 3-phosphoglycerate (3PG), 
forming an ether bond (Figure 2.1).[2] The reaction is similar to that of 
geranylgeranylglyceryl phosphate synthase (GGGPS) for synthesizing Archaea-type 
phospholipids.[3] However, unlike GGGPS whose product retains the all-trans 
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configuration of the isoprenyl chain, the farnesyl group transferred by MoeO5 undergoes 
a trans-to-cis isomerization at the C2-C3 double bond.[4] The crystal structures of 
GGGPS and the bacterial homologue PcrB reveal a triose phosphate isomerase (TIM)-
barrel fold, which had not been observed previously in prenyltransferases (PTs).[3, 5] The 
sequences of GGGPS and PcrB share 35% amino acid identity, but MoeO5 shows only 
10% identity to both enzymes (Figure 2.2). Here we report the X-ray crystallographic 
structures of MoeO5 bound to the product 2-Z,E-farnesyl-3-phosphoglycerate (FPG), a 
substrate analogue farnesyl thiopyrophosphate (FsPP), magnesium ion (Mg2+), and 
pyrophosphate ion (PPi) that, together with additional biochemical and bioinformatics 
results, shed light on the possible mechanisms of action of this unusual enzyme. 
 
2.3 Results and Discussions 
Molecular-replacement (MR) approaches to determine the MoeO5 structure by 
using GGGPS and PcrB as search models were not successful, reflecting perhaps the 
significant variations in the protein sequences. Because MoeO5 contains no Cys residue, 
to solve the structure by using multiple isomorphous replacement (MIR), we produced 
the mutant H97C for efficient preparation of mercury-based MIR derivatives (Table 2.1). 
The other structures were solved by MR (Figure 2.3 and Table 2.2). See the Supporting 
Information (SI) for details. MoeO5 crystallizes as a homodimer (Figure 2.4 and Table 
2.3). The dimer interface buries 1200 Å2, or more than 10% surface area, on each 
monomer and mainly involves hydrophobic residues in helices α4 and α5. The cis-
peptide of Pro141 binds to a Mg2+ ion at the molecular dyad (Figure 2.4). These helices 
also mediate dimerization in GGGPS and PcrB, but here one of the TIM barrels is rotated 
by 180° (Figure 2.5). More description of the protein structure as well as the bound 
ligands can be found in the SI. Despite its Cα deviation of about 2.0 Å from the GGGPS 
and PcrB monomer (Figure 2.6), the similar protein fold with a connecting loop (denoted 
λ3) between strands β3 and β4 clearly places MoeO5 among this new class of TIM-barrel 
PTs. 
The wild-type MoeO5 co-crystallized with a bound product FPG, of which the C15 
tail moiety makes a U-turn mainly at the C10-C11 bond (Figure 2.7), rather than 
extending straight into a nonpolar groove along helix α4 as supposed in GGGPS and 
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PcrB.[3,5] The equivalent groove in MoeO5 is obstructed by the λ3 loop (Figure 2.8), 
which contains His97 and is four-residues longer than in GGGPS and PcrB (Figure 
2.2).[4] This loop may act as a swinging door for binding and enclosure of the prenyl 
substrate in GGGPS,[3] but the door is virtually locked up in MoeO5 and the resulting 
small volume seems barely able to accommodate a C10 group. However, substitution of a 
Tyr residue of GGGPS and PcrB by Ala157 in strand β5 makes a “nook” for the bent C15 
group in MoeO5 (Figure 2.8). Neither the C10 GPP nor the C20 GGPP is a substrate of 
MoeO5, and soaking with the thio-analogue GGsPP has no effect on the bound FPG. 
Clearly the cavity is specific for FPP, and the bent conformation is likely to be important 
in precisely positioning the C15 group for the trans-to-cis conversion. 
On the other hand, the 3PG head group binding site is equivalent to that for 
glycerol 1-phosphate (G1P) in GGGPS (Figure 2.9).[3] The 3’-phosphate, sandwiched 
between loop β7-α7 and helix α8’, is fastened by three backbone NH groups (Figure 
2.10a). The 1’-carboxyl group, together with His97, also binds to a water molecule. 
When the crystals were soaked with FsPP, partial substitution of FPG occurred in three 
hours, and it was mostly replaced overnight. The β-phosphate group of FsPP occupies the 
same position as does the 3’-phosphate of FPG, but the α-phosphate is loosely bound 
(Figure 2.10b). Each active site also shows a Mg-PPi complex adjacent to the FsPP, 
which may represent an alternative disposition of the PPi moiety of FsPP (Figure 2.11). 
Here, the Mg2+ ion binds to Asp41, which is highly conserved in MoeO5, GGGPS and 
PcrB. A similar site containing Mg2+ and PO43- was found with a 3PG soak, but PPi alone 
did not bind to this site (detailed in the SI). Like most other PTs, MoeO5 requires Mg2+ 
for activity and the network of interactions with Mg2+ is expected to facilitate FPP 
ionization, the first step in catalysis.  
In GGGPS and PcrB the prenyl carbocation is directly attached to the C3’-hydroxyl 
of G1P, and the trans-configuration is conserved (Figure 2.12a). However, in MoeO5 
Doud et al. recently proposed catalytic mechanisms in which either nerolidyl 
pyrophosphate (NPP) was formed after ionization, facilitating bond rotation and the 
trans-to-cis conversion (Figure 2.12b), or that Z,E-FPP was an intermediate.[4] The 
observation that trans-FPP and NPP react at the same rate while cis-FPP reacts ~5x faster 
(Figure 2.13) suggests that all three species may be involved. Another possibility is that 
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the His97-bound water molecule, which is 3.6 Å from the C3 atom, can be activated and 
associate with the farnesyl cation, transiently forming nerolidol (NOH), facilitating bond 
rotation (Figure 2.12c), and we do find that H97C is an inactive mutant, supporting a vital 
role of His97, although R,S-trans-NOH (+ 3PG + PPi + Mg2+) is not a substrate. 
 
2.4 Conclusions 
In summary, MoeO5 forms a TIM barrel structure and binds FPG in a curved 
pocket, mainly as a result of its long λ3 loop. An FPP ionization site containing Asp41 
and Mg2+ is located nearby, and the results obtained here are consistent with formation of 
a Z,E-FPP intermediate. We also find that His97 in the λ3 loop is essential for activity. 
Except for using Asp41 to bind Mg-PPi, the cis-bond formation catalyzed by MoeO5 is 
distinct from those of other cis-PTs.[6] To further study this novel mechanism by 
mutagenesis, kinetic analysis and other physicochemical measurements, the various 
ligand-complex structures presented here provide a good starting point. 
 
2.5 Materials and Methods 
Expression and purification of MoeO5 
The gene encoding MoeO5 from Streptomyces ghanaensis was synthesized 
chemically and amplified by polymerase chain reaction (PCR) with forward primer 5'- 
GGTATTGAGGGTCGCGCTGGTGCTGGTGCTATGAACGCCAGCCCTCAACTGG
ATCAT-3' and reverse primer 5'-
AGAGGAGAGTTAGAGCCATTAGCGACCGCTACCTGGACGAGCTGG-3', and 
then cloned into the pET32 Xa/LIC vector. Because MoeO5 does not contain any Cys 
residue, for efficient preparation of mercury-containing derivatives for multiple 
isomorphous replacement (MIR) phasing, we made the H97C mutant near the C-terminus 
of strand β3 (Figure 2.2). Based on the sequence alignment, this residue should be 
accessible to the solvent but not too flexible for a heavy atom site. The H97C mutant was 
prepared with MoeO5–pET32a Xa/LIC vector as the template and a forward primer of 5'-
CCGCTGCCTGTCGTACTGTGCTTCCCGCCGCGCCCTGGT-3' was used. The 
recombinant plasmids were transformed to E. coli BL21 (DE3) and the protein was 
induced with 0.4 mM isopropyl-thiogalactopyranoside (IPTG) at 20 °C for 24 hours.  
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Cell paste was harvested by centrifugation at 7,000 x g and resuspended in a lysis 
buffer containing 25 mM Tris-HCl, pH 7.5, 150 mM NaCl and 20 mM imidazole. Cell 
lysate was prepared with a French Press Instrument, and then centrifuged at 17,000 x g to 
remove cell debris. The proteins were purified by FPLC using a Ni-NTA column. The 
buffer and gradient for the Ni-NTA column were 25 mM Tris, pH 7.5, 150 mM NaCl, 
and 20–250 mM imidazole. His-tagged MoeO5 was eluted at about 110 mM imidazole. 
The protein solution was dialyzed against a buffer containing 25 mM Tris-HCl, pH 7.5, 
150 mM NaCl and then subjected to Factor Xa digestion to remove the His tag. The 
mixture was then passed through Ni-NTA column again and the untagged MoeO5 was 
eluted with 20 mM imidazole-containing buffer. The protein was then purified by FPLC 
using DEAE column, the buffer and gradient for the DEAE column were 25 mM Tris, pH 
7.5, and 0–500 mM NaCl. The protein was eluted at about 225 mM NaCl. The purified 
protein was finally concentrated to 5 mg mL-1 in a 25 mM Tris, 150 mM NaCl, pH 7.5 
buffer. The preparation procedure of H97C mutant was almost identical to that of the 
wild-type protein. 
 
Crystallization, data collection, structure determination and refinement 
The wild-type MoeO5 protein was first crystallized by using the PEG/Ion 2 screen 
kit (Hampton Research) and sitting-drop vapor diffusion method. The reservoir solution 
(No. 6) contained 0.2 M sodium malonate, pH 6.0, and 20% w/v PEG3350. Better 
crystals were obtained by optimizing the reservoir composition, which contained 0.2 M 
sodium malonate, pH 6.0, and 22% PEG3350. The reservoir for crystallizing the H97C 
mutant was slightly different; it contained 0.2 M sodium malonate, pH 6.0 and 26% 
PEG3350. All crystals were prepared at room temperatures.  They reached suitable sizes 
for X-ray diffraction in 2 days. Various ligands were used in soaking the wild-type 
crystals before data collection. The “native” crystal had actually been soaked in 5 mM 
GGsPP, 10 mM MgCl2, 23% PEG 3350, 0.2 M sodium malonate, pH 6.0, for 3 hours. 
The first FsPP-soaked (for 3 hours) crystal was prepared using 20 mM FsPP, 10 mM 
MgCl2, 23% PEG 3350, 0.2 M sodium malonate, pH 6.0. The second FsPP-soaked 
(overnight) crystal used 100 mM instead of 20 mM FsPP in the solution, whereas the PPi-
soaked and 3PG-soaked (both for 3 hours) crystals used 100 mM sodium pyrophosphate 
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and 20 mM 3PG, respectively. For heavy-atom derivatives, the Hg-containing reagents of 
Heavy Atom Screen Hg (Hampton Research) were used. Cryoprotectant solutions (0.2 M 
sodium malonate, pH 6.0, 28% w/v PEG3350 and 10% glycerol) containing 2 mM Hg 
derivatives were used in soaking the H97C mutant crystals for 3 to 5 hours. 
The X-ray diffraction data sets were collected at beam lines BL13B1 and BL13C1 
of the National Synchrotron Radiation Research Center (NSRRC, Hsinchu, Taiwan) and 
processed by using the program of HKL2000.[7] Prior to structural refinement, 5% 
randomly selected reflections were set aside for calculating Rfree as a monitor. The MIR 
datasets of mercury-containing derivatives were collected at a wavelength of 0.9763 Å 
(BL13C1). Using SOLVE and RESOLVE,[8] combinations of datasets from different Hg-
derivative crystals with the “native” dataset from the wild-type crystal improved the 
figure of merit (FOM) values from 0.46 to 0.51, the Z-scores from 16.4 to 40.1, and the 
number of auto-built amino acid residues up to 384. The best results were obtained using 
the derivatives of ethylmercurithiosalicylic acid, mercury potassium iodide, ethylmercury 
chloride, and tetrakis(acetoxymercuri)methane. Statistics of the four Hg-derivative data 
sets and the MIR phasing are summarized in Table 2.1. Because there are two MoeO5 
molecules in an asymmetric unit of the monoclinic crystal, a more continuous electron 
density map was constructed by superimposing all of the initial crude models, and a more 
complete model was manually reconstructed. The model and map were further improved 
by computational refinement using Refmac5.[9] Finally a complete model (still missing 
the N-terminal residues) with most side chains was built by ARP/wARP.[10] Structures of 
the triclinic crystals were solved by molecular replacement (MR) using a monomeric 
model from the monoclinic crystal and the program CNS.[11] It turned out that each 
crystal contains the same dimeric arrangement of two MoeO5 molecules. All of the 
following structural refinements were carried out using the programs CNS and Coot.[12] 
The electron densities for the active site bound ligands are shown in Figure 2.3. Data 
collection and refinement statistics of these crystals are summarized in Table 2.2. All 
diagrams of the protein structures were prepared by using the software PyMOL 
(http://www.pymol.org/). 
 
Description of the overall protein structure 
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The monomer of MoeO5 folds into a TIM barrel, but the helix α3 connecting the 
two adjacent strands β3 and β4 in most other TIM-barrel structures is replaced by a loop 
that lacks significant secondary structure formation. This loop is denoted λ3 as shown in 
the sequence alignment diagram of Figure 2.2 here and the molecular diagram of Figure 
2.7. As observed in GGGPS, PcrB, and many other TIM-barrel proteins, the N-terminal 
helix α0 located on the N-terminal side of the parallel β strands seals the bottom of the 
barrel. before the three helices α4, α5 and α8, three associated helices denoted α4’, α5’ 
and α8’ are found on the C-terminal side, or top of the barrel. In all crystal forms of 
MoeO5, an asymmetric unit contains a homodimer (Figure 2.4). The dimer interface of 
MoeO5 is comparable to those of GGGPS and PcrB, buries an average of 1200 Å2 
surface area, and accounts for more than 10% of the solvent-accessible surface on each 
monomer. It involves a number of hydrophobic interactions contributed by Leu121, 
Tyr127, Val129, Trp130, Phe133, Leu134, Leu137, Ala138, Phe140, Val189, Ala192, 
Phe193 and Phe195 from helices α4 and α5, as well as Leu154 from strand β5 and the N-
terminal Trp20. Two salt bridges are formed by the side chains of Arg21 and Glu135*. 
(Residues from the other monomer are denoted by asterisks.) The side chain of Lys131 is 
hydrogen bonded to the carbonyl groups of Phe193* and Gly194*, in addition to the salt 
bridge to Asp126. The flat guanidinium group of Arg185 stacks with the imidazole group 
of His188*. Moreover, near the C-terminus of helix α4, the carbonyl groups of Leu137, 
Ala138 and Phe140, together with their equivalents in the dyad-related monomer, form a 
six-coordinated complex with a Mg2+ ion at the dimer interface. This Mg2+ is not found in 
GGGPS or PcrB. Interestingly, as shown in Figure 2.5, the two monomers in a MoeO5 
homodimer are arranged differently than those in the GGGPS and PcrB dimers. Although 
the same helices α4 and α5 form the dimer interface, the dyad axis relating the two 
MoeO5 monomers is roughly perpendicular to that relating the GGGPS or PcrB 
monomers. Consequently, MoeO5 has its two TIM barrels facing the opposite sides, 
whereas GGGPS and PcrB have theirs facing the same side. The monomer of MoeO5 
also deviates more from those of GGGPS and PcrB than between the latter two (Figure 
2.6).  
Consistent with the canonical rule for a TIM-barrel protein, the active site of 
MoeO5 is located on the C-terminal end of the parallel β-strands that form a funnel-
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shaped structure, or the top of the barrel. As shown in Figure 2.8, the product FPG and 
the Mg-PPi complex are both bound to this site, which contains a deep pocket. A citrate 
and a glycerol 1-phosphate are also located in the equivalent binding site of GGGPS 
(Figure 2.9). The shape and size of the cavities in MoeO5 and GGGPS are different. In 
GGGPS the tunnel-like cavity, or the nonpolar slide, is long and presumably can 
accommodate a C20-geranylgeranyl chain in an extended conformation. By contrast, the 
equivalent cavity in MoeO5 is blocked half-way mainly because of the longer λ3 loop. 
On the other hand, the substitution of Tyr124 in GGGPS by Ala157 in MoeO5 created a 
“nook” for the C15-farnesyl group, which is bound in a curved manner. Despite the 
different crystal forms and the presence of different bound ligands, the protein 
conformation of MoeO5 remains unchanged. The dimer models of MoeO5 superimpose 
well on one another, either in a straight forward way or with the two monomers swapped 
(Table 2.3). A unique cis-peptide of Phe140-Pro141, consistently observed in all crystals, 
binds to a Mg2+ ion at the dimer interface and this should be important in maintaining the 
protein structure. In the refined model, the peptide dihedral angles in a Ramachandran 
plot showed a few outliers. These include Leu19, Trp130 and Glu205. Electron density of 
the N-terminal Leu19 is very clear. It is in the second position of a type II’ turn,[13] where 
the carbonyl C=O group of Pro18 is hydrogen bonded to the amide NH of Arg21. The 
conformation of Trp130 is also well defined. It is located in a theoretically allowed 
region to the far left side of the α-helical region. This Trp130 is at the junction of helices 
α4’ and α4 and heavily involved in the dimer interface. Glu205 is located on the protein 
surface, but its NH and C=O groups are bound to the side chains of Ser202 and Asn230, 
which in turn are bound to the C=O of Phe160 and Arg203, respectively. 
 
Description of ligand structures in the native MoeO5 and after FsPP, PPi and 3PG 
soaking 
In the MoeO5 crystal a bound product FPG was observed in each active site, 
probably because both substrates should be present in significant levels inside the E. coli 
cells when the protein was expressed. 3PG is a central metabolite in glycolysis, and FPP 
is also widely utilized in the various cellular activities. The product does not dissociate 
easily, and presumably would require the presence of other downstream enzymes for 
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direct transfer, because FPG is a secondary metabolite for antibiotics production. As 
mentioned above, soaking with GGsPP had little effect on the bound FPG molecule. The 
larger C20 geranylgeranyl chain is unable to fit into the cavity that is specific for binding 
to the C15 farnesyl chain. However, soaking with FsPP turned out to be effective in 
replacing the bound product, although it occurred gradually. The PPi moiety of FsPP is 
bound at the same site as is the 3PG moiety of FPG. The presence of Mg2+ in the FsPP 
soaking condition also allowed the binding mode of the Mg-PPi complex to be observed. 
The bound FsPP to the 3PG site, however, does not have a Mg2+ ion associated with the 
PPi, and consequently the 3PG site is not specific for the PPi-moiety of FPP. In fact, the 
FsPP overnight-soak structure can be alternatively refined with the PPi moiety of FsPP 
swapped with that of the Mg-PPi complex (Figure 2.11a). This model showed acceptable 
geometry and yielded R and Rfree values of 0.162 and 0.191 using the same data set. 
However, judging by the electron density, a majority of PPi in the FsPP is still bound to 
the 3PG site. 
The enzyme-ligand interactions are shown in Figure 2.10 of the main text. In the 
Mg-PPi binding site, the six-coordinated Mg2+ ion is chelated by a water molecule and 
the side chains of Asp41, Ser69 and Asp71 in addition to two oxygen atoms of the PPi. 
The side chains of Lys44, Thr70, Arg165 and Arg203, together with the backbone NH 
group of Thr70, make several hydrogen bonds to the PPi. Although not charged, the 
shorter and more rigid side chain of Thr70 can be important in properly orienting the 
substrate molecule for the catalyzed reaction. Extensive soaking experiments with PPi 
showed that PPi alone did not bind to this site, but to a more remote site between two 
protein molecules at lattice contact. The level of PPi in the solution was 10-fold higher 
than the level of Mg2+, and probably Mg2+ was mostly chelated by two or three molecules 
of PPi and consequently was depleted. (We also found salt crystals in the same drop.) 
Soaking with 3PG also had little effect on the tightly bound FPG, but showed a bound 
Mg-phosphate in the Mg-PPi binding site. Interestingly, in the heavy-atom free H97C 
mutant crystals, the active site contained an unknown ligand with a longer hydrocarbon 
moiety that is also bent. Substitution of the imidazole group by a sulfhydryl enlarged the 
cavity. A phosphate group was seen in the equivalent position as was that in 3PG. 
However, it seemed to be attached to a carbonyl group, which made a hydrogen bond to 
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the side chain of Ser228. Although the ligand size appeared to resemble the Archaea-type 
lipid GGGP, the electron density did not suggest such an identity. It was modeled as a 1-
phospho-palmitic acid, which contains a C15 tail in addition to the head group, and the 
structure refined to R and Rfree values of 0.169 and 0.211 at 1.82 Å. The disposition of the 
hydrocarbon tail is quite different from that of FPG (Figure 2.11b). Whatever the ligand 
is, these observations suggest that the mutant H97C is no longer capable of synthesizing 
FPG, and the trans-to-cis conversion machinery for the farnesyl group is not functional. 
 
Preparation of Z,E-FPP with Rv1086 and MoeO5 activity assay 
Rv1086 was expressed and purified as previously described.[14] To make Z,E-FPP, 
1 μM Rv1086 was added into 10 ml 50 mM Tris-HCl buffer (pH 7.2) containing 300 μM 
GPP, 1 mM IPP, 1 mM MgCl2 and 300 mM NaCl. The mixture was incubated at 37 °C 
for overnight. After the reaction, Rv1086 and precipitated Z,E-FPP was removed by 
passing the reaction mixture through an Amicon centrifuge tube (10 kDa). Z,E-FPP 
concentration was determined by LC/MS with a standard curve generated with E,E-FPP. 
LC/MS analyses were carried out using an Agilent LC/MSD Trap XCT Plus instrument. 
Compounds were separated on a 5 μm (4.6 x 150 mm) Eclipse XDB-C8 column 
(Agilent) using a 0 – 100% acetonitrile (in 25 mM NH4HCO3 buffer with 0.1% 
triethylamine) gradient, and monitored by using negative-ion mode ESI. 
Activity of MoeO5 was measured as previously described.[15] In brief, the assays 
were performed in 50 mM Tris-HCl at pH 7.2, 300 mM NaCl, 1mM MgCl2 with 1 mM 3-
D-phosphoglyceric acid, and 0.5 μM MoeO5. E,E-FPP or Z,E-FPP was added at a 
saturated concentration (200 μM for E,E-FPP and 91 μM for Z,E-FPP). The reactions 
were incubated at 37°C, quenched with an equal volume of methanol and then analyzed 
by LC/MS. The results are shown in Figure 2.13. Other substrates NPP, NOH, GPP and 
GGPP were also tested for MoeO5 activity under similar conditions. 
 
Analysis of the TIM-barrel PT sequences 
In order to assess the likely importance of different residues in catalysis, we used 
the Scorecons program to rank order residues in terms of their essentiality.[16] We used as 
input a JPRED3  alignment based on the S. ghanaenesis MoeO5 sequence,[17] then 
 32
ordered the Scorecons results based on the scores obtained. The most essential residue in 
MoeO5 is Asp41 with a score of 0.904. 
 
A possible catalytic mechanism that involves NOH 
The bound ligands to the wild-type MoeO5 in the refined crystal structures are 
superimposed in Figure 2.14. Based on the ligand arrangements and the measured 
distances, the Mg-PPi is 3.0 Å and 3.6 Å from the C1 atom of FPG and FsPP, but at least 
5 Å from C3. Thus it is unlikely for the PPi to move to the C3 atom, forming a NPP, but 
the PPi tends to associate with C1 of the intermediate to form Z,E-FPP under proper 
conditions. A possible catalytic mechanism is thus proposed. The reaction starts by 
sequential binding to 3PG and FPP, the latter substrate FPP should be in the form of 
Mg2+ complex in order to interact properly with Asp41, Ser69, Thr70 and Asp71, as well 
as the positively charged Lys44, Arg165 and Arg203. Asp41, important in Mg-PPi 
binding, is highly conserved in the TIM barrel PTs. The imidazole side chain of His97 as 
a general acid-base then activates the water molecule by subtracting a proton from it. The 
water then attacks at the C3 atom of FPP, forming NOH. The double-bonded group of 
C1=C2 then rotates about the single bond C2-C3 and converts the conformation of the 
intermediate from a trans-like conformation to a cis-like conformation. The rotation is a 
small change in term of the molecular structure, and can be assisted by the nearby Mg-
PPi complex, which is a good leaving group but still likely to re-associate with the 
intermediate to form Z,E-FPP. Meanwhile, the 3-OH group of NOH obtains a proton 
from His97, and the farnesyl group re-develops a positively charged nature among the 
C1-C2-C3 bonds. Glu167 in GGGPS has been suspected to act as a general base to 
polarize and subtract a proton from the 3’-OH group of G1P,[3] but the equivalent Tyr201 
in MoeO5 is not positioned in a proper orientation for the same role. Instead, the adjacent 
Mg-PPi can serve to accept a proton from the 2’-OH group of 3PG, which in turn forms a 
new bond with the Z,E-farnesyl group. The resulting FPG remains in the active-site 
pocket of MoeO5, whereas the Mg-PPi seems not so tightly bound. Other possibilities 
exist, including the possibility that in cells, Z,E-FPP is used directly, but then the 
observation that FPP, NPP and Z,E-FPP all react at not dissimilar rates would have to be 
coincidental, rather than indicative of an ionization/isomerization mechanism. 
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2.6 Schemes, Charts, Tables and Figures 
Table 2.1 Summary of Hg-derived protein data collection and phasing statistics. 
 
Name H97C- native 
H97C- 
C9H9HgNaO2S 
H97C- 
K2HgI4 
H97C- 
C2H5HgCl 
H97C- 
C(HgOOCCH3)4 
Data collection 
Wavelength (Å) 
 
0.9763 
 
0.9763 
 
0.9763 
 
0.9763 
 
0.9763 
Resolution (Å) 25-1.82 (1.89-1.82) 
25-1.49 
(1.54-1.49) 
25-1.83 
(1.90-1.83) 
25-1.75 
(1.81-1.75) 
25-1.71 
(1.77-1.71) 
Space group P21 
Unit-cell      
a (Å) 58.80 58.43 58.39 58.12 58.27 
b (Å) 84.57 84.62 84.48 84.04 84.31 
c (Å) 59.48 59.52 59.46 59.41 59.35 
β (o) 112.01 111.75 112.03 111.72 111.68 
No. of measured 
reflections 
153907 
(15347) 
496607 
(49447) 
201166 
(19089) 
170748 
(16972) 
175642 
(17270) 
No. of unique 
reflections 
48096 
(4796) 
85622 
(8381) 
46783 
(4656) 
53359 
(5304) 
56659 
(5571) 
Completeness 
(%) 
99.8 
(100.0) 97.6 (95.9) 99.6 (99.9) 99.7 (99.6) 98.5 (97.6) 
Rmerge (%)a 7.8 (50.0) 6.0 (39.6) 6.0 (22.2) 6.6 (48.2) 5.0 (14.3) 
Mean I/　(I) 18.9 (3.4) 29.1 (6.0) 21.5 (8.4) 18.4 (3.5) 21.5 (11.5) 
Multiplicity 3.2 (3.2) 5.8 (5.9) 4.3 (4.1) 3.2 (3.2) 3.1 (3.1) 
Phasing      
No. of sites 4 
Z-score 40.06 
Figure of merit 0.51 
Values in parentheses are for the highest resolution shell. 
a Rmerge = ∑hkl∑i|Ii(hkl)-<I(hkl)>| ∑hkl∑iIi(hkl). 
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Table 2.2 Data collection and refinement statistics for the MoeO5 crystals. All positive 
reflections were used in the refinement. Values in parentheses are for the outermost 
resolution shells. 
 
 Native FsPP (3 hours) 
FsPP 
(overnight) PPi 3PG 
Data collection      
Space group P21 P1 P1 P1 P1 
Unit-cell      
a (Å) 59.0 46.6 46.7 46.7 46.8 
b (Å) 84.5 58.9 58.6 59.7 58.7 
c (Å) 59.6 58.8 58.9 59.1 59.2 
α (°) 90.0 97.6 97.7 66.7 97.8 
β (°) 112.3 108.4 112.2 71.1 112.6 
γ (°) 90.0 112.5 108.6 66.0 108.2 
Resolution (Å) 
25 – 1.39 
(1.44 – 
1.39) 
25 – 1.57 
(1.63 – 
1.57) 
25 – 1.8 
(1.86 – 
1.80) 
25 – 1.66 
(1.72 – 
1.66) 
25 – 1.66 
(1.72 – 
1.66) 
Unique 
reflections 
105467 
(10291) 
70651 
(6964) 
46862 
(4623) 
59540 
(5880) 
59984 
(5912) 
Redundancy 5.1 (5.0) 4.0 (4.0) 4.0 (3.9) 4.0 (4.0) 4.0 (4.0) 
Completeness 
(%) 97.5 (95.5) 96.8 (95.1) 96.6 (95.2) 
96.1 
(94.8) 96.2 (95.0) 
Average I/σ(I) 24.8 (3.4) 42.4 (6.4) 37.3 (9.0) 37.1 (9.4) 39.9 (11.4) 
Rmerge (%) 6.9 (55.6) 3.3 (26.6) 3.2 (9.9) 3.1 (9.8) 3.5 (8.6) 
Refinement      
No. of reflections 99738 (8573) 
69049 
(6216) 
46545 
(4495) 
59066 
(5627) 
59609 
(5666) 
Rwork (95% of 
data) 
0.168 
(0.222) 
0.163 
(0.203) 
0.161 
(0.179) 
0.161 
(0.184) 
0.158 
(0.179) 
Rfree (5% of data) 
0.189 
(0.250) 
0.191 
(0.243) 
0.192 
(0.209) 
0.186 
(0.227) 
0.187 
(0.220) 
R.m.s.d. bonds 
(Å) 0.020 0.019 0.020 0.020 0.020 
R.m.s.d. angles 
(°) 1.9 1.9 2.0 1.9 2.0 
Dihedral angles      
Most favored 
(%) 96.2 95.8 95.8 96.2 96.0 
Allowed (%) 2.6 3.0 3.2 2.8 2.8 
Disallowed (%) 1.2 1.2 1.0 1.0 1.2 
No. of non-H 
atoms      
Protein 3927 3927 3943 3932 3927 
Water 590 467 405 432 470 
Ligand 53 53 72 62 59 
Average B (Å2)      
Protein 13.1 18.6 18.0 13.9 14.1 
Water 26.9 31.6 28.6 26.1 26.4 
Ligand 12.6 21.2 25.3 17.6 15.8 
PDB ID code 3VK5 3VKA 3VKB 3VKC 3VKD 
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Table 2.3 Deviations between the MoeO5 models.  
The root-mean-square deviations were calculated by superimposing 2000 backbone 
atoms in a dimer and expressed in Å. Values along the diagonal are for the self 
comparison by superimposing chain A on chain B and vice versa. Values in the upper 
triangle are calculated by direct superposition of the different models, and those in the 
lower triangle are for cross comparison by superimposing chain A on chain B and vice 
versa. 
 
 Native FsPP (3h) FsPP (ON) PPi 3PG 
Native 0.237 0.162 0.276 0.159 0.131 
FsPP (3h) 0.229 0.179 0.184 0.138 0.107 
FsPP (ON) 0.287 0.224 0.169 0.242 0.219 
PPi 0.224 0.216 0.267 0.197 0.154 
3PG 0.215 0.198 0.254 0.218 0.178 
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Figure 2.1 The first step in moenomycin biosynthesis. The reaction is catalyzed by 
MoeO5, which transfers the C15 farnesyl group from FPP to 3PG. The carbon atoms are 
numbered 1 – 15 in FPP and 1’ – 3’ in 3PG. Importantly, the original all-trans 
configuration is converted to 2-cis,6-trans (Z,E) upon the farnesyl transfer, forming FPG 
and PPi. 
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Figure 2.2 Sequences of the TIM-barrel PTs. The amino-acid sequence of MoeO5 is 
aligned with those of GGGPS and PcrB based on their three-dimensional structures. The 
cyan bars and green arrows at the bottom denote the locations of α-helices and β-strands, 
respectively, in the MoeO5 structure. The λ3 loop which replaces the helix α3 commonly 
observed in other TIM-barrel proteins is represented as a pink bar. Identical amino acids 
in any two proteins are highlighted in yellow, but marked orange when they occur in all 
three proteins. The numbers on the top are for MoeO5. 
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Figure 2.3 Electron densities for the bound ligands. The refined models are superimposed 
on the composite omit maps calculated using CNS. The maps are contured at 3-σ level 
and shown as mesh representations. The last two pictures are for the mutant H97C, of 
which the structure was refined to Rwork / Rfree = 0.169 / 0.211 at 1.82-Å resolution. Each 
of the difference Fourier maps with scaled Fo-Fc coefficients were calculated by 
combining 20 “omit models” each had the target atoms removed and was then subjected 
to simulated-annealing at 2500 K in order to remove model bias. The omitted models are 
shown as thick sticks and balls in the figures, while the remaining parts are shown as thin 
sticks.  
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Figure 2.3 (cont.) 
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Figure 2.4 Structure of the MoeO5 dimer. One monomer is shown as a ribbons diagram 
and the other monomer as a surface representation. Not found in GGGPS and PcrB, a 
Mg2+ ion is bound at the dimer interface of MoeO5. The coordination involves the cis-
peptide of Phe140-Pro141, as well as the backbone carbonyl groups of Leu137 and 
Ala138. 
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Figure 2.5 Difference of the MoeO5 dimer from two other dimers. The dimers of 
GGGPS, PcrB and MoeO5 are shown in two orthogonal views. Although the overall 
shapes of the dimers seem to be similar, the dyad axis which relates the two MoeO5 
monomers is disposed differently from those of GGGPS and PcrB. In the dimers shown 
on the top of the figure, for example, the dyad axes of GGGPS and PcrB are 
perpendicular to the plane of the page, but that of MoeO5 lies inside the plane. The two 
different ways of dimer arrangement can be described by two cups. In GGGPS and PcrB, 
the opening of the TIM barrels are both facing the same side, whereas in MoeO5 they are 
facing the opposite sides.  
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Figure 2.6 Structure comparison of the TIM-barrel PTs. The monomers of MoeO5, 
GGGPS and PcrB are superimposed and shown as worm diagrams colored in red, green 
and blue, respectively. The root-mean-square deviations (rmsd) between the matched 
numbers of Cα atoms are also indicated, as well as the numbers of identical residues. 
Note that the GGGPS and PcrB structures are much more similar to each other than to 
MoeO5. The additional diagram at the bottom shows that the dimers of GGGPS and PcrB 
also superimpose very well. However, the MoeO5 dimer has a different arrangement and 
cannot be superimposed as a whole on either of the other two dimers. 
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Figure 2.7 Structure of the MoeO5 monomer. The central eight-stranded β-barrel and the 
surrounding α-helices (numbered 0 – 8) in the ribbon diagram are colored green and 
cyan. The unusual loop of λ3 is highlighted in magenta. The bound FPG and Mg-PPi 
complex (from the FsPP-soak crystal) are depicted as ball-and-stick models. A fraction of 
the other monomer in the MoeO5 dimer is also shown, as a yellow surface presentation.  
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Figure 2.8 Comparison of the prenyl substrate binding pockets. The monomers of MoeO5 
(red), GGGPS (green) and PcrB (blue) are superimposed and shown as worm models in 
the upper panel. The side chains in the λ3 loop and the bound FPG (yellow) are shown as 
stick models. In the lower panels the surface representations of the enzymes are 
superimposed on the stick models. The ligand shown here is the product FPG from 
MoeO5. Here the hydrocarbon-binding tunnels of MoeO5 and GGGPS have different 
shapes. The Mg-PPi binding site and the unique “nook” in MoeO5 are indicated, as well 
as the residues Pro99, Pro100, Phe106 and Leu120 that block the “hydrophobic slide”, 
which is supposed to accommodate the longer prenyl chain in GGGPS. Some equivalent 
residues in GGGPS are also labeled. 
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Figure 2.9 Comparison of the bound acceptor substrates. The solvent accessible 
molecular surfaces of the monomers are viewed from the “top” of the TIM barrel, 
revealing a deep substrate binding pocket in the active site. The surface is color-coded 
from red to white and from white to blue according to the electrostatic potentials from -
65 kBT to 0 and from 0 to +65 kBT. On the left the “native” MoeO5 protein contains a 
bound product FPG, which is shown as a stick model. The Mg-PPi complex from the 
FsPP-complex crystal is also shown. In the active site of GGGPS, a bound citrate 
molecule is shown (PDB 2F6U). The pocket of GGGPS appears to be deeper and more 
open than that of MoeO5. In the lower panel the FPG from MoeO5 (yellow carbons) and 
the G1P from GGGPS (PDB 2F6X; cyan carbons), after protein superposition focusing 
on the two phosphate-binding loops, show an giving an rmsd of 0.42 Å for eight matched 
atoms.  
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Figure 2.10 MoeO5 interactions with the bound ligands. a) In a stereo view, the FPG is 
depicted by thick stick model with gray carbon atoms, and the surrounding amino acids 
are shown as thin sticks with green carbons. Hydrogen bonds between FPG and the 
protein are shown as dashed lines. The water molecule bound to His97 is consistently 
observed in all wild-type crystals. b) The bound FsPP and Mg-PPi along with the active-
site amino acids are shown in a similar way as in a). The coordinate bonds to the Mg2+ 
ion and other hydrogen bonds to the ligands are shown as dashed lines. Note that PPi is 
closer to C1 than C3 of the FsPP. 
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Figure 2.11 Alternative interpretations for the bound ligands. a) The PPi in the bound 
Mg-PPi was switched with the PPi moiety of FsPP in the model of the overnight soak 
crystal. The switched model is shown with pink carbon atoms, while the original model 
has blue carbons. The Mg2+ ion is shown as a purple sphere. b) The model for bound 
ligand in the H97C mutant crystal is shown with carbon atoms colored gray. For 
comparison, it is superimposed on the FPG (yellow carbons) and FsPP (blue carbons) 
models. 
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Figure 2.12 Proposed mechanisms for the TIM-barrel PTs. The reactions start by 
ionization (bold arrow) of the prenyl pyrophosphate, which requires a bound Mg2+. a) In 
catalysis by GGGPS and PcrB, the 3’-OH of G1P is deprotonated by Glu167 (Glu160 in 
PcrB) and associates directly with the carbocation, forming an ether bond. The prenyl 
chain length varies from n = 3 in GGGPS to n = 5 in PcrB. b) In MoeO5, trans-FPP, Z,E-
FPP and NPP all react to form FPG, consistent with an ionization/isomerization 
mechanism, but shorter and longer chain species do not. c) His97 is essential for catalysis 
and may play a role in isomerization, possibly via NOH. 
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Figure 2.13 Z,E-FPP and its reaction rate relative to trans-FPP. The upper panel shows 
HPLC results. Reaction buffer: Tris-HCl, pH 7.5, 1 mM MgCl2; column: C8. The lower 
panel shows the curves used for calculating the reaction rates. The results indicate Vmax 
(trans-FPP) = 2.16 μM/min and Vmax (cis-FPP) = 10.63 μM/min, or Kcat (trans-FPP) = 
4.32 min-1 and Kcat (cis-FPP) = 21.26 min-1. That is, cis-FPP as substate is ~ 5x more 
active than is trans-FPP, which itself has the same activity as NPP. 
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Figure 2.14 Possible catalytic mechanism of MoeO5. The various ligands bound to the 
wild-type MoeO5 are superimposed and displayed in stereo as ball and stick models. 
These are colored yellow, green, blue, orange and red for the “native” crystal (though 
soaked with GGsPP), and crystals soaked with FsPP (3 hours), FsPP (overnight), G3P, 
and PPi, respectively. The water molecule is 3.4 – 3.6 Å from the C3 atom of the farnesyl 
group. The PPi is 3.3 Å from the O2’ atom of FPG and 3.0 – 3.6 Å from C1, but it is 5.0 
– 5.3 Å from C3. A series of models and a proposed catalytic mechanism are followed. 
Here a vital role is assumed by His97, which activates a water molecule for, and thus 
allows the C3-C2 bond rotation from trans-like to cis-like conformation. The negatively 
charged Mg-PPi then accepts a proton from the 2’-OH group of 3PG, forming the product 
FPG. 
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Chapter 3: Insights into TIM‐barrel Prenyl Transferase Mechanisms: Crystal 
Structures of PcrB from Bacillus subtilis and Staphylococcus aureus 
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3.2 Introduction 
Many enzymes involved in isoprenoid (or terpene/terpenoid) biosynthesis are prenyl 
transferases (PTs) that catalyze condensation reactions between prenyl diphosphates and 
various acceptors and structurally, most contain one of six main folds: α, β, γ, δ, ε, or [1]. 
Recently, several new PT structures that contain a triose phosphate isomerase (TIM) 
barrel fold have been discovered[2], and there is considerable interest in their mechanisms 
of action[2b, 2e]. The first structure published was that of Archaeoglobus fulgidus 
geranylgeranylglyceryl phosphate synthase (AfGGGPS)[2d], which catalyzes the reaction 
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between geranylgeranyl diphosphate (GGPP) and glycerol-1-phosphate (G1P) to form 
geranylgeranylglyceryl phosphate (GGGP) (Scheme 3.1), a precursor of the 
(perhydro)geranylgeranyl-based phospholipids found in Archaea[3]. A very similar 
reaction is carried out by the enzyme PcrB in several Bacilli but in this case the prenyl 
donor is heptaprenyl diphosphate (HepPP)[4]. The PcrB product, heptaprenylglyceryl 
phosphate (HepGP), is then dephosphorylated to heptaprenylglycerol, then acetylated, 
Scheme 3.1[4]. The function of this ester product is unknown. However, PcrB forms part 
of an operon with PcrA, an essential DNA helicase[5], and a ∆pcrB mutant (in Bacillus 
subtilis) has a deranged, “cloggy” pattern of growth[4], so it seems likely that PcrB is 
important for growth (or perhaps, virulence) in other Bacilli, such as the pathogen 
Staphylococcus aureus, and may be of interest as a drug target. 
In GGGPS or PcrB, there is no isomerization of the isoprenoid chain during catalysis. 
However, in a third TIM-barrel PT, Streptomyces ghanaensis MoeO5 (SgMoeO5), 
involved in the first committed step in biosynthesis of the antibiotic moenomycin[2c], 
there is a remarkable trans  cis isomerization during the prenylation reaction, as shown 
in Scheme 3.1[2b, 2c], and we recently reported the structure of MoeO5 containing its 
bound product, FPG (2-(Z, E)-farnesyl-3-phosphoglycerate)[2e]. Here, we report the 
structures of PcrB from B. subtilis and S. aureus containing bound substrates as well as 
other ligand molecules which help define the catalytic mechanism, in addition to site-
directed mutagenesis and bioinformatics results that point to the specific roles of several 
residues in PcrB catalysis. 
 
3.3 Results and Discussions 
BsPcrB structures were solved by using a previous BsPcrB structure (1VIZ)[2a] as a 
search model, then the new BsPcrB structure was used as a search model for solving the 
SaPcrB structures by using the molecular replacement method (Table 3.1 and 3.2 in the 
Supporting Information). Detailed experimental procedures for protein expression, 
crystallization, data collection and structure determination are provided in the Supporting 
Information. The electron densities of the ligands were clear and are shown in Figure 3.1 
in the Supporting Information. BsPcrB and SaPcrB both crystallize as dimers, and the 
dimer interface involves mainly hydrophobic residues in helices α4 and α5. This interface 
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is different from that in the structure (1VIZ) reported previously[2a], but is the same as 
predicted by Peterhoff et al.[6] (Figure 3.2 in the Supporting Information). 
We show in Figure 3.3a the superimposed structures of the monomer subunits of 
BsPcrB (in green) and SaPcrB (in cyan) and in Figures 3.3b and 3.3c we show the 
BsPcrB structure (in green) superimposed on that of AfGGGPS (in yellow; Figure 3.3b) 
and SgMoeO5 (in orange; Figure 3.3c) in which it can be seen that there is high similarity 
between the structures of the TIM barrel folds in each system with Cα root mean square 
deviations (RMSD) in the range 0.98 – 1.51 Å over ~210 atoms, Figure 3.3. (The RMSD 
between BsPcrB and SaPcrB, GGGPS and MoeO5 are 0.98 Å, 1.06 Å and 1.51 Å, 
respectively, for 210, 204 and 167 matched atoms.)[7] The major difference occurs in the 
region around loop λ3, which replaces helix α3 in a canonical TIM barrel structure. This 
loop is rather open in PcrB and GGGPS, acting as a swinging gate to the hydrophobic 
substrate-binding tunnel, but it collapses inward in MoeO5, making a unique pocket for 
binding substrate in a bent conformation. [2] 
With BsPcrB we also obtained structures of the protein with bound G1P, FsPP (S-
thiolo-farnesyl diphosphate) and FsPP + G1P (Figure 3.4a), and with SaPcrB we obtained 
structures with a bound PEG (Figure 3.4b) and a sulfate ion. In BsPcrB-G1P/FsPP the 
G1P orientation is slightly different from that in the BsPcrB-G1P complex, suggesting 
flexibility. Consequently, BsPcrB-G1P and BsPcrB-FsPP are used for structural analyses 
of these two ligands. Detailed interactions of G1P and FsPP are shown in Figures 3.4c 
and 1d, respectively. The phosphate group of G1P is bound between two loops and forms 
hydrogen bonds to several peptide NH groups, as well as the side chain of N209. Both the 
2‐OH and 3‐OH are hydrogen bonded to the side chain of E160 and Y158, Figure 3.4c. In 
the SaPcrB-SO4 structure, a bound sulfate ion binds to the G1P binding site (Figure 3.5). 
In the BsPcrB-FsPP structure, the diphosphate group of FsPP is buried in a polar pocket 
with its prenyl moiety in a straight hydrophobic tunnel, and in the SaPcrB-PEG structure, 
the PEG polymer is seen in the same hydrophobic tunnel (Figure 3.4d). These structures 
are of interest since they show the positions of the reactive “head-groups” that condense 
to form the HepGP product. In addition, they help define experimentally the hydrophobic 
tunnel into which the C35 side-chain can bind, in addition to confirming the nature of the 
dimer structure predicted by Peterhoff et al[6]. 
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The reaction catalyzed by PcrB involves the attack of the nucleophile G1P via its C-3 
OH group at C1 in HepPP. This reaction can reasonably be thought to require: 1) 
activation of the C-3 OH to facilitate nucleophilic attack; 2) removal of the product 
diphosphate and 3) a route to removal of the C-3 OH proton that is lost during the 
reaction, from the active site region. To see which residues are most essential for 
catalysis and might thus be involved in these steps, we used the SCORECONS program[8] 
which enables a rank-ordering of residues in terms of their conserved nature. 
Many PTs such as farnesyl diphosphate synthase, undecaprenyl diphosphate synthase 
and squalene synthase, have an absolute requirement for a divalent cation, typically 
Mg2+[9], and in these systems Mg2+ is “anchored” by one or more Asp residues. We thus 
assumed that there would be a “most essential” Asp in PcrB. However, as can be seen in 
Table 3.3, the results of the SCORECONS analysis (using JPRED3 [10] alignments based 
on BsPcrB or SaPcrB) clearly indicate that the three most conserved residues in both 
species are Y and E: Y118, Y159 and E161 in S. aureus and Y118, Y158 and E160 in B. 
subtilis, Table 3.3. On inspection of the crystal structures of BsPcrB (+FsPP+G1P) it can 
clearly be seen that E160 is only ~2.7Å from the C-3 OH oxygen (Figure 3.6), which 
could facilitate removal of the OH proton, and two Tyr OH oxygens are also quite close 
by (both 4.2Å to the E160 carboxyl oxygens) and are poised to aid proton abstraction 
from the active site. We thus propose that these three residues are involved in C-3 OH 
activation and H+ removal from the active site region. We also see, Table 3.3, that D14 is 
quite highly conserved, and based on an alignment with the MoeO5 structure (which 
contains an Mg2+, Figure 3.6) we propose that D14 binds to Mg2+ which – as with other 
PTs, is important in removal of the diphosphate product of the reaction. We tested the 
activity of wild type protein in the presence of 50 μM EDTA as well as in the absence of 
MgCl2. No product was found, indicating that Mg2+ is likely essential for catalysis. We 
also tested the activity of D14A mutants of both SaPcrB and BsPcrB and found no 
activity.  
The reaction catalyzed by GGGPS is very similar to that catalyzed by PcrB - the only 
obvious chemical difference being that GGGPS uses a shorter prenyl diphosphate, and a 
SCORECONS analysis shows that Y124, Y165 and E167 are the three most essential 
residues and that D13 is also highly conserved, Table 3.3. Other highly conserved 
56 
 
residues are all Glys that are presumably of structural importance. The role of the 
conserved D76 (or 77) is unknown. Based on these results then, the YYED set of residues 
is common to PcrB as well as GGGPS proteins and is involved in proton abstraction 
(YYE) and diphosphate removal (D). 
Next, we consider the nature of the hydrophobic pocket that accommodates the C35 
side-chain. In recent work, Guldan et al.[4] have used computational docking (together 
with geometry optimization) of HepPP to a BsPcrB dimer model to propose a model for 
bound HepPP[4]. This model (in yellow) is shown in Figure 3.7a superimposed on the 
FsPP substrate (in cyan) plus the PEG ligand (in green) and as can be seen in Figure 3.7a, 
there is very good accord between the disposition of HepPP in the computational model 
and the positions of the two ligands in the x-ray structures, albeit with some small 
differences in the head-group region, Figure 3.7a. Also of interest are the positions of 
residue A100 and Y104: A100 allows binding of substrates longer than GGPP (length 
defined by FsPP plus PEG), and Y104 locates near the terminus of HepPP and may play 
a role in chain length limitation. The residue corresponding to A100 in PcrB is W99 in 
GGGPS, and a previous study on a W99A mutant of GGGPS showed that mutation of 
this bulky residue to alanine allowed the protein to use substrates longer than GGPP[4]. 
Interestingly, although Y104 is not highly conserved (Table 3.3), this position is either Y 
or F in essentially all sequences annotated as HepGPS, as highlighted in green, but is 
random in the GGGPS sequences. Correspondingly, W100 is conserved in the same 
GGGPS sequences (highlighted in yellow), but is Ala in the corresponding HepGPS 
sequences (highlighted in blue), enabling formation in long chain products. 
To see to what extent there might be chain length discrimination in PcrB, we 
produced A100W and Y104A mutants of SaPcrB and tested the effects of these 
mutations on the conversion of C20, C25, C30, C35 and C40 prenyl diphosphates to the 
corresponding glyceryl phosphate products. To investigate these effects, we used a radio-
TLC assay with a distribution of polyprenyl diphosphate chain length substrates, obtained 
from the reaction of FPP with [14C]-IPP, catalyzed by E.coli octaprenyl diphosphate 
synthase[11]. The results obtained, illustrated in Figure 3.7b and Figure 3.8 in the 
Supporting Information, show that conversion of A100 to W100 results in strong 
inhibition of the formation of the longer chain products, presumably because the bulky 
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W100 side-chain inhibits binding of the longer chain substrates, while conversion of 
Y104 to A104 favors formation of longer-chain products. The observation that the 
Y104A mutant makes more C40 products than does the wild-type protein implies, then, 
that Y104 is located at or near the terminus of the C35 chain since, if it were not, there 
would be little effect on the chain length distribution. Of course, in cells, the actual 
product chain length distribution depends on the amounts of FPP, GGPP, HepPP and 
other prenyl diphosphates that are present, and this is likely to vary with growth 
conditions. S. aureus does, however, make quinones with C40 side-chains[12] and it is 
possible that Y104 contributes to chain-length discrimination in the PcrB reaction since 
primarily C35 products are found in the heptaprenylglycerol diester product[4], but of 
course chain length discrimination can also occur in reactions occurring after the PcrB-
catalyzed reaction. 
Finally, we consider the structural differences between the BsPcrB and MoeO5 
structures. As can be seen in Figure 3.9, in MoeO5 the prenyl side-chain in the FPG 
product (in yellow) is highly bent. The chain terminus in this bent structure would occupy 
the position of the Y118 side-chain in BsPcrB, and binding in this bent manner is only 
possible because the residue at this position in MoeO5 is an alanine, as shown in Figure 
3.9. In addition, the conserved catalytic E160 (in BsPcrB) in MoeO5 is a tyrosine, Y201, 
which as with BsPcrB, is likely to be involved in H+ abstraction, this time from the 2-OH 
group of 3-phosphoglycerate, illustrated in Figure 3.9. The residue corresponding to D14 
(BsPcrB) or D13 (GGPPS) in MoeO5 is D41, which interacts with Mg2+ in the active 
site[2e]. 
 
3.4 Conclusions 
In summary: we report the structures of PcrBs from B. subtilis (4 structures) and S. 
aureus (2 structures), the first substrate (or other ligand) containing structure of these 
enzymes and the first structure of the S. aureus protein. The results clearly show the G1P 
and F(s)PP binding sites, plus, they map out much of the C35 side-chain binding pocket, 
and there is good accord with earlier computational predictions as to the nature of this 
binding site, as well as the nature of the dimer structure. The most highly conserved 
residues are two Tyr and one Glu in the active site, proposed to be involved in 3-OH 
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activation as well as H+ removal from the active site region, together with a conserved 
Asp, involved in Mg2+ binding and diphosphate removal. In addition, we propose that 
Y104 is involved in chain-length regulation. The overall structures are similar to those 
previously reported for MoeO5 but there, the bent FPG side-chain occupies the Y118 
(BsPcrB) A124 (MoeO5) site, and E160 (BsPcrB) is replaced by Y201 (MoeO5), 
involved in 2-OH proton abstraction. 
 
3.5 Materials and Methods 
Expression and purification of PcrB from B. subtilis and S. aureus 
The genes encoding PcrB from Bacillus subtilis subsp. subtilis str. 168 and 
Staphylococcus aureus subsp. aureus Mu3 were amplified by polymerase chain reaction 
(PCR) with a forward primer 5'-GGTATTGAGGGTCGCGCTGGTGCTGGTGCTATGT 
ACGATGTAACGGAGTGGAAGCAT-3' and a reverse primer 5'-AGAGGAGAGTTAG 
AGCCATTACTCGCCTTTCACAGCCGCTACTGT-3' for BsPcrB; and a forward 
primer 5'-GGTATTGAGGGTCGCGCTGGTGCTGGTGCTATGTATGACATTAAAAA 
ATGGCGCCAT-3' and a reverse primer 5'-AGAGGAGAGTTAGAGCCATTATTTACT 
AGACTCCTTTATTTTTAC-3' for SaPcrB, and then cloned into the pET32 Xa/LIC 
vector. Mutants were prepared with BsPcrB-pET32a Xa/LIC and SaPcrB-pET32a 
Xa/LIC plasmids as the templates. The recombinant plasmids were transformed to E. coli 
BL21 (DE3) and proteins were induced with 1 mM isopropyl-thiogalactopyranoside 
(IPTG) at 30 °C for 12 hours. The cell pastes were harvested by centrifugation at 7,000 x 
g and resuspended in a lysis buffer containing 25 mM Tris-HCl, pH 7.5, 150 mM NaCl 
and 20 mM imidazole. Cell lysates were prepared with a French Press Instrument, and 
then centrifuged at 17,000 x g to remove cell debris. Proteins were purified by FPLC 
using a Ni-NTA column. The buffer and gradient for the Ni-NTA column were 25 mM 
Tris, pH 7.5, 150 mM NaCl, and 20–250 mM imidazole. The proteins were eluted at 
about 130 mM imidazole for BsPcrB and 135 mM imidazole for SaPcrB. The proteins 
were dialyzed against the buffer containing 25 mM Tris-HCl, pH 7.5, 150 mM NaCl and 
then subjected to Factor Xa digestion to remove the tag. The mixture was then passed 
through another Ni-NTA column and subsequently untagged BsPcrB and SaPcrB were 
eluted with 10 mM imidazole-containing buffer and then dialyzed twice against 5 L 
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buffer (25 mM Tris-HCl, pH 7.5, and 150 mM NaCl) for storage. SDS-PAGE analysis 
was used to check the purity (>95%) of GGPPs and its mutants. 
 
Crystallization, data collection, structure determination and refinement 
Crystals of apo BsPcrB were prepared by mixing 2 μL protein solution (10 mg/mL in 
25 mM Tris-HCl, pH 7.5 and 10 mM MgCl2) with equal amounts of mixture solution and 
mother liquor, and equilibrating with 500 μL of the mother liquor at room temperature by 
using the sitting drop method using Hampton Research (Laguna Niguel, CA) kits. The 
monoclinic BsPcrB crystal was obtained from a solution that contained 2.5 M NaCl and 
14% PEG6000. The BsPcrB-FsPP crystal is obtained by co-crystallizing BsPcrB protein 
solution with 5 mM FsPP under the same conditions. The BsPcrB-G1P crystal was 
prepared by soaking the apo BsPcrB crystals with 50 mM G1P in cryoprotectant (2.5 M 
sodium chloride, 17% PEG 6000, 10 mM MgCl2, and 5% glycerol) for 3 h. The BsPcrB-
G1P/FsPP crystals were obtained by soaking the BsPcrB-FsPP crystals with 50 mM G1P 
and 5 mM FsPP in the same cryoprotectant mentioned above.  
Crystals of the SaPcrB were prepared by mixing 2 μL protein solution (10 mg/ml in 
25 mM Tris-HCl, pH 7.5, 10 mM MgCl2) with equal amounts of mixture solution and 
mother liquor, and equilibrating with 500 μL of the mother liquor at room temperature by 
using the sitting drop method. Two SaPcrB structures with different space groups were 
solved. Orthorhombic SaPcrB crystals (P212121) were obtained from a solution that 
contained 0.1 M Tris, pH 8.5, and 21% PEG3350, after 3 days. Tetragonal SaPcrB 
crystals (P41212) were obtained from 0.1 M Tris, pH 8.5, and 2.5 M ammonium sulfate 
after 2 days. 
Diffraction data were collected at beam lines BL13B1 and BL13C1 of the National 
Synchrotron Radiation Research Center (NSRRC, Hsinchu, Taiwan), and processed using 
the program HKL2000[13]. Prior to structural refinements, 5% randomly selected 
reflections were set aside for calculating Rfree as a monitor.[14] The BsPcrB complex 
structures solved in this study were determined by using the previously solved BsPcrB 
structure (1VIZ). The initial phase of SaPcrB was determined by using the molecular 
replacement method (MR) with BsPcrB-FsPP as the search model. All following 
structural refinements were carried out using the programs Coot[15] and CNS[16]. Data 
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collection and refinement statistics for BsPcrB and SaPcrB crystals are summarized in 
Table 3.1 and 3.2. All diagrams of the protein structures were prepared by using PyMOL 
(http://www.pymol.org/). 
 
Kinetic measurements on SaPcrB proteins  
Expression and purification of E. coli OPPS were carried out as described 
previously[11].  14C labeled prenyl diphosphates with C20 to C50 were synthesized by 
adding 1 mM FPP, 20 μM GGPP, 100 μM [14C]IPP and 1 μM EcOPPS into 50 μL of 50 
mM HEPES (pH 7.5), 50 mM KCl and 0.5 mM MgCl2, and reacting at 37°C for 40 min. 
Equal amount of SaPcrB wild type or mutants, together with 4 mM MgCl2 and 4 mM 
glycerol phosphate, were added to the mixture of 14C labeled prenyl diphosphate 
substrates, and the resulting reaction mixture incubated at 37°C for 6 hours. 
Dephosphorylation of the PcrB product (polyprenyl glycerol phosphate) was then carried 
out by adding potato acid phosphatase and 100 μL of 40 mM sodium acetate (pH 4.7), 20% 
1-propanol and 0.1% Triton X-100. The reactions were then terminated after overnight 
incubation at 37°C by adding 500 μL NaCl saturated H2O, and the polyprenyl glycerol 
extracted with n-hexane. The solution was then concentrated and spotted onto a C18 
reverse phase TLC plate. The TLC plate was developed with acetone/methanol (2:8) and 
the product distribution analyzed by using a Storm 840 PhosphorImager and Quantity 
One (Bio-Rad, Hercules, CA). 
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3.6 Schemes, Charts, Tables and Figures 
Scheme 3.1 Structures of molecules and reactions of interest. a) Reactions catalyzed by 
PcrB (n=5) or GGGPS (n=2) b) Reaction catalyzed by MoeO5. 
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Table 3.1. Data collection and refinement statistics for BsPcrB crystals 
 BsPcrB-apo BsPcrB-
G1P 
BsPcrB-FsPP BsPcrB-
G1P/FsPP 
PDB code 3VZX 3VZY 3VZZ 3W00 
Data collection     
space group P21 P21 P21 P21 
unit-cell     
a [Å] 54.1 53.9 54.1 54.1 
b [Å] 56.0 55.8 56.1 56.4 
c [Å] 77.3 76.7 77.5 77.7 
β [°] 108.5 108.8 108.0 108.1 
resolution [Å] a 25-1.54 
(1.60-1.54) 
50-1.63 
(1.69-1.63) 
25-2.04 (2.11-
2.04) 
25-2.50 (2.59-
2.50) 
unique 
reflections 
63317 (6150) 52267 
(4962) 
27153 (2560) 15342 (1440) 
redundancy 3.9 (3.3) 3.7 (3.6) 4.0 (3.0) 3.4 (2.2) 
completeness 
[%] 
97.9 (95.5) 96.9 (92.9) 96.4 (91.7) 98.6 (92.8) 
average I/σ(I) 25.7 (3.0) 23.3 (3.7) 21.7 (3.4) 16.1 (2.7) 
Rmerge [%] 5.3 (44.2) 4.9 (28.5) 5.9 (31.9) 9.2 (31.0) 
     
Refinement     
no. of 
reflections 
61084 (4969) 51321 
(4368) 
24893 (1289) 13598 (779) 
Rwork (95% of 
data) 
0.182 (0.248) 0.175 
(0.231) 
0.178 (0.213) 0.187 (0.221) 
Rfree (5 % of 
data) 
0.225 (0.283) 0.215 
(0.264) 
0.246 (0.265) 0.259 (0.338) 
r.m.s.d. bonds 
[Å] 
0.020 0.020 0.020 0.020 
r.m.s.d. angles 
[°] 
2.0 2.0 2.0 2.1 
dihedral angles     
most favored 
[%] 
91.7 90.4 91.2 89.2 
allowed [%] 7.6 9.0 8.1 10.6 
disallowed  [%] 0.7 0.5 0.7 0.2 
no. of non-H 
atoms / average 
B [Å2 ] 
    
protein 3508 / 21.5 3504 /22.1 3504 / 25.2 3486 / 25.5 
water 529 / 34.6 503 / 34.6 308 / 33.9 153 / 29.7 
ligand 15 / 25.9 25 / 29.6 28 / 45.1 39 / 61.7 
aValues in the parentheses are for the highest resolution shells. 
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Table 3.2 Data collection and refinement statistics for SaPcrB crystals 
 SaPcrB-PEG SaPcrB-SO4 
PDB code 3W01 3W02 
Data collection   
space group P212121 P41212 
unit-cell   
a [Å] 65.3 141.6 
b [Å] 80.8 141.6 
c [Å] 85.8 107.9 
β [°] 90.0 90.0 
resolution [Å] a 25-1.54 (1.60-
1.54) 
25-2.98 (3.09-
2.98) 
unique reflections 66696 (5680) 22795 (1987) 
redundancy 7.6 (5.2) 6.4 (4.8) 
completeness [%] 98.1 (84.5) 98.4 (87.4) 
average I/σ(I) 44.8 (3.7) 31.9 (2.5) 
Rmerge [%] 5.3 (44.9) 5.6 (47.9) 
   
Refinement   
no. of reflections 64963 (4884) 20225 (1050) 
Rwork (95% of 
data) 
0.184 (0.261) 0.194 (0.258) 
Rfree (5 % of data) 0.218 (0.280) 0.234 (0.268) 
r.m.s.d. bonds [Å] 0.020 0.020 
r.m.s.d. angles [°] 1.9 2.0 
dihedral angles   
most favored [%] 93.0 83.3 
allowed [%] 6.8 16.6 
disallowed  [%] 0.2 0 
no. of non-H 
atoms / average B 
[Å2 ] 
  
protein 3584 / 23.4 3573 / 34.8 
water 608 / 37.8 94 / 31.0 
ligand 10 / 44.7 20 / 70.5 
aValues in the parentheses are for the highest resolution shells. 
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Table 3.3 Scorecons results for BsPcrB, SaPcrB and AfGGGPS 
 
a Protein used as input to JPRED3[10]; alignment used as input to the SCORECONS[8] 
program. 
b Conservation scores from SCORECONS. 1.000 means the most highly conserved 
residue. 
c SCORECONS residue number in query protein sequence. 
d Vertical columns show residues of interest for a given protein. 16/25 proteins shown 
annotate as HepGPS (=PcrB or PcrB-like). 
e as d but here 17/25 proteins annotate as GGGPS. The Trp residues (shown in yellow) 
are involved in chain-length regulation in GGGPS: not found (typically WA) in 
HepGPS. Note that residues at the 103/104 positions in GGGPS are essentially random, 
since they are not involved in chain length regulation. 
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Figure 3.1  Electron density maps of the bound ligands. The Fo-Fc maps without 
including any ligand in the refinement steps are contoured at 1.0 and 2.0 σ level, and are 
colored in green and red. a) G1P in BsPcrB-G1P; b) FsPP in BsPcrB-FsPP; c) G1P and 
FsPP in BsPcrB-G1P/FsPP; d) PEG in SaPcrB-PEG; e) SO4 ion in SaPcrB-SO4. 
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Figure 3.2 Dimer interface of PcrB. a) IVIZ dimer interface; b) Dimer interface of 
BsPcrB; c) predicted dimer interface proposed by Peterhoff et al[6]. 
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Figure 3.3 Structure comparison of monomers of BsPcrB, SaPcrB, AfGGGPS and 
SgMoeO5. a) Superimposition of BsPcrB (in green) and SaPcrB (in cyan). b) 
Superimposition of BsPcrB (in green) and AfGGGS (in yellow). c) Superimposition of 
BsPcrB (in green) and SgMoeO5 (in orange). 
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Figure 3.4 PcrB complex structures. a) BsPcrB-FsPP-G1P structure is shown with FsPP 
and G1P as a stick model and BsPcrB as a cartoon. The ligands in BsPcrB-FsPP and 
BsPcrB-G1P are very close to those in BsPcrB-FsPP-G1P. b) SaPcrB-PEG structure is 
shown with PEG as a stick model and SaPcrB as a cartoon. c) Detailed ligand-protein 
interactions in BsPcrB-G1P. d) Detailed ligand-protein interactions in BsPcrB-FsPP.  
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Figure 3.5 Superimposition of SO4 ion and G1P from SaPcrB-SO4 and BsPcrB-
G1P/FsPP, respectively. The SO4 ion is colored in black, and the G1P and FsPP are 
colored in cyan. 
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Figure 3.6 Most conserved residues in BsPcrB shown together with FsPP and G1P, as 
well as a catalytic Mg2+ from a superimposed MoeO5 structure. 
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Figure 3.7 Hydrophobic tunnel in BsPcrB with TLC product distribution results. a) 
HepPP model (in yellow) by Guldan et al. is shown superimposed on FsPP (in cyan) from 
the BsPcrB-FsPP-G1P structure and PEG (in green) from the SaPcrB-PEG structure. b) 
TLC product distribution results for SaPcrB mutants with different chain length prenyl 
diphosphate substrates. 
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Figure 3.8 TLC product distribution results for SaPcrB mutants. 
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Figure 3.9 Structures of BsPcrB ligands (FsPP and G1P, in cyan), GGGPS ligands (G1P, 
in magenta) and MoeO5 ligands (FGP, in yellow). Conserved residues are also shown as 
stick models for the proteins. 
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Chapter 4: Structure and Function of Bacillus subtilis YisP: Biofilm 
Production and Virulence in Bacteria 
 
4.1 Notes and Acknowledgements 
Y. Hu, Y. Zheng, C.-H. Huang and X. Feng cloned, expressed and purified BsYisP 
proteins. Y. Hu, Y. Zheng, H.-C. Chan, T.-P. Ko and R.-T. Guo carried out 
crystallization, data collection, structure determination and refinement. X. Feng and S. 
Bogue characterized the enzymatic activity of BsYisP and carried out mutagenesis study. 
K. Li performed Bacillus subtilis pigment extraction experiments. W. Zhu performed 
DSC experiments. D. López and R. Kolter performed biofilm formation experiments. M. 
Nega and F. Götz provided staphyloxanthin. C. Nakano and T. Hoshino provided 
tuberculosinol. X. Feng, E. Oldfield and R.-T. Guo analyzed the data. I sincerely thank 
all the colleagues and collaborators.  
This work was supported by grants from the National High Technology Research and 
Development Program of China (2012AA022200), the National Basic Research Program 
of China (2011CBA00805 and 2011CB710800) and the United States Public Health 
Service (National Institutes of Health grant GM065307). X.F. was supported by a Pre-
doctoral Fellowship from the American Heart Association, Midwest Affiliate 
(13PRE14510056). The synchrotron data collection was conducted on beamline BL13B1 
of the NSRRC (National Synchrotron Radiation Research Center, Taiwan) supported by 
the National Science Council (NSC), Taiwan. 
This chapter was reproduced in part with permission from X. Feng, Y. Hu, Y. Zheng, 
W. Zhu, K. Li, C.-H. Huang, T.-P. Ko, F. Ren, H.-C. Chan, M. Nega, S. Bogue, D. 
López, R. Kolter, F. Götz, C. Nakano, T. Hoshino, R.-T. Guo, E. Oldfield, paper 
submitted to J. Am. Chem. Soc. on March 10, 2014. X. Feng, Y. Hu and Y. Zheng 
contributed equally to this work. 
 
4.2 Introduction 
There is currently considerable interest in the structure, function and inhibition of the 
enzymes involved in isoprenoid biosynthesis since in many instances these enzymes 
represent new drug targets.1,2 One such class of molecules catalyze the “head-to-head” 
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condensation of isoprenoid diphosphates to form tri- terpenes such as squalene and 
dehydrosqualene, reactions catalyzed by squalene synthase (SQS) and dehydrosqualene 
synthase (CrtM), respectively (Scheme 4.1a). Inhibition of squalene synthase is of 
interest in the context of the development of cholesterol-lowering drugs3, and of 
antiparasitics targeting ergosterol biosynthesis4.  
CrtM is of interest since in Staphylococcus aureus it is involved in formation of 
staphyloxanthin5,6, a virulence factor for the organism providing resistance to killing from 
host reactive oxygen species.7,8 Interestingly, staphyloxanthin levels are elevated in S. 
aureus biofilms9 and the CrtM inhibitor zaragozic acid inhibits biofilm formation, 
apparently by affecting lipid micro-domain (“raft”) organization.10 An effect of 
staphyloxanthin on bacterial membrane structure (order) has also been shown via 
fluorescence depolarization (of a 1,3,5-diphenylhexatriene probe) and cells with more 
rigid or ordered membranes appear to be more resistant to host defense peptides as well 
as to the antibiotic daptomycin.11  
The CrtM gene (or a close analog) is also present in Bacillus subtilis (yisP) and it was 
recently reported10 that YisP was involved in biofilm and pigment formation and had 
squalene synthase activity which was blocked by zaragozic acid (Scheme 4.1b), a known 
SQS/CrtM inhibitor.12 Zaragozic acid was also reported to block biofilm formation in S. 
aureus, but had no effect on cell growth in either organism. To learn more about the 
structure and function of YisP, we have solved its structure by x-ray crystallography and 
determined the structure of the product formed by YisP from farnesyl diphosphate (FPP). 
The results obtained lead to a proposed mechanism of action model for both this product 
as well as the CrtM product, staphyloxanthin, on biofilm formation and with 
staphyloxanthin, on its role as a virulence factor. 
With YisP, there are four main questions of interest: What is its structure? What does 
it make? How does it function?  How do its products work? Protein structure predictions 
of YisP using the Phyre2 program13 indicate an -fold1 structure akin to that seen in SQS 
and CrtM, making it likely that the BsYisP product would be a C30 isoprenoid. The 
BsYisP sequence is shown in the alignment in Figure 4.1a and it appears on initial 
inspection to contain the two expected “Asp-rich” (DDXXD/E and DXXXD) domains14 
found in many prenyl transferases, with DDLDE and a DLGTD motifs being found in the 
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sequence. However, as can be seen in the alignment of YisP, CrtM and SQS in Figure 
4.1a, there are some puzzling features. First, the region of the first aspartate-rich motif 
(FARM) seen in the alignments of many prenyl synthases, in YisP, is aspartate-poor: 
AASAD. Second, the DDLDE motif is actually between the FARM and second aspartate- 
rich motif (SARM) found in HsSQS and CrtM. These results suggest either that YisP 
might not make squalene (or dehydrosqualene), or that it has an unusual fold that is not 
suggested by the sequence alignments.  
 
4.3 Results and Discussions 
In recent work15 we cloned, expressed, purified, crystallized and obtained diffraction 
data on B. subtilis YisP. The crystals belonged to the orthorhombic space group P212121 
with unit-cell parameters a = 43.966 Å, b = 77.576 Å, c = 91.378 Å, and diffracted to 
1.92 Å. Here, we solved the YisP structure by using two Hg-containing derivatives 
(BsYisP has only 23% sequence identity with S. aureus CrtM and the structure could not 
be solved by molecular replacement). Full data collection and refinement statistics are 
given in Table 4.1. We obtained one structure (Figures 4.1b,c) with a  molecule bound in 
the  active site region, most likely a polyethylene glycol (PEG) from the crystallization 
buffer and not a bound substrate or product isoprenoid since as can be seen in the electron 
density (Figure 4.2), there are no methyl substituents and no planar groups. Numerous 
attempts to obtain structures of YisP with FPP, S-thiolo-FPP, S-thiolo-GGPP or farnesol 
ligands were unsuccessful. 
The YisP molecule does indeed adopt the ε-fold expected, Figure 4.1b, but the 
DDLDE motif is located some 20 Å outside of the active site region found in the CrtM 
and SQS structures (Figures 4.1d, e) while the AASAD motif superimposes on the first 
Asp-rich motif found in these proteins, as does the second Asp-rich motif. A possible 
implication of these results is that YisP might not function as a head-to-head prenyl 
synthase since the first Asp residue found in CrtM and SQS is actually an alanine in YisP, 
and the DDLDE motif is well outside the active site region found in CrtM and SQS. 
There is one main pocket in the YisP structure with a total volume (calculated using 
PocketFinder16) of ~1000 Å3. This pocket (Figure 4.1b, black mesh) is occupied by the 
single PEG molecule, Figure 4.1c, which is located in the S2 (prenyl donor) site 
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identified previously in CrtM and SQS17. Notably, this pocket volume is much smaller 
than that found in CrtM protein structures (~1600 Å3, on average, Figure 4.1d) or HsSQS 
(~1900 Å3, on average, Figure 4.1e), suggesting the possibility that the YisP product 
might be smaller than that the C30 species produced by CrtM and SQS. We next sought 
evidence for formation of head-to-head (squalene or squalene-like) condensation 
products since only phosphate release was detected in earlier work10. We carried out 
reactions with many combinations of isopentenyl diphosphate (IPP) /dimethylallyl 
diphosphate (DMAPP)/geranyl diphosphate (GPP)/FPP/geranylgeranyl diphosphate 
(GGPP) with Mg2+, in the presence or absence of NADH/NADPH, but found no evidence 
for condensation products (by radio-TLC or by GC-MS) under conditions where large 
amounts of squalene/dehydrosqualene were readily detected with SQS or CrtM. We also 
used several different detergents (Triton X-100, Tween 80 and IGEPAL), but were again 
unable to detect any squalene/dehydrosqualene (or related) products. Nevertheless, 
consistent with earlier work, we did find that there was phosphate release using the 
preferred substrate, FPP, as a substrate, but the reaction rate was only minimally affected 
by NADH or NADPH, Figure 4.3a. The product found was, however, the sesquiterpene 
alcohol farnesol, as determined by radio-TLC using [14C]-FPP (produced from GPP and 
[14C]-IPP, Figure 4.3b). Plus, FPP reacted 2.5 times faster than did GPP and 6 times 
faster than did  DMAPP, and GGPP is not active, in accord with results reported 
previously.10 These results thus indicate that YisP acts as a phosphatase, not as a terpene 
synthase.  
Site-directed mutagenesis results indicate that mutation of A54 and A55 in the 
AASAD motif to D had only a small effect on phosphate-release activity (Figure 4.4) and 
again no condensation products were formed, but D58A, D167A and D171A mutants had 
only background levels of activity, Figure 4.4, indicating a role in catalysis. These results 
are consistent with the x-ray crystallographic result that the DDLDE motif is not in the 
active site region seen in CrtM or SQS, and the 1st Asp in the DXXXD first Asp-rich 
motif found in CrtM and SQS in YisP is an Ala. Mutations at this position in SQS are 
known to abrogate activity and in SQS, this Asp is very highly conserved.18,19 Therefore, 
YisP adopts the -fold seen in SQS/CrtM but acts as a phosphatase, raising the question 
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as to the origin of the pigmentation reported earlier10 and the function of the possible 
YisP biological product, farnesol. 
B. subtilis was reported in early literature to not produce carotenoids20, consistent 
with our observation that YisP-the only “head-to-head” prenyl synthase-like enzyme in 
the B. subtilis genome, is a phosphatase. The question is, then, the nature of the 
pigmentation seen in B. subtilis under some growth conditions (light exposure). As 
shown in Figure 4.3c, the UV-VIS spectrum of a B. subtilis cell culture supernatant has 
two main features: a broad absorption centered at ~490 nm, and a three-peak absorption 
at shorter wavelengths (343, 364, 385 nm). The red pigment (λmax ~ 490 nm) has 
previously been shown to arise in B. subtilis from the complex formed between Fe3+ and 
pulcherriminic acid21-23, Scheme 4.1. The triple-peak absorption is suggestive of a 
carotenoid spectrum, but carotenoids absorb at much longer wavelengths, and the actual 
absorption wavelengths suggest a hexaene fragment, (CH=CH)6, and is known in B. 
subtilis to arise from the eponymous bacillaene and bacillaene B324-26. There is, therefore, 
no evidence for squalene/polyene-derived carotenoid pigments in B. subtilis and earlier 
conclusions to the contrary are hereby revised. We then investigated possible effects of 
the YisP product, farnesol, on B. subtilis biofilm formation. We used the ∆yisP mutant 
which is unable to form biofilms and whose construction was reported earlier10 and as 
shown in Figure 4.3d, upon addition of farnesol, biofilm formation is clearly visible (at 
right) in the ∆yisP mutant. Similar results were obtained in Msgg culture, Figure 4.5, and 
there were no effects on wild-type biofilm formation. 
The question then arises as to the likely role of farnesol in biofilm formation, and why 
zaragozic acid blocks biofilm formation- both in B. subtilis as well as in S. aureus. In 
previous work, an important role for lipid micro-domains in biofilm formation in B. 
subtilis (as well as S. aureus) was demonstrated10 so we hypothesized that farnesol might 
be involved since it is well known to affect lipid bilayer structure, as shown by both 
differential scanning calorimetry (DSC) and by solid-state 2H-NMR spectroscopy.27-30 
Specifically, farnesol shifts and broadens phospholipid gel-to-liquid crystal phase 
transitions and decreases ∆H – as does cholesterol31,32, involved in lipid micro-domain 
(or raft) structures in eukaryotes, as illustrated in Figure 4.6a with 
dipalmitoylphosphatidyl choline (DPPC). Interestingly, we find that staphyloxanthin also 
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shifts and broadens the gel-to-liquid crystal phase transition and decreases ∆H. The 
polyene in staphyloxanthin cannot be readily “bent”, due to the presence of 9 conjugated 
double bonds, in which case the molecule will act as a rigid body in the lipid bilayer (as 
does cholesterol) and its long/short side-chain structure suggests it may form an inter-
digitated structure, Figure 4.6b. This rigidifying effect of staphyloxanthin has been 
proposed (based on diphenylhexatriene fluorescence depolarization results) to “subvert 
non-oxidative host defenses mediated by cationic peptides”11 and could also block access 
of reactive oxygen species into S. aureus-an anti-virulence effect, and changes in lipid 
micro-domain structure also affect biofilm formation.10 So, both the YisP product 
farnesol, as well as staphyloxanthin, affect lipid bilayer structure – effects that would be 
inhibited by zaragozic acid, as reported earlier.10  
Staphyloxanthin is an isoprenoid virulence factor. In M. tuberculosis, tuberculosinol 
and the iso-tuberculosinols are also isoprenoid virulence factors, blocking phagolysosome 
maturation33 as well as the uptake of opsonized zymosan particles into macrophages.34 
Essentially 100% of the tuberculosinol/iso-tuberculosinols in M. tuberculosis reside 
within the cell membrane35, which strongly suggests that their role as virulence factors 
could also be to modulate lipid membrane structure. The chemical structures of the 
tuberculosinols suggest that they might have cholesterol-like effects on bilayer domain 
structure and indeed, as shown in Figure 4.6b, we do see that tuberculosinol again shifts 
and broadens the gel-to-liquid crystal phase transition (of DPPC) in a similar manner to 
that seen with farnesol, cholesterol and staphyloxanthin. 
 
4.4 Conclusions 
We report the first x-ray structure of the YisP protein, from Bacillus subtilis. The fold 
is very similar to that seen in S. aureus CrtM or human SQS. There are two “DDXXD”-
like motifs, but one is ~20Å from the active site seen in SQS and CrtM. We find that 
YisP is a phosphatase, producing farnesol (from farnesyl diphosphate). The pigments and 
polyene formed by B. subtilis are not poly-isoprenoids, rather, the ferric iron complex of 
pulcherriminic acid, and bacillaenes. We also show that farnesol, the S. aureus virulence 
factor staphyloxanthin, as well as the M. tuberculosis tuberculosinol virulence factor, all 
affect lipid bilayer structure, shifting and broadening the main gel-to-liquid crystal phase 
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transition temperature, a cholesterol-like effect that we propose could play a role in their 
activity, in cells: modulating micro-domain (raft) structure. 
 
4.5 Materials and Methods 
Crystallization and Data Collection for BsYisP  
BsYisP was cloned, expressed and purified as described previously.15 Wild-type 
BsYisP was first crystallized by using the Grid Screen PEG/LiCl screen kit (Hampton 
Research, Aliso Viejo, CA) and the sitting-drop vapor diffusion method. The reservoir 
solution (No. C6) contained 1 M LiCl, 0.1 M Bicine, pH 9.0 and 20% w/v polyethylene 
glycol 6000. Better crystals were obtained by optimizing the crystallization condition to 1 
M LiCl, 0.1 M Bicine, pH 9.0 and 18-20% w/v polyethylene glycol 6000 at 25 oC for 2 
days. To prepare heavy-atom derivatives, the Hg-containing reagents of Heavy Atom 
Screen Hg (Hampton Research) were used. Cryoprotectant solutions (1 M LiCl, 0.1 M 
Bicine, pH 9.0, 20% w/v polyethylene glycol 6000 and 10% glycerol) containing 2 mM 
Hg derivatives were used for soaking the wild-type crystals for about 1 hour. 
 The X-ray diffraction datasets were collected at beam lines BL13B1 of the 
National Synchrotron Radiation Research Center (NSRRC, Hsinhu, Taiwan) and 
processed by using the HKL2000 program36. Prior to structural refinement, 5 % randomly 
selected reflections were set aside for calculating Rfree as a monitor. The MIR datasets of 
mercury-containing derivatives were collected at a wavelength of 0.97622 Å (BL13B1). 
Combination of datasets from different Hg-derivative crystals with the “native” dataset 
from the wild-type crystal using SOLVE and RESOLVE37 improved the figure of merit 
(FOM) values from 0.24 to 0.41, the Z-scores from 8.56 to 18.51, and the number of 
auto-built amino acid residues up to 177. The best results were obtained using mersalyl 
acid and mercuric acetate derivatives. Statistics of the two Hg-derivative data sets and the 
MIR phasing are summarized in Table 4.1. The model and map were further improved by 
computational refinement using Refmac538. Finally, a complete model ( but missing 
residues 57-81) with most side-chains was built using ARP/wARP39. Structural 
refinements were carried out using CNS40 and Coot41. Data collection and refinement 
statistics are summarized in Table 4.1. All diagrams of protein structures were prepared 
by using PyMol (http://www.pymol.org/). 
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Mutant Preparation 
The mutants were prepared with a BsYisP–pET32 Xa/LIC vector as the template and 
forward primers 5'-GTATTGTCGTTTTGCCACACGGATGCCAGTGCAGACGAAAA 
GGTA-3' for A54D, 5'-TGCCACACGGCGGCCAGTGCAGCGGAAAAGGTATTGCC 
CGCATTT' for D58A, 5'-CAGCTGGTTCGCTTCTTAAGTGCGCTTGGCACAGATC 
AGCAAAAA-3' for D167A, 5'-TTCTTAAGTGATCTTGGCACAGCGCAGCAAAAA 
AACCGCATTCCC-3' for D171A, and 5'-TTGTCGTTTTGCCACACGGATGATAGTG 
CAGACGAAAAGGTATTG-3' for A54D/A55D, were used. The recombinant plasmids 
were transformed to E. coli BL21 trxB (DE3) and proteins were expressed and purified as 
for wild type BsYisP15. 
 
BsYisP/Human SQS Activity Assay and Product Determination 
The reaction of FPP catalyzed by BsYisP was monitored at 360 nm by using a 
continuous spectrophotometric assay42 for diphosphate release in 96-well plates with 200 
μL reaction mixtures containing 400 μM 7-methyl-6-thioguanosine (MESG), 0.1 U/mL 
purine nucleoside phosphorylase (PNP) and inorganic diphosphatase, 100 μM FPP, 100 
μM NADPH or NADH, 25 mM Tris·HCl (pH 7.5), 0.2% detergent, and 1 mM MgCl2. 
Detergents tested were Triton X-100, Tween 80 and IGEPAL, with IGEPAL giving the 
best activity. 
Product identification of BsYisP and human SQS was carried out using radio-TLC 
with 14C-labeled FPP as substrate. 14C-labeled FPP was synthesized by adding 100 μM 
GPP, 100 μM [14C]IPP and 1 μM HsFPPS to 50 μL of 25 mM Tris·HCl (pH 7.5), 0.2% 
detergent, and 1 mM MgCl2, and reacting at 37°C for 30 min. BsYisP or human SQS 
(and 100 μM NADPH) was then added, and the resulting reaction mixture incubated at 
37°C for 2 hours. The reactions were then terminated by adding 500 μL NaCl saturated 
H2O, and the product extracted with n-hexane. The n-hexane solution was then 
concentrated and spotted onto a C18 reverse phase TLC plate (Whatman Ltd, Maidstone, 
UK). The TLC plate was developed with acetone/methanol (2:8) and the product 
distribution analyzed by using a Storm 840 PhosphorImager and Quantity One (Bio-Rad, 
Hercules, CA).  
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Biofilm Formation Assay 
Biofilm formation assays in B. subtilis were carried out as described previously10. 
 
Differential Scanning Calorimetry (DSC) 
1,2-dihexadecanoyl-sn-glycerophosphoryl choline (DPPC) was obtained from Avanti 
Polar Lipids (Alabama, USA). Farnesol and cholesterol were obtained from Sigma-
Aldrich (Missouri, USA). Tuberculosinol and staphyloxanthin were made as previously 
described.6,43 20 mol % farnesol, cholesterol, tuberculosinol or staphyloxanthin were co-
dissolved with DPPC in chloroform. The organic solvent was removed under a stream of 
dry nitrogen and the remaining solvent traces removed in vacuo, overnight. 10 μL 
deionized water was added and the mixtures homogenized by hand. Weighed amounts of 
the mixtures were then sealed into solid sample inserts (stainless steel tubes). The DSC 
experiments were performed on a Microcal VP-DSC instrument. The scans covered the 
range from 10 to 60 °C at a scan rate of 90 °C/h. The DSC thermograms were analyzed 
using Origin 7.1 (Massachusetts, USA). Water vs. water scans were used for baseline 
correction.  
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4.6 Schemes, Charts, Tables and Figures 
Scheme 4.1 Structures of compounds of interest. a) Biosynthesis of virulence factors, 
sterols and farnesol. b)  A biofilm inhibitor and some B. subtilis pigments. 
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Table 4.1 Data collection and refinement statistics of BsYisP and Hg crystals. All 
positive reflections were used in the refinement. Values in parentheses are for the 
outermost resolution shells. 
Name BsYisP C13H17HgNO6 Hg(OOCCH3)2 
Data collection 
Wavelength (Å) 
 
0.97622 
 
0.97622 
 
0.97622 
Resolution (Å) 25.00-1.92 (1.99-1.92) 
25.00-2.34 
(2.42-2.34) 
25.00-2.92 
(3.02-2.92) 
Space group P212121 P212121 P212121 
Unit-cell    
a (Å) 43.97 43.95 44.38 
b (Å) 77.58 77.58 77.60 
c (Å) 91.38 91.46 91.55 
No. of measured 
reflections 
166594 
(16746) 84584 (8379) 45046 (4428) 
No. of unique 
reflections 
24603 
(2427) 13675 (1330) 7249 (692) 
Completeness (%) 99.9 (100.0) 99.9 (99.9) 100.0 (100.0) 
Rmerge (%) [a] 6.9 (48.2) 10.5 (49.6) 11.8 (47.6) 
Mean I/σ(I) 32.7 (5.5) 19.6 (4.5) 16.8 (4.8) 
Redundancy 6.8 (6.9) 6.2 (6.3) 6.2 (6.4) 
Phasing    
No. of sites 3 
Z-score  18.51  
Figure of merit  0.74  
Refinement    
No. reflections used 23740 (2178)   
Rwork (%) 21.1 (26.2)   
Rfree (%) 23.3 (30.7)   
Geometry deviations    
Bond lengths (Å) 0.013   
Bond angles (o) 2.08   
No. of atoms / Mean 
B-values (Å2)    
Protein atoms 2007 / 29.3   
Water molecules 219 / 39.0   
PEG molecules 9 / 48.1   
Ramachandran plot (%)    
Most favored 97.1   
Additionally allowed 2.5   
Disallowed 0.4   
PDB ID code 3WE9   
[a] Rmerge = ∑hkl∑i|Ii(hkl)-<I(hkl)>| / ∑hkl∑iIi(hkl). 
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Figure 4.1 YisP, CrtM and SQS sequences and structures. a) ClustalW alignment of 
BsYisP,  SaCrtM and HsSQS showing 1st and 2nd Asp-rich domains and the DDLDE 
domain in BsYisP.  b) X-ray structure of YisP (PDB ID code 3WE9) showing the 
conserved SARM, the DDLED domain, and the ~1000 Å
3
 pocket.  c) As b) but zoomed 
in to show the PEG ligand in S2, the  SARM, and the location of the missing FARM. 
Structure superimposed on the S-thiolo-farnesyl diphosphates bound to CrtM (PDB ID 
code 2ZCP) showing PEG in the S2 site. d) CrtM liganded structure (PDB ID code 3ADZ) 
showing (canonical) ~ 1600 Å
3
 pocket for S1+S2. The FARM and SARM are both 
conserved in the head-to-head prenyl synthases. e) Human SQS structure (PDB ID code 
3LEE) showing larger pocket volume (~1900 Å
3
 on average) due to the need for NADPH 
to bind in SQS but not in CrtM. The smaller pocket in YisP suggests a smaller product 
than that produced by CrtM or SQS. 
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Figure 4.2 Electron density (contoured at 2σ (red) and 1σ (grey)) for the ligand in the 
YisP S2 site, modeled as a PEG fragment. 
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Figure 4.3 YisP activity, pigment formation and biofilm formation in B. subtilis. a) 
NADPH or NADH shows little effect on Kcat of YisP. b) FPP forms farnesol with YisP but 
squalene with SQS+NADPH. The top trace is the control (14C-FPP, no YisP). c) UV-VIS 
of B. subtilis. Cells were grown in the dark and produced a dark pink pigment 
(pulcherrimin); the 3-band peak is from the bacillaenes. d) Biofilm formation requires the 
production of an extracellular matrix, which is correlated with the amount of wrinkles 
observed in the colony10. Treatment with 500 µM farnesol restores biofilm formation in 
the ΔyisP mutant. 
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Figure 4.4 Relative actives of wild-type and mutant YisP. 
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Figure 4.5 Effects of treatment with 500 µM farnesol on biofilm formation in wild-type B. 
subtilis and ΔyisP mutant in Msgg culture. 
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Figure 4.6 Effects of virulence factors/raft modulators on lipid bilayers. a) DSC 
thermograms for 1,2-dipalmitoyl-sn-glycerophosphatidyl choline (DPPC, structure shown 
in b)) in the presence of 20 mole% additive. The additives were farnesol (FOH); 
staphyloxanthin (STX); tuberculosinol (TOH) and cholesterol (CHOL). The numbers in 
parentheses are the ∆H for the main gel-to-liquid crystal phase transitions (in kcal/mole). 
Samples were in excess water. b) Cartoon showing proposed organization of virulence 
factors/raft modulators in membranes. The black stick DPPC structure serves as a “ruler” 
for CHOL, FOH, STX and TOH. The orange cartoons represent ordered or disordered 
DPPC molecules. 
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Chapter 5: Structure, function and inhibition of ent-kaurene synthase 
from Bradyrhizobium japonicum  
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5.2 Introduction 
Terpenes (or terpenoids) represent the largest class of small molecules on the planet1 
and most are synthesized by enzymes that contain one or more of six main types of fold: 
, , , ,  and 2. About 20% of terpenes are diterpenes, molecules that contain a core 
of 20 carbon atoms, and most of these are made by plants and fungi. Diterpenes have, 
however, also been found in bacteria3-11, and these compounds are of interest since some 
have activity as anti-infective and anti-cancer drug leads, virulence factors, as well as 
plant growth hormones. There are two different classes of terpene cyclases, Class I and 
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Class II, defined by the amino acid motifs that are essential for catalysis12-14. Class I 
cyclases contain two conserved motifs, DDXXD, and (N,D)DXX(S,T,G)XXX(E,D) 
(hereafter referred to as NTE), in which the boldface residues generally bind to the three 
Mg2+ that facilitate ionization of an isoprenoid diphosphate group, generating a reactive 
carbocation intermediate. In contrast, Class II cyclases typically contain only a DXDD 
motif in which the boldface aspartic acid protonates an isoprenoid double bond or an 
oxirane to, once again, generate a reactive carbocation intermediate. In some cases, both 
Class I as well as Class II motifs are present and these molecules are bi-functional or in 
one reported case, tri-functional15.  For example, abietadiene synthase from Abies grandis 
(AgABS) is bi-functional and converts geranylgeranyl diphosphate (GGPP) to copalyl 
diphosphate (CPP) in a Class II reaction and then CPP is converted to abietadiene in a 
Class I reaction, Scheme 5.1a. Similarly, the moss Physcomitrella patens utilizes a 
trifunctional CPPS/KS (PpCPPS/KS) to convert GGPP to ent-CPP in a Class II reaction 
and then to ent-kaur-16-ene (20%) and 16-hydroxy-ent-kaurane (80%) via a Class I 
reaction with, in the case of kauranol, carbocation quenching16, Scheme 5.1b.     
Here, we report the first structure of a bacterial diterpene cyclase, ent-kaurene 
synthase from the soil bacterium Bradyrhizobium japonicum (BjKS; gene # blr2150)4. 
BjKS catalyzes the cyclization of ent-CPP which is produced by ent-copalyl diphosphate 
synthase (ent-CPPS; blr2149) from GGPP (Scheme 5.1c), and one possible mechanism of 
action 17 for the ent-kaurene synthase reactions is shown in Scheme 5.1c. The ent-KS 
reactions proceed via initial diphosphate loss from ent-CPP (catalyzed by Mg2+) and 
cyclization to form the 8-carbonium ion, the pimaren-8-yl cation, which then undergoes 
secondary cyclization with Wagner-Meerwein migration of C-12 to C-16 to form the ent-
kauran-16-yl cation. This cation can then loose a proton to form ent-kaur-16-ene, or in P. 
patens the ent-kauranyl cation can also be quenched by a water molecule to form 16--
hydroxy-ent-kaurane, Scheme 5.1b16.  
Structurally, Class I proteins contain a catalytic  domain while Class II proteins 
contain two domains, , and with bi-functional species such as abietadiene synthase, all 
three domains () are present18. In previous work19 it was proposed that these  
domain proteins might have arisen by the fusion of the genes of + proteins in 
ancestral, perhaps soil dwelling, bacteria, so determining the structures of bacterial  
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(and ) cyclases is of interest not only from a mechanism of action perspective, but also 
from an evolutionary one. Is, for example, the structure of BjKS (a predicted19  domain 
protein) most similar to that of the  domains seen in modern plant terpene cyclases? To 
investigate this and other questions we determined the structure of BjKS in the presence 
of its ent-CPP substrate, as well as apo- and inhibitor-bound structures, and we used site-
directed mutagenesis to probe its catalytic activity. In addition, we compared the BjKS 
structure with the structures of diverse other terpene cyclases, and synthases. 
 
5.3 Results and Discussions 
Structure of apo-ent-kaurene synthase 
We cloned, expressed and purified ent-kaurene synthase from B. japonicum then 
crystallized it and solved its structure using a SeMet-labeled protein (Supplementary 
Table 5.1). Full data acquisition and crystallographic details for two native (i.e. apo) 
crystals are given in Table 5.2. The final models were refined at a resolution of 1.9 – 2.0 
Å using the data obtained with two apo crystals. A stereo-view of the apo-1 structure 
(PDB ID code 4KT9) is shown in Figure 5.1a from which it can be seen that the structure 
is mainly composed of twelve  helices, Figure 5.1a, as found in many other terpene 
cyclases as well as synthases such as farnesyl diphosphate synthase. There is, however, a 
missing loop (residues ~211-221) in both chains C and D in the apo-1 structure (PDB ID 
4KT9) and this loop is also missing (that is, disordered) in all other structures (Table 5.3). 
BjKS crystallizes as a dimer (Figure 5.1b) and there is a cluster of side-chains of 
hydrophobic residues (M235, Y232 and F240, cyan spheres) from both chains at the 
"bottom" of the dimer interface that form a hydrophobic core, Figure 5.1b, with a buried 
surface area of ~1000 Å3. Further up (green spheres), the E244 side-chain interacts with 
the N-terminus of the helix starting at Y155 in the other subunit in the dimer, and salt 
bridges exist between the E157(A) and R250(B) side-chains, and between E157(B) and 
R250(A) (purple spheres). Using gel filtration, we find (Figure 5.1c and Figure 5.2) that 
BjKS also exists as a dimer in solution (Mr = 68.4 kDa; 61.9 kDa calc. from the 
sequence).  However, as can be seen in Figure 5.1b the predicted catalytic motifs 
(DDXXD and NTE) are ~20Å from the dimer interface and unlike some other prenyl 
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synthases20, there is no chain inter-digitation. This suggests that the presence of a dimer is 
not essential for catalysis. 
The BjKS structure is generally similar to that found in the  domains (c19) of 
terpene cyclases from bacteria, fungi as well as plants: some representative examples are 
shown in Figure 5.3. Figure 5.3a shows a superposition between BjKS (red; PDB ID 
4KT9) and pentalenene synthase (green; PDB ID 1HM7)21 from the bacterium 
Streptomyces UC5319 where there is a 2.7 Å C rmsd (root mean square deviation) 
between C atoms over 204 residues; Figure 5.3b shows a superposition with 1, 8-
cineole synthase (PDB ID 2J5C) from the flowering plant Salvia fruticosa (Sf-CinS1, 
blue), an “” domain protein19 in which the C rmsd in 2.4 Å over 195 residues, while 
Figure 5.3c shows a superposition with abietadiene synthase from the gymnosperm Abies 
grandis (AgABS; PDB ID 3S9V), an  domain protein18.  As can be seen in Figure 
5.3c, the BjKS structure (red) is similar to the  domain of AgABS (yellow) and has a 
2.6 Å C rmsd over 224 residues. The C rmsd value for the three other  domain 
proteins: taxadiene synthase (PDB ID 3P5R); ent-copalyl diphosphate synthase (PDB ID 
3PYB) and bisabolene synthase (PDB ID 3SDV) are 2.6 Å/201 residues, 3.5 Å/169 
residues, and 2.9 Å/226 residues for taxadiene synthase, ent-copalyl diphosphate synthase 
and (the sesquiterpene) bisabolene synthase, respectively, and the close similarity to 
abietadiene synthase may be due to the fact that AgABS produces a C20 species that is 
structurally more similar to ent-kaurene than are the products of the three other  
proteins. Remarkably, however, there is only a 17% sequence identity between BjKS and 
AgABS.  
We next sought to see how the BjKS structure compared with a broad range of , , , 
δ, ε, and ζ-fold proteins using their Q-scores 22. The Q-score attempts to minimize 
difficulties than may arise by use of e.g. just C rmsd values because the numbers of 
aligned residues as well as the numbers of residues in target and query proteins, and their 
structural deviations, are all important. The Q-score is defined as 22,23: 
ܳ ൌ	 ௔ܰ௟௚௡ ∗ ௔ܰ௟௚௡ሺ1 ൅ ሺݎ݉ݏ݀ ܴ଴⁄ ሻଶሻ ∗ ௥ܰ௘௦ଵ ∗ ௥ܰ௘௦ଶ 
where Nalgn is the number of aligned residues, determined here by using the secondary 
structure matching (SSM) program22; Nres1 and Nres2 are the total numbers of residues in 
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the two aligned proteins whose structures are to be compared, rmsd in the C root mean 
square deviation of the C residues in the two proteins, and Ro is an empirical parameter, 
set (by the program) to 3 Å22,23. The Q-score is 1 if two structures are identical but 
obviously decreases as the rmsd increases, Nalgn decreases, or if Nres1 or Nres2 are much 
larger than Nalgn. As expected, Figure 5.4, the use of complete structures results in a 
clustering of BjKS with other bacterial and fungal cyclases (which are all small proteins, 
as is BjKS), while the plant  or  proteins are very distant because of the large Nres 
in these systems. Q-scores for Figure 5.4 are shown in Table 5.4. However, since we are 
primarily interested in structural comparisons between  domains, it is logical to 
construct a second tree using just the highly -helical domain-containing proteins to see 
where BjKS clusters: the  and  head-to-tail prenyl diphosphate synthases such as 
FPPS; the head-to-head synthases (which have an -fold) squalene and dehydrosqualene 
synthase (which utilize cyclic transition states/reactive intermediates), and the bacterial, 
fungal and plant cyclases (that contain ,  or  domains). As shown in Figure 5.3d, 
using this subset of structures we see that BjKS now clusters with the plant  domains, 
while the other bacterial and fungal cyclases are separate, as are other  proteins such as 
farnesyl diphosphate synthase and geranylgeranyl diphosphate synthase. Q-scores for 
Figure 5.3d are shown in Table 5.5. Interestingly, using the Q-score metric the  
domain protein ent-CPPS from the plant Arabidopsis thaliana is rather distant from the 
other  domain plant proteins (based on just the  domain structure) due, we propose, 
to the fact that the  domain in ent-CPPS is not catalytic in this protein, so its structure is 
less likely to be conserved.  
There are, therefore, several pieces of information that are consistent with (or in 
support of) the + gene fusion hypothesis19 for the origin of modern plant terpene 
cyclases. The BjKS structure most closely resembles the  domain structures in plant 
terpene cyclases, and as noted previously4,19, in B. japonicum, the ent-CPPS and ent-KS 
genes overlap by a single nucleotide4, a potential route to bifunctional species. Moreover, 
in primitive plants such as mosses and liverworts16 there are bi-functional ent-KS 
enzymes, again suggesting a gene fusion origin for more modern plant terpene cyclases. 
 
 99
Mutagenesis and A Substrate-bound Structure 
We next sought to investigate the catalytic mechanism of BjKS. We first used the 
BjKS and AgABS sequences to generate a set of 354 homologous proteins (using the 
JPRED3 program24) which was then used as input to the SCORECONS server25 which 
ranks residues in terms of their essential nature: 1.000 is essential, 0 is non-essential. The 
top 10 most essential residues are shown in Figure 5.5a. We show in Figure 5.5b the 
locations of the top 10 non-structural (i.e. not Gly or Pro) residues that are most 
conserved, from which it can be seen that D75, D76, D79, R204 and D208 (red spheres) 
are close to the catalytic site seen in other terpene cyclases while the other residues are 
more distant. We elected to mutate D75, D79 and R204 (to D75A, D75C, D79C and 
R204A) to test whether they were essential for catalysis since D75 and D79 are part of 
the highly conserved (Figure 5.6) DDXXD motif found in many Class I cyclases, and 
R204 is also highly conserved, as part of the RLX(N,D)DXX(S,TR,G)XXX(E,D) 
(Figure 5.6) motif. As can be seen in Figure 5.5c and Table 5.6, mutation of D75, D79 or 
R204 (to Ala or Cys) greatly reduced activity to, on average, 1.7 ± 1.6%. Clearly, these 
residues are likely to be part of the active site, raising the question: where does the ent-
CPP substrate bind?  
In other articles26 there have been reports of the binding of CPP isosteres (containing 
nitrogen) to terpene cyclases, but there have been no reports of ent-CPP (or CPP) bound 
to a terpene cyclase (or synthase). We therefore next determined the structure of the 
substrate ent-CPP (Scheme 5.1) bound to the BjKS D75C mutant. Full data acquisition 
and crystallographic details are given in Table 5.2. Electron densities are in Figure 5.7a, b. 
The BjKS structure with ent-CPP bound is shown in Figures 5.8a and 4b, and in Figure 
5.8c, the BjKS-ent CPP structure is shown superimposed on that of 2-F-geranylgeranyl 
diphosphate (FGG) bound to the  domain of taxadiene synthase (TXS; PDB ID 3P5R). 
The 3 Mg2+ are from the taxadiene synthase structure. Four Asp residues (D75, D76, D79 
and D208) in BjKS are located in very similar positions to the corresponding Asp 
residues in TXS (C rmsd of 0.8 Å for these 4 Asp residues), and are expected to 
coordinate to a [Mg2+]3 cluster which was, however, not observed in our BjKS crystals. 
C rmsd for these 4 Asp residues is 0.8 Å between BjKS and AgABS (3S9V), and 0.9 Å 
between BjKS and AgBIS (3SDQ). The hydrophobic side-chain of ent-CPP is buried in a 
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hydrophobic pocket composed of I36, L68, L71, F72, Y136, I166, A167, Y168 and N207, 
shown as the orange surface in Figure 5.8c. In this conformation, the exo-methylene 
group is poised (~4 Å distant) to interact with the carbocation formed on diphosphate 
ionization, forming the first initial reactive intermediate, the pimaren-8-yl ion (Scheme 
5.1).  
 
Inhibition by a Bisphosphonate 
We also obtained the structure of an inhibitor-bound complex since such compounds 
might be of interest as leads for plant growth hormones targeting gibberellin biosynthesis. 
The structures of several bisphosphonates bound to the  domain in the  protein 
bisabolene synthase have been reported27, so we chose to investigate a bisphosphonate 
inhibitor, BPH-629 (Figure 5.9a), which has a C19O side-chain, comparable in size to the 
side-chain in ent-CPP. We found that BPH-629 inhibited BjKS with an IC50 = 9.5 µM, 
Figure 5.9a. We obtained the structure (at 2.34 Å resolution) shown in Figure 5.9b, and 
found the inhibitor occupies the same site as does ent-CPP, Figure 5.9c. Full data 
acquisition and crystallographic details are given in Table 5.2. Ligand electron densities 
are in Figure 5.7c. The bisphosphonate has hydrogen bonds from the bisphosphonate 
group to D75, S165, R204 and N207, Figure 5.9b, but just as with the ent-CPP complex, 
there is no Mg2+ observed. The lack of a [Mg2+]3 cluster in this case cannot be due to use 
of a D75C mutant (as used with the ent-CPP structure) since wild type protein was 
employed for the bisphosphonate structure. Reasons are not known. 
 
Structural Basis for Formation of ent-kaurene and kauranol 
The results described above delineate the active site in BjKS together with several 
residues (D75, D79 and R204) that are essential for catalysis. These residues comprise 
part of the conserved DDXXD/NTE motif involved in diphosphate loss to form 
carbocation transition states/reactive intermediates (Scheme 5.1c) that need to be 
protected from solvent attack in BjKS raising the question:  which residues provide this 
protection? As noted above, in the moss Physcomitrella patens, there is in fact solvent 
attack in the PpCPPS/KS protein16 which results in the formation of only 20% ent-
kaurene but 80% 16--hydroxy-ent-kaurane and Kawaide et al.15 identified a key residue 
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(A710, corresponding to L140 in BjKS) that enabled water access, quenching the 
kauranyl cation.  A comparison between the two protein structures would be of interest 
since it would help clarify the BjKS mechanism of action, but the structure of the P. 
patens protein has not been reported. There is, however, a 45% sequence identity 
between PpCPPS/KS and the A. grandis abietadiene synthase and a Phyre228 structure 
prediction of the tri-functional P. patens protein is shown in Figure 5.10a. As expected, 
the protein is predicted to have an  domain structure and the 45% conserved residues, 
shown in red in Figure 5.10a, are distributed over all three domains. When the P. patens 
active site structure prediction is superimposed on the BjKS structure (with ent-CPP from 
the BjKS structure) it is clear that BjKS contains larger residues (Y136 and L140) 
adjacent the ent-CPP ligand-binding site than those found in P. patens (Leu and Ala), and 
these larger residues (Figure 5.10b) prevent water from quenching the kauranyl cation 
(Scheme 5.1). The increase in side-chain volume is expected to be ~100 Å3 (based on 
amino-acid volumes) and such steric differences might be particularly important in the 
presence of Mg2+, because Class I terpenoid synthases typically undergo a structural 
transition from an open to a closed active-site conformation after the binding of three 
Mg2+ to the substrate’s diphosphate group, helping to protect the reactive carbocation 
intermediates from premature quenching by bulk solvent.  
In addition to Y136 and L140 protecting the carbocation intermediates, we propose 
that F72 plays a similar role since F72 is very close to the ent-CPP substrate, as shown in 
Figure 5.10c. The phenyl group in F72 could also be involved in cation-π stabilization of 
one or more reactive intermediates, a widely used catalytic strategy adopted by terpenoid 
cyclases29-31. Based on the x-ray structural results and structure comparison, it thus 
appears that Y136 and L140 can protect carbocations from solvent attack on one side of 
the intermediate(s), while F72 protects from solvent attack from the other face, as shown 
in Figure 5.10c. 
 
5.4 Conclusions 
The results presented above are of interest for several reasons.  First, we report the 
first X-ray crystallographic structure of a bacterial diterpene cyclase. The structure is 
most similar to that found in the  domain in plant diterpene cyclases. Second, we report 
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the first structure of a diterpene diphosphate (ent-copalyl diphosphate) bound to a 
diterpene cyclase. The structure is of interest because it helps define the diterpene cyclase 
substrate-binding site using a native substrate, and the diphosphate group is found to be 
close to three residues that we find (using site-directed mutagenesis) are essential for 
catalysis. Third, we obtained the structure of an aromatic bisphosphonate inhibitor. The 
bisphosphonate binds in or very close to the ent-CPP diphosphate-binding site, while the 
dibenzofuran side-chain occupies basically the same site as does the 
decahydronaphthalene ring in ent-CPP: such compounds might find use as plant growth 
regulators. Fourth, the results of computational modeling of a P. patens tri-functional KS 
together with a comparison with the BjKS structure provide strong evidence in support of 
the roles of L140, Y136 and F72, in carbocation protection in the bacterial enzyme. 
 
5.5 Materials and Methods 
Cloning, expression and purification of ent-kaurene synthase from Bradyrhizobium 
japonicum (BjKS).   
The gene encoding KS from Bradyrhizobium japonicum USDA 110 DNA was 
amplified by polymerase chain reaction (PCR) with a forward primer 5'-
GGTATTGAGGGTCGCGAGAATCTTTATTTTCAGGGCGCTGGTGCTGGTGCTAT
GAT-3' and a reverse primer 5'-AGAGGAGAGTTAGAGCCGTTATTAGGCCGGCGC 
GCGCTGGCCTCCCCTCAC-3', then cloned into the pET32 Xa/LIC vector. A tobacco 
etch virus protease (TEV protease) cutting sequence (ENLYFQG) was added before the 
KS gene. The recombinant plasmids were transformed to E. coli BL21trxB (DE3) and 
protein was induced with 0.5 mM isopropyl-thiogalactopyranoside (IPTG) at 16 °C for 
20 hours. The cell lysate was harvested by centrifugation and the resulting supernatant 
loaded onto a Ni-NTA column equilibrated in buffer containing 25 mM Tris, pH 7.5, 150 
mM NaCl, and 20 mM imidazole. His-tagged KS was eluted using an imidazole gradient 
(20-250 mM). The protein solution was then dialyzed against a buffer containing 25 mM 
Tris, pH 7.5, 150 mM NaCl and subjected to TEV protease digestion, to remove the 
thioredoxin and His tags. The mixture was then again passed through a Ni-NTA column 
and untagged KS eluted with a 5 mM imidazole-containing buffer. Protein was further 
purified by FPLC using a DEAE column, 25 mM Tris, pH 8.0, and a 0-500 mM NaCl 
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gradient. The protein eluted at ~170 mM NaCl and was then concentrated to 10 mg/mL in 
25 mM Tris, pH 7.5, and 150 mM NaCl. Expression of selenomethionine-substituted 
(SeMet) KS was carried out as described previously32 and the purification procedures 
were the same as those used for the wild-type enzyme, but the DEAE column was 
omitted. The protein was then concentrated to 6.4 mg/mL in 25 mM Tris, pH 7.5 and 150 
mM NaCl. 
 
Gel filtration chromatography 
Gel filtration chromatography with a HiLoad 16/60 Superdex 200 column (column 
volume Vc= 121 mL) was used to determine the oligomeric state of wild type BjKS. The 
column was washed with 2 column volumes of 25 mM Tris, pH 7.5, and 150 mM NaCl 
buffer to equilibrate before sample injection, and 1 mL Blue Dextran 2000 (3 mg/mL) 
was injected to obtain the column void volume (Vo = 48 mL). A LMW calibration kit was 
used (GE Healthcare, 28-4038-41) which contains aprotinin (6.5 kDa), ribonuclease A 
(13.7 kDa), carbonic anhydrase (29 kDa), ovalbumin (43 kDa), conalbumin (75 kDa) and 
Blue Dextran 2000 (>2000 kDa) was used. The above protein standards and BjKS were 
all dissolved in 25 mM Tris, pH 7.5, and 150 mM NaCl, at 1 mg/mL for ovalbumin and 
0.8 mg/mL for the others. 1 mL of sample was loaded to the column at a flow rate of 0.5 
mL/min. Kav is calculated as a function of elution volume Ve, column volume Vc and 
column void volume Vo as shown below. 
Kୟ୴ ൌ Vୣ െ V୭Vୡ െ V୭ 
A calibration curve was obtained by plotting Kav for the protein standards versus the 
logarithm of their molecular weights, and the molecular weight of BjKS was calculated to 
be 61.0 kDa using an elution volume Ve =74.7 mL and the standard curve. 
 
Crystallization, data collection and structure determination of BjKS.  
The wild-type KS protein containing 1 mM MgCl2 and 10 mM DTT was first 
crystallized by using the Index Kit (Hampton Research, Aliso Viejo, CA) and the sitting-
drop vapor diffusion method. The reservoir solution (No. 26) contained 1.1 M 
ammonium tartrate dibasic, pH 7.0. Better crystals were obtained by optimizing the 
 104
reservoir composition to 0.7 M ammonium tartrate dibasic, pH 7.0 and 2-4% w/v 
PEG4000. There are two different crystals with different space groups (P21 for Apo-1; 
P41 for Apo-2) appeared in the same crystallization condition drop. Crystallization 
conditions for SeMet KS were 0.8 M ammonium tartrate dibasic, pH 7.0. For the 
inhibitor BPH-629 complex, the KS protein solution containing 1 mM MgCl2 and 10 mM 
DTT was co-crystallized with 2.5 mM BPH-629 under the same conditions as the wild-
type protein. To obtain the KS-CPP structure, the D75C mutant crystal was prepared 
under the same crystallization conditions and then soaked with the cryoprotectant 
containing 5 mM CPP for 5 hours. All crystals were prepared at 4oC for 12 hours and 
were then transferred to room temperature. They reached suitable size for X-ray 
diffraction in 2-3 days. The cryoprotectant was 1.0 M ammonium tartrate dibasic, pH 7.0, 
10% w/v PEG4000 and 20% glycerol. 
X-ray diffraction data sets were processed by using the HKL2000 program33. Prior to 
structure refinement, 5% randomly selected reflections were set aside for calculating Rfree 
as a monitor of model quality34. The multiple-wavelength anomalous diffraction (MAD) 
data sets of the selenium-containing derivatives were collected at wavelengths of 0.9789 
Å (peak), 0.9790 Å (inflection) and 0.9611 Å (remote). Using SOLVE and RESOLVE35, 
we obtained the figure of merit (FOM) values of 0.52, Z-scores from 82.58 to 90.28, and 
up to 430 auto-built amino acid residues. The BPH-629 and CPP complex structures were 
solved by using molecular replacement. All following structural refinements were carried 
out by using Coot36 and CNS37. Data collection and refinement statistics are summarized 
in Supplementary Table 5.1, 5.3, 5.5 and 5.6. All graphics for the protein structures as 
well as electrostatic surface calculation were prepared by using the PyMOL program 
(http://www.pymol.org/). 
 
BjKS Mutant Preparation 
The KS mutants were created by using QuickChange Site-Directed Mutagenesis Kit 
with KS-pET32 Xa/LIC gene as the template. The mutagenic oligonucleotides were 5'-
GCGCTGCTGTTCTGGCTCTGCGATTGCAACGACCTTGG-3' for D75C, 5'-
CTGGCGCTGCTGTTCTGGCTCGCGGATTGCAACGACCTTGGCCTG-3' for D75A, 
5'-TGGCTCGACGATTGCAACTGCCTTGGCCTGATCTCGCC-3' for D79C, and 5'-
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CGGCTCATCTCCGCGATAGGGGCGCTGCAGAACGATCTGCATGGA-3' for 
R204A. The constructs were transformed to E. coli BL21trxB (DE3) for protein 
expression. The expression and purification of mutants were the same as those used for 
the wild-type enzyme. 
 
SCORECONS Analysis of BJKS 
A library of 10 KS sequence homologs and 342 AgABS sequence homologs were 
obtained by using the Jpred 3 server24. Multiple sequence alignment was carried out with 
the ClustalW2 server38. The aligned sequence library was then uploaded to the 
SCORECONS server25 to calculate the conservation scores for each residue of BjKS. 
 
Activity Assay for BjKS Proteins 
BjKS activity assays were carried out as described previously39. Briefly, the 
dephosphorylation and cyclization of ent-CPP catalyzed by BjKS was monitored by 
using a continuous spectrophotometric assay for diphosphate release40 in 96 well plates 
with 200 µL reaction mixtures containing 400 µM 2-amino-6-mercapto-7-methylpurine 
(MESG), 50 µM ent-CPP, 25 mM Tris-HCl (pH 7.5), 0.01% Triton X-100 and 1 mM 
MgCl2. The IC50 values were obtained by fitting the inhibition data to a rectangular 
hyperbolic dose-response function in OriginPro 8.5 (OriginLab, Northampton, MA). 
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5.6 Schemes, Charts, Tables and Figures 
Scheme 5.1 Reactions catalyzed by AgABS, PpCPPS/KS and BjKS, and proposed 
catalytic mechanism for the BjKS reaction. (a) Abietadiene is formed from GGPP by a 
bifunctional terpene cyclase abietadiene synthase, in Abies grandis.  (b) Formation of ent-
CPP, ent-kaurene and kauranol from GGPP catalyzed by Physcomitrella patens 
CPPS/KS. (c) Two proteins are used to produce ent-kaurene in the soil bacterium, 
Bradyrhizodium japonicum. Proposed carbocation intermediates are shown. 
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Table 5.1 Summary of Se-Met KS protein data collection and phasing statistics. Values in 
parentheses are for the outermost resolution shells. 
Name  Se-Met KS  
 peak inflection remote 
Data collection    
Wavelength (Å) 0.9789 0.9790 0.9611 
Resolution (Å) 25.0 - 2.7  (2.8 - 2.7) 
25.0 - 2.7  
(2.8 - 2.7) 
25.0 - 2.7  
(2.8 - 2.7) 
Space group P41 P41 P41 
Unit-cell a, b, c 
(Å) 
66.0, 66.0, 
136.3 
66.0, 66.0, 
136.3 
66.0, 66.0 
136.3 
No. of unique 
reflections 31514 (3170) 31480 (3200) 31668 (3210) 
Redundancy 4.1 (4.2) 4.2 (4.1) 4.1 (4.0) 
Completeness (%) 99.6 (100.0) 99.8 (100.0) 99.8 (99.9) 
Mean I/(I) 16.1 (3.9) 15.6 (3.8) 14.3 (3.0) 
Rmerge (%) 9.7 (38.8) 10.1 (39.8) 10.9 (48.4) 
Phasing    
No. of sites 10 
Z-score 82.58 - 90.28 
Figure of merit 0.52 
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Table 5.2 Data collection and refinement statistics for KS crystals. Values in parentheses 
are for the outermost resolution shells. 
 Apo-1 Apo-2 D75C+CPP WT+ BPH- 629 
Data collection     
Resolution (Å) 25.0 – 2.0 (2.1 – 2.0) 
25.0 - 1.9 
(2.0 - 1.9) 
25.0 – 1.8 
(1.9 – 1.8) 
25.0 - 2.0 
(2.1 - 2.0) 
Space group P21 P41 P41 P41 
Unit-cell a, b, c 
(Å) 
 
β (°) 
65.0, 130.1, 
66.4 
95.6 
65.8, 65.8, 
135.2 
 
65.8, 65.8, 
136.2 
 
65.8, 65.8, 
135.7 
 
No. of Unique 
reflections 
72234 
(6728) 
43643 
(4390) 
51614 
(5123) 
38697 
(3888) 
Redundancy 3.0 (2.7) 5.6 (5.8) 4.9 (4.4) 3.4 (3.3) 
Completeness 
(%) 98.0 (91.5) 99.8 (100.0) 99.5 (98.9) 99.4 (100.0) 
Mean I/σ(I) 18.1 (3.1) 42.9 (4.5) 42.3 (3.6) 29.2 (3.3) 
Rmerge (%) 5.6 (20.7) 5.9 (46.7) 3.5 (37.2) 3.9 (46.3) 
Refinement     
No. of chain(s) 4 2 2 2 
No. of reflections 70362 (6036) 
42679 
(3982) 
50837 
(3310) 
37623 
(3499) 
Rwork (95% of 
data) 
0.176 
(0.230) 
0.191 
(0.251) 0.206 (0.28) 
0.197 
(0.279) 
Rfree (5% of data) 
0.220 
(0.276) 
0.232 
(0.287) 
0.239 
(0.309) 
0.235 
(0.291) 
R.m.s.d. bonds 
(Å) 0.020 0.010 0.008 0.010 
R.m.s.d. angles 
(°) 1.7 1.3 1.2 1.3 
Ramachandran 
plot (%)     
Most favored 
(%) 97.3 96.7 97.5 96.6 
Allowed (%) 2.2 2.8 2.1 2.8 
Disallowed (%) 0.5 0.5 0.4 0.6 
Mean B (Å2) 
/atoms 27.8 / 9417 39.3 / 4926 42.2 / 4540 48.0 / 4692 
PDB ID code 4KT9 3W3F 3WBV 3W3H 
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Table 5.3 Summary of observed protein residues and ligands  
Name PDB 
ID 
Chain ID Residues Ligands 
Apo-1 4KT9 A 3-290 - 
  B 3-281 - 
  C 2-290 (213-220 are missing) - 
  D 2-280 (211-222 are missing) - 
Apo-2 3W3F A 1-281 (211-221 are missing) - 
  B 3-290 (211-222 are missing) - 
D75C + 
CPP 
3WBV A 1-275 (212-220 are missing) CPP 
  B 2-277 (147-150 and 211-221 are 
missing) 
CPP 
WT + 
BPH-
629 
3W3H A 1-281 (211-221 are missing) 629 
  B 3-290 (149-150 and 211-222 are 
missing) 
- 
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Table 5.4 Q-score table for homology tree shown in Figure 5.4. 
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Table 5.5 Q-score table for homology tree shown in Figure 5.3d. 
 
  
 112
Table 5.6. Activities of BjKS wild-type and mutant proteins using ent-CPP substrate and 
a PPi-release assay. 
protein specific activity, nmol min−1mg−1 
WT 64±2.9 
D75C 2.4±0.32 
D75A 0.81±0.18 
D79C 0.20±0.86 
R204A 0.77±0.51 
CPP only -0.32±0.21 
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Figure 5.1 Structure of BjKS. (a) Stereoview of (Apo-1) BjKS (PDB ID code 4KT9) 
showing highly -helical structure. (b) Dimer interface in B. japonicum ent-kaurene 
synthase. There is a cluster of side-chains of hydrophobic residues (M235, Y232 and 
F240, cyan spheres) from both chains at the "bottom" of the interface which form a 
hydrophobic core; further up, the E244 side-chain interacts with the N-terminus of the 
helix starting at Y155 in the other subunit (green spheres), and salt bridges exist between 
the E157(A) and R250(B) side-chains, and between E157(B) and R250(A) (purple 
spheres).  The two predicted catalytic motifs (DDXXD and NTE) are also shown with 
spheres (red and orange, respectively). (c) Gel filtration results show BjKS exists as a 
dimer in solution (Mr = 61.0 kDa). 
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Figure 5.2 Gel filtration calibration. (a) Protein makers used. (b) Calibration curve for 
protein markers. 
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Figure 5.3 Superimposition of the overall structure of BjKS (red; PDB ID 4KT9) with 
other terpene cyclases. (a) Superimposition of BjKS with pentalenene synthase from 
Streptomyces UC5319 which has only an  domain (green; 1HM7); (b) Superimposition 
of BjKS with 1, 8-cineole synthase from Salvia fruticosa which has two domains (; 
blue; 2J5C); (c) Superimposition of BjKS with abietadiene synthase from Abies grandis 
which has three domains (; yellow; 3S9V); d) Homology tree (based on  domain Q-
scores22, 23) showing clustering of BjKS with the plant  domain proteins. Note that the  
domains in the terpene cyclase (top) are distant from the  domains in the synthases such 
as FPPS, and have previously been referred to as “c” domains19. 
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Figure 5.4 Homology tree of α, β, γ, δ, ε, and ζ-fold proteins obtained by using the Q-
score program. 
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Figure 5.5 Essential residues and catalysis. (a) SCORECONS25 results. (b) Highly 
conserved residues; residues in red were mutated to A or C. (c) Activity of mutant 
proteins. 
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Figure 5.6 Sequence alignment of Bradyrhizobium japonicum ent-kaurene synthase 
(BjKS) with abietadiene synthase (AgABS), taxadiene synthase (TbTXS), 1, 8-cineole 
synthase (SfCinS1), ent-kaurene synthase (AtKS) and (+)-bornyl diphosphate synthase 
(BPPS). Sequence alignments were performed with ClustalX41. Strictly conserved 
residues are highlighted in red, conservatively substituted residues are boxed. The 
conserved DDXXD and RL(N,D)DXX(S,T,G)XXX(E,D) motifs are boxed. Mg2+-
binding residues are indicated by an asterisk. The Figure was produced by using 
ESPript42. 
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Figure 5.7 Ligand electron density results contoured at 1σ. (a) ent-CPP in chain A (PDB 
ID 3WBV). (b) ent-CPP in chain B (PDB ID 3WBV). (c) BPH-629 (PDB ID 3W3H).  
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Figure 5.8 BjKS ent-CPPS structure. (a) Stereo-view of dimer structure (PDB ID 3WBV). 
(b) Rotated stereo-view of structure of BjKS in a). (c) Stereo-view of structure of ent-
CPP (yellow) bound to BjKS superimposed on 2-F-geranylgeranyl diphosphate (FGG, 
cyan) bound to the  domain of taxadiene synthase (TXS) (PDB ID code 3P5R). The 
highly conserved “DDXXD” Asps of BjKS are indicated. The 3 Mg2+ are from the TXS 
structure and are not observed in BjKS. The hydrophobic side-chain of ent-CPP is buried 
in a hydrophobic pocket composed of I36, L68, L71, F72, Y136, Y168 and N207, shown 
as an orange surface. 
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Figure 5.9 BPH-629 inhibition and inhibitor-bound structure. (a) IC50 for BPH-629 
inhibition. (b) Possible hydrogen bonds form between BPH-629 and BjKS activity site 
residues in BPH-629/BjKS structure (PDB ID 3W3H). (c) Stereo view of structure of 
BjKS bound to the bisphosphonate inhibitor BPH-629 (pink) superimposed on ent-CPP 
(yellow).  
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Figure 5.10 (a) Phyre228 homology model of Physcomitrella patens ent-CPPS/ent-KS 
showing the 45% of residues (in red) that are identical to those in abietadiene synthase, 
uniformly dispersed over the , β and γ domains. (b) ent-CPP (yellow) bound to BjKS 
(PDB ID 3WBV) superimposed on corresponding P. patens KS residues. The large BjKS 
residues adjacent ent-CPP are in cyan. The smaller P. patens residues are in magenta and 
permit water quenching of the kauranyl-16-yl cation. (c) Stereo view of residues that are 
proposed to stabilize the carbocation intermediates in BjKS (PDB ID 3WBV). Distances 
between ent-CPP C12 and Y136 O, ent-CPP C12 and L140 Cδ, ent-CPP C8 and F72 C 
are 5.1 Å, 6.2 Å and 4.2 Å, respectively. 
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Chapter 6: Structure and Inhibition of Tuberculosinol Synthase and 
Decaprenyl Diphosphate Synthase from Mycobacterium tuberculosis 
 
6.1 Notes and Acknowledgements 
H.-C Chan, X. Feng, C.-H. Huang, Y. Hu, W. Liu and Y. Zheng, cloned, expressed 
and purified Rv3378c proteins. X. Feng and S. Bogue cloned, expressed and purified 
Rv2361c proteins. H.-C Chan, T.-P. Ko and R.-T. Guo carried out crystallization, data 
collection, structure determination and refinement of Rv3378c proteins. X. Feng and S. 
Bogue carried out crystallization, data collection, structure determination and refinement 
of Rv3378c proteins. X. Feng and S. Bogue characterized the enzymatic activity of 
Rv3378c and Rv2361c, and carried out mutagenesis study. X. Feng and S. Bogue carried 
out ITC studies. C. Nakano and T. Hoshino provide tuberculosinyl diphosphate, and 
measured Rv3378c mutants activities. X. Feng, P.-H. Liang, A. H.-J. Wang, E. Oldfield 
and R.-T. Guo analyzed the data. I sincerely thank all the colleagues and collaborators.  
This work was supported by the National Basic Research Program of China 
(2011CB710800 and 2011CBA00805), the Tianjin Municipal Science and Technology 
Commission (12ZCZDSY12500), and the United States Public Health Service (National 
Institutes of Health grant GM065307). X.F. was supported by a Pre-doctoral Fellowship 
from the American Heart Association, Midwest Affiliate (13PRE14510056). We thank 
the National Synchrotron Radiation Research Center of Taiwan for beamtime allocation 
and data collection assistance. 
This chapter was reproduced in part with permission from H.-C Chan, X. Feng, T.-P. 
Ko, C.-H. Huang, Y. Hu, Y. Zheng, S. Bogue, C. Nakano, T. Hoshino, L. Zhang, P. Lv, 
W. Liu, D. C. Crick, P.-H. Liang, A. H.-J. Wang, E. Oldfield, R.-T. Guo. J. Am. Chem. 
Soc., 2014, 136 (7), pp 2892–2896. Copyright © 2014 American Chemical Society. H.-C 
Chan, X. Feng. and T.-P. Ko contributed equally to this work. 
 
6.2 Introduction 
Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, is a major source 
of morbidity and mortality worldwide with almost two million deaths annually, and the 
rise in multi-drug resistant and extensively drug resistant strains is of great concern1-3. 
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There is thus considerable interest in the development of new drugs and new leads such 
as SQ109 and TMC-2074, which target cell wall biosynthesis and ATP formation, 
respectively, and also in the development of new therapeutic approaches that target 
virulence factor (VF) formation. VFs are by definition not essential for bacterial growth 
outside of host cells, but are involved in processes such as invasion, persistence, lysis, 
and evasion of innate immune system responses, as found for example with 
staphyloxanthin in Staphylococcus aureus5,6. This carotenoid VF provides resistance to 
host-based reactive oxygen species-based killing, and inhibiting staphyloxanthin 
biosynthesis is a novel route to anti-infective therapy6. In M. tuberculosis, one class of 
VFs are the tuberculosinols7-9: tuberculosinol (TOH) and the (±) iso-tuberculosinols (iso-
TOH), Scheme 6.1. The latter were first isolated from a marine sponge from the Nosy Be 
island, Madagascar, and are thus also known as (±) nosyberkols10 (Scheme 6.1). The 
original structures proposed7-10 have been confirmed by total synthesis11,12. The 
biosynthesis of the tuberculosinols is catalyzed by two enzymes: Rv3377c, tuberculosinyl 
(halama-5,13-dien-15-yl) diphosphate synthase, and Rv3378c, tuberculosinol/(±)iso-
tuberculosinol synthase (Scheme 6.1). Both proteins are essential for bacterial survival 
inside macrophages13 with the tuberculosinols inhibiting phagolysosome maturation, as 
well as macrophage phagocytosis8,9,14. The three-dimensional structures of both Rv3377c 
and Rv3378c are thus of considerable interest since they are thought to represent novel 
anti-virulence therapeutic targets for tuberculosis15. Rv3377c is a diterpene cyclase that 
converts geranylgeranyl diphosphate (GGPP) into tuberculosinyl diphosphate (TPP), 
while Rv3378c converts TPP into TOH and the iso-TOHs, acting as a 
phosphatase/isomerase, as shown in Scheme 6.1. Here, we report the structure of 
Rv3378c both in its apo form as well as bound to its TPP substrate, and to a 
bisphosphonate inhibitor, BPH-629 (Scheme 6.1). We also report the structure of the M. 
tuberculosis cis-decaprenyl diphosphate synthase (Rv2361c) with another 
bisphosphonate inhibitor, BPH-640 (Scheme 6.1) which has a similar structure and 
inhibitor-binding mode as found with Rv3378c-the phosphatase. 
 
6.3 Results and Discussions 
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We cloned, expressed, purified, crystallized and solved the Rv3378c protein structure 
by using multiple isomorphous replacement in a tetragonal crystal, then by molecular 
replacement in a monoclinic crystal, Table 6.1 and Table 6.2 in the Supporting 
Information. Residues 46-50 could not be modeled in one crystal, or 82-90 in another, 
due to lattice packing and disorder. Nevertheless, the two structures superimposed well 
and a continuous protein dimer model could be constructed (Figure 6.1a and Figure 6.2a 
in the Supporting Information), consistent with the observation that Rv3378c also exists 
as a dimer in solution9. The overall fold shows close structural homology to that seen in 
M. tuberculosis cis-farnesyl diphosphate synthase (Rv1086; 2.33 Å Cα rmsd over 201 
residues; PDB ID code 2VFW), M. tuberculosis decaprenyl diphosphate synthase 
(Rv2361; 2.23 Å over 195 residues; PDB ID code 2VG4), and E. coli undecaprenyl 
diphosphate synthase (UPPS; 2.44 Å over 203 residues; PDB ID code 1JP3), although 
there is only ~12-14% sequence identity with these proteins.  
 There is a potential substrate-binding site at the “top” of the structure (Figure 6.1b 
and Figure 6.2b in the Supporting Information) but this cavity16 is smaller  than that seen 
in UPPS, which makes the C55 diphosphate used in bacterial cell wall biosynthesis (~600 
Å3  versus ~900-1700 Å3, depending on the presence or absence of bound ligands, Figure 
6.1c and Figure 6.2c in the Supporting Information). The Rv3378c protein thus adopts the 
same fold as seen in cis-head-to-tail prenyl diphosphate synthases and this structure is 
unprecedented in enzymes involved in terpene biosynthesis. Attempts to obtain the 
structures of Rv3378c in the presence of its substrate TPP (by soaking and co-
crystallization) were unsuccessful, so we next used computational docking17 to see how 
TPP might bind to Rv3378c, to guide the design of inactive mutants. The docking results 
obtained (Figure 6.3 in the Supporting Information) indicated that the fused rings bound 
to a large hydrophobic pocket while the allyl side-chain docked close to Y51 and Y90, 
suggesting that these residues might be involved in activating water molecules for 
nucleophilic attack at C13 and/or C15.  To test this hypothesis, we made a Y51F mutant 
and a Y51F/Y90F double mutant finding ~13% and ~5% wild type activity, respectively, 
Figure 6.4 in the Supporting Information. We then obtained structures of both mutants in 
the presence of TPP.  In both, TPP occupies the polar-top/nonpolar-bottom cavity shown 
in Figure 6.1b (Figure 6.5a and Figure 6.6a in the Supporting Information), with more 
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complete electron densities found in the Y51F/Y90F double mutant (Figure 6.5b and 
Figure 6.6b in the Supporting Information, yellow) than in the Y51F single mutant 
(Figure 6.7 in the Supporting Information), due presumably to more residual activity in 
the Y51F single mutant crystal. A similar though not identical hydrophobic pocket is 
occupied by S-thiolo farnesyl diphosphate (FSPP) when bound to UPPS, as illustrated in 
the superposition shown in Figure 6.5b (FSPP in cyan). In UPPS, the two most conserved 
residues from a SCORECONS18 analysis (which ranks residues in terms of their 
conserved nature) are D26 and R30 (Table 6.3 in the Supporting Information) which in 
UPPS are involved in binding to Mg2+ and farnesyl diphosphate (FPP), facilitating 
diphosphate activation and removal. These two residues correspond to D34 and R38 in 
Rv3378c (a 2.2 Å C rmsd), and based on this homology to UPPS, might therefore be 
expected to play a role in diphosphate activation and release. 
  To examine the role of these residues in catalysis, we mutated both to Ala.  Activity 
results for these mutants together with Y51F, Y51F/Y90F, Y90F as well as the single 
DDXXD mutants reported previously9 are shown in Figures 6.5c and 6.5d as well as in 
Figure 6.4 in the Supporting Information. Whereas the WT protein has 41% iso-TOH 
activity and 59% TOH activity, D34A, R38A and Y90F mutants produced on average ~1% 
iso-TOH but on average 49% TOH, meaning that D34, R38 and Y90 are all important for 
iso-TOH production, a more SN1-like reaction that requires D34 and R38 to facilitate 
dephosphorylation and carbocation formation, Figure 6.5d.  On the other hand, Y51 is 
involved in both TOH and iso-TOH formation since production of both is reduced in the 
Y51F mutant.  In addition, the Y51F/Y90F double mutant has essentially no activity. 
Taken together, these results indicate that D34, R38, Y51 and Y90 are involved in 13R, 
13S-iso-tuberculosinol formation (Figure 6.5d), while it is primarily Y51 that is involved 
in TOH formation, since both Y51F and the Y51F/Y90F mutants produce little or no 
TOH, as illustrated in Figure 6.5c. The single DDXXD mutants have activities ranging 
from 32% to 53%, whereas the double Asp mutants are not active9.  This suggests that the 
DDXXD motif, although not immediately adjacent to the active site, may also play a role 
in catalysis, perhaps by helping remove the Mg2+-PPi formed, since 2 Asps would be 
required for Mg2+ chelation. 
 
 
 
129
Since Rv3378c is a target for anti-virulence therapeutics, we were also interested in 
discovering Rv3378c inhibitors. We identified BPH-629 as one such inhibitor having a 
Kd~560 nM, Figure 6.8a in the Supporting Information. Co-crystallization of Rv3378c 
and BPH-629 in the presence of Mg2+ yielded a complex structure containing two 
molecules of BPH-629 and one Mg2+ per Rv3378c monomer. Figure 6.9a and Figure 
6.10a in the Supporting Information show the location of the inhibitor binding sites in the 
dimer. In each monomer, there are two bound BPH-629 molecules: one (BPH-629 (1)) is 
buried in the substrate binding site (Figure 6.9b and Figure 6.10b in the Supporting 
Information), the other (BPH-629 (2)) is located in the dimer interface, between a helix of 
monomer A and a loop of monomer B (Figures 6.9a and 6.9b). In both cases, the 
bisphosphonate head-groups chelate to a single Mg2+, that is, in turn, coordinated to the 
side-chain of D34, Figure 6.9c and Figure 6.10c in the Supporting Information. Moreover, 
as shown in Figure 6.9c, the side-chain in BPH-629(1) makes extensive nonpolar 
interactions with numerous hydrophobic amino acids in the TPP binding site, and BPH-
629(2) is sandwiched between H41 of monomer A and Y259, S260 and L267 of 
monomer B. 
Interestingly, a similar surface binding site is also found in M. tuberculosis DPPS 
(Rv2361c) in complex with another bisphosphonate, BPH-640, a close analog of BPH-
629, as shown in Figures 6.9d to 6.9f and Figures 6.11a to 6.11c in the Supporting 
Information. BPH-640 is a 410 nM inhibitor of DPPS (Figure 6.8b in the Supporting 
Information), but lacks the O and CH2 groups present in BPH-629. Full crystallographic 
data acquisition and structure refinement details for this structure are shown in Table 6.1 
and electron density results are in Figure 6.9f. As with BPH-629 (2), BPH-640 also 
occupies a dimer interface binding site, sandwiched between G77, N78, G79, R80, T83, 
R89 and R127 of monomer A and R292 and F293 of monomer B (Figure 6.9f). 
The results shown in Figure 6.9 indicate that the terpene synthase (phosphatase) 
Rv3378c and the cis-prenyl transferase DPPS both have the same overall fold. They both 
also exist as dimers in solution9,19 as well as in crystals (Figure 6.9a and 3d), and both are 
inhibited by structurally similar bisphosphonates, with closely-related binding modes 
(Figure 6.9b and 3e) and similar affinities. These observations lead to the idea that in the 
future it may be possible to design multi-target inhibitors20-22 that target both enzymes in 
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TB bacteria inside macrophages, inhibiting growth (DPPS/cell wall biosynthesis) as well 
as virulence (Rv3378c/tuberculosinol biosynthesis/invasion). 
 
6.4 Conclusions 
We report the first structure of any bacterial diterpene synthase, tuberculosinol/iso-
tuberculosinol synthase (Rv3378c) from M. tuberculosis, a target for anti-infective 
therapies that block virulence factor formation. This phosphatase adopts the same fold as 
found in the Z or cis-prenyltransferases.  We also obtained structures in the presence of 
TPP and with a bisphosphonate inhibitor where one molecule occupied the TPP substrate 
binding site; the second located at the dimer interface site. An unusual surface site was 
also found with a related bisphosphonate inhibitor bound to the M. tuberculosis DPPS 
(Rv2361c). In addition, we used the X-ray structures of Rv3378c together with the results 
of site-directed mutagenesis to propose mechanisms of action for formation of 
tuberculosinol and the iso-tuberculosinols in which two Tyr residues play an important 
role. Given the similarity in local and global structure between Rv3378c and Rv2361,the 
possibility exists that in the future it might be possible to develop multi-target inhibitors 
that target not only virulence, but also cell wall biosynthesis, based in part on the 
structures reported here. 
 
6.5 Materials and Methods 
Cloning, expression and purification of Rv3378c (tuberculosinol/(13R,S)iso-
tuberculosinol synthase) 
The gene encoding Rv3378c from Mycobacterium tuberculosis H37Rv was 
synthesized chemically and amplified by polymerase chain reaction (PCR) with forward 
primer 5'-GGTATTGAGGGTCGCATGAACCTGGTTAGCGAGAAAGAGTTC-3' and 
reverse primer 5'-
AGAGGAGAGTTAGAGCCATTAACCCTCAGCAAACCAGATACCGTCATG-3', 
then cloned into the pET32 Xa/LIC vector. The Rv3378c recombinant plasmids were 
transformed to E. coli BL21 (DE3) and protein expression induced with 0.4 mM 
isopropyl-thiogalactopyranoside (IPTG) at 20 °C for 24 hours. The cell lysate was 
harvested by centrifugation and the resulting supernatant loaded onto a Ni-NTA column 
 
 
 
131
equilibrated in buffer containing 25 mM Tris, pH 7.5, 150 mM NaCl, and 20 mM 
imidazole. His-tagged Rv3378c was eluted using an imidazole gradient (20-250 mM). 
The protein solution was then dialyzed against a buffer containing 25 mM Tris, pH 7.5, 
150 mM NaCl and subjected to Factor Xa digestion, to remove the thioredoxin and His 
tags. The mixture was then again passed through a Ni-NTA column, and untagged 
Rv3378c eluted with a 20 mM imidazole-containing buffer. Protein was further purified 
by FPLC using a DEAE column, 25 mM Tris, pH 7.5, and a 0-500 mM NaCl gradient. 
The protein eluted at ~225 mM NaCl and was then concentrated to 5 mg/mL in 25 mM 
Tris, pH 7.5, and 150 mM NaCl.  
 
Crystallization, data collection and structure determination of Rv3378c 
For tetragonal crystals, wild-type Rv3378c protein containing 10 mM MgCl2 and 10 
mM DTT was first crystallized by using the Crystal Screen I Kit (Hampton Research, 
Aliso Viejo, CA) and the sitting-drop vapor diffusion method. The reservoir solution (No. 
48) contained 0.1 M Tris-HCl, pH 8.5, and 2.0 M NH4H2PO4. Better crystals were 
obtained by optimizing the reservoir composition to 0.1 M Tris-HCl, pH 8.5, and 2.0-2.2 
M NH4H2PO4. All crystals were prepared at room temperature. They reached suitable 
size for X-ray diffraction in 2 days. For heavy-atom derivatives, the Hg-containing 
reagents of Heavy Atom Screen Hg (Hampton Research) were used. Cryoprotectant 
solutions (0.1 M Tris-HCl, pH 8.5, 2.2 M NH4H2PO4, 2.5 mM MgCl2 and 14% glycerol) 
containing 2 mM Hg derivatives were used in soaking the native crystals for 3 to 5 hours. 
For the BPH-629 inhibitor complex, the Rv3378c protein solution containing 2.5 mM 
MgCl2 and 10 mM DTT was co-crystallized with 2.5 mM BPH-629 under the same 
conditions as described above. To obtain the Rv3378c-TPP structure, Y51F and 
Y51F/Y90F mutant crystals were prepared under the same crystallization conditions. 
Cryoprotectant solution (0.1 M Tris-HCl, pH 8.5, 2.2 M NH4H2PO4, 2.5 mM MgCl2 and 
14% glycerol) containing 5 mM TPP was used in soaking the Y51F and Y51F/Y90F 
crystals, for 5 hours. For monoclinic native crystals, the wild-type Rv3378c protein 
containing 2.5 mM MgCl2 and 10 mM DTT was crystallized in 0.15 M DL-malic acid, 
pH 7.0 and 19% PEG 3350. The cryoprotectant was 0.15 M DL-malic acid, pH 7.0, 19% 
PEG 3350, 14% glycerol, and 2.5 mM MgCl2. 
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X-ray diffraction data sets were processed by using the HKL2000 program23. Prior to 
structure refinement, 5% randomly selected reflections were set aside for calculating Rfree 
as a monitor of model quality24. For Rv3378c, the MIR datasets of the mercury-
containing derivatives were collected at a wavelength of 0.97622 Å. Using SOLVE and 
RESOLVE25, combinations of datasets from different Hg-derivative crystals with the 
“native” dataset from the wild-type crystal improved the figure of merit (FOM) values 
from 0.52 to 0.66, the Z-scores from 10.85 to 14.1, and the number of auto-built amino 
acid residues to 181. Structures of the monoclinic crystals and the complex with BPH-
629 were solved by molecular replacement using CNS26 and a monomeric model from 
the tetragonal crystal. All subsequent structure refinements were carried out by using 
Coot27 and CNS26. Data collection and refinement statistics are summarized in Table 6.1 
and Table 6.2 in the Supporting Information. All Rv3378c crystals diffracted well to 2.1-
2.8 A with Rmerge of 0.050-0.065 (Table 6.1).  
 
Crystallization, data collection and structure determination for Rv2361c (decaprenyl 
diphosphate synthase) 
Rv2361c was expressed and purified as described previously19. For apo crystals, 
Rv2361c in 20 mM Tris (pH 7.2) containing 0.15 mM MgCl2 and 3mM DTT was 
concentrated to 10mg/mL, and screened for crystallization using the JCSG Core Suites 
(QIAGEN, Valencia, CA) and the hanging drop method. Once initial crystallization 
conditions were found, they were optimized by varying the precipitant and protein 
concentrations. Optimal crystallization conditions were found to be 0.1 M HEPES (pH 
7.5), 10% glycerol, 25% PEG 400, 7% PEG 3000, with 10 mg/mL Rv2361c. Apo 
Rv2361c crystals were then soaked in 1 mM BPH-640 in the same buffer for 5 hours to 
obtain inhibitor bound crystals. The X-ray diffraction data were indexed, integrated, and 
scaled by using the HKL2000 package23. Structures were determined by using molecular 
replacement with the program ccp4i28 with the Rv2361c apo structure (PDB code 2VG4) 
as a template. Further model building and refinement employed Coot27 and the ProDRG29 
server. All protein structure graphics were prepared by using the PyMOL program 
(http://www.pymol.org/). 
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Rv2361c Inhibition assay 
Inhibition of Rv2361c by BPH-629 and BPH-640 was evaluated using [3H]-IPP. 
Protein (0.1 µM) in 25 mM Tris buffer (pH 7.5) containing 0.01% Triton X100, 1mM 
MgCl2, 15 μM GPP and compound in a total volume of 50 μL was incubated at room 
temperature for 10 min. Then, 3.6 μL of IPP (containing 0.9 nmol cold IPP and 54.24 nCi 
[3H]-IPP) was added, and the resulting mixture incubated at 37 °C for 20 min. The 
reaction was stopped with 500 µM NaCl saturated H2O. Prenyl alcohols were then 
extracted with 500 μL butanol, and a 300-μL aliquot was transferred to a scintillation vial 
for radioactivity counting. IC50 values were obtained by using Origin software 
(OriginLab, Northampton, MA). 
 
Tuberculosinol/(13R,S) iso-tuberculosinol synthase activity assay 
A reaction mixture (2.5 mL) containing 50 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 50 
µg (44.4 µM) TPP, and 150 µg (1.76 µM) enzyme was incubated at 37°C for 14 hr. 
Reaction product analysis protocols were as described previously30. 
 
Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) measurements were carried out as described 
previously31.  
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6.6 Schemes, Charts, Tables and Figures 
Scheme 6.1 Biosynthesis of Mycobacterium tuberculosis virulence factors 
(tuberculosinols) and decaprenyl diphosphate, which is essential for cell wall 
biosynthesis. 
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Table 6.1 Data collection and refinement statistics for the Rv3378c crystals. Values in 
parentheses are for the outermost resolution shells. 
 Rv3378c Native 1 
Rv3378c 
Native 2 
Rv3378c 
Y51F 
with 
TPP 
Rv3378c 
Y51F/Y90F 
with TPP 
Rv3378c 
with 629 
Rv2361c 
with 640 
Data 
collection       
Resolution (Å) 
25.0 - 
2.3 
(2.4 - 
2.3) 
25.0 - 
2.1 
(2.2 - 
2.1) 
25.0 - 
2.7 
(2.8 - 
2.7) 
25.0 – 2.4 
(2.5 – 2.4) 
25.0 - 
2.1 
(2.2 - 
2.1) 
50-1.8 
(1.9-1.8) 
Space group P43212 C2 P43212 P43212 P43212 P212121 
Unit-cell a (Å) 105.9 208.4 106.5 106.3 105.4 77.8 
b (Å) 105.9 56.5 106.5 106.3 105.4 89.2 
c (Å) 66.6 114.4 66.4 66.8 66.0 93.9 
β (°) 90.3 90.3 90.3 90.3 90.3 90.0 
No. of Unique 
reflections 
18334 
(1794) 
77301 
(6681) 
11190 
(1049) 
15419 
(1505) 
21574 
(2082) 
58370 
(2875) 
Redundancy 7.9 (8.1) 3.9 (2.7) 7.2 (7.7) 10.3 (10.6) 10.2 (10.2) 
14.8 
(14.8) 
Completeness 
(%) 
99.9 
(100.0) 
98.1 
(85.6) 
99.3 
(96.8) 
99.7 
(100.0) 
99.3 
(97.6) 
100.0 
(100.0) 
Mean I/σ(I) 43.6 (6.5) 
19.2 
(2.3)
47.1 
(3.6) 37.2 (4.3) 
52.4 
(6.4) 
41.6 
(3.4) 
Rmerge (%) 
5.0 
(43.3) 
6.5 
(41.6) 
5.6 
(39.1) 6.5 (52.1) 
5.3 
(39.7) 
7.8 
(69.4) 
Refinement       
No. of chain(s) 1 4 1 1 1 2 
No. of 
reflections 
17676 
(1634) 
65562 
(2237) 
10756 
(946) 
14914 
(1326) 
20950 
(1961) 
55357 
(3783) 
Rwork  
(95% of data) 
0.212 
(0.250) 
0.198 
(0.222) 
0.240 
(0.342) 
0.231 
(0.293) 
0.197 
(0.242) 
0.157 
(0.227) 
Rfree 
(5% of data) 
0.239 
(0.308) 
0.239 
(0.302) 
0.261 
(0.365) 
0.260 
(0.363) 
0.237 
(0.243) 
0.198 
(0.294) 
R.m.s.d.  
bonds (Å) 0.007 0.006 0.006 0.008 0.008 0.025 
R.m.s.d. angles 
(°) 1.3 1.2 1.3 1.2 1.4 2.4 
Ramachandran 
plot (%)       
Most favored 
(%) 95.1 96.3 94.4 94.7 96.9 94.0 
Allowed (%) 4.9 3.7 5.6 5.3 3.1 5.8 
Disallowed 
(%) 0.0 0.0 0.0 0.0 0.0 0.2 
Mean B  
(Å2) /atoms 
55.2 / 
2611 
28.6 / 
10274 
89.0 / 
2520 
55.7 / 
2444 
46.8 / 
2757 
26.9 / 
4510 
PDB ID code 3VX5 3VXA 3W3I 4KT8 3VX9 4H21 
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Table 6.2 Summary of data collection and phasing statistics for Rv3378c crystals using 
Hg-derivatives. Values in parentheses are for the outer-most resolution shells. 
Crystal Native C13H17HgN
O6 
(C2H5HgO)HPO2 C(HgOOCCH3)4 C7H5ClHgO
2 
Data 
collection      
Resolution (Å) 25.0 - 2.3 (2.4 - 2.3) 
25.0 - 2.3 
(2.4 - 2.3) 
25.0 - 2.3 
(2.4 - 2.3) 
25.0 - 2.4 
(2.5 - 2.4) 
25.0 - 2.3 
(2.4 - 2.3) 
Space group P43212 P43212 P43212 P43212 P43212 
 
Unit-cell a, b, 
c (Å) 
 
105.9, 
105.9, 
66.6 
106.2, 
106.2, 
66.4 
105.9, 105.9, 
66.6 
106.4, 106.4, 
66.9 
105.8, 
105.8, 
66.3 
No. of Unique 
reflections 
17923 
(1750) 
17431 
(1707) 17392 (1687) 15685 (1542) 
17194 
(1676) 
Redundancy 13.5 (14.4) 8.9 (9.1) 10.8 (11.0) 14.0 (14.5) 14.0 (14.4) 
Completeness 
(%) 
99.0 
(100.0) 
99.9 
(100.0) 99.9 (100) 99.9 (100.0) 100.0 (99.8) 
Mean I/σ(I) 52.5 (5.3) 30.1 (5.8) 47.4 (6.4) 42.6 (8.5) 60.9 (6.1) 
Rmerge (%) 6.2 (45.7) 4.9 (47.7) 7.6 (52.1) 7.6 (47.1) 6.1 (47.8) 
Phasing      
No. of sites   6   
Z-score   14.1   
Figure of merit   0.66   
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Table 6.3 SCORECONS result for EcUPPS (and homologous/aligned residues in 
Rv3378c). 
Ranking E. coli Residue No. 
SCORECONS 
Score Residue 
E. coli UPPS 
Catalytic Role 
Aligned Residue 
in Rv3378c 
1 26 0.988 D binds Mg2+ D34 
2 30 0.984 R binds FPP R38 
3 28 0.976 N H-bond FPP O1 T36 
4 74 0.968 N binds IPP L84 
5 20 0.964 H  V28 
6 190 0.96 D  D202 
7 77 0.953 R binds FPP G87 
8 204 0.945 F  D214 
9 145 0.941 Y  F161 
10 194 0.937 R binds IPP G206 
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Figure 6.1 Structures of tuberculosinol/(13R,S)-iso-tuberculosinol synthase (Rv3378c) 
and undecaprenyl diphosphate synthase (UPPS). a) Rv3378c dimer. Both N and C 
termini of both monomers locate at the top of the dimer structure. b) Predicted Rv3378c 
ligand binding site. c) E. coli UPPS ligand binding sites (PDB ID code 2E98). 
Electrostatic surfaces are shown for Rv3378c and UPPS cavities, colored blue in positive 
region, red in negative region, calculated using PyMOL. 
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Figure 6.2 Stereo-views of the structures shown in Figure 6.1. 
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Figure 6.3 Docking pose for TPP in Rv3378c. 
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Figure 6.4 GC-MS chromatograms of mutant Rv3378c products. 
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Figure 6.5 Structures and activities of Rv3378c. a) Rv3378c Y51F/Y90F double mutant 
structure with bound TPP. b) Rv3378c/TPP (yellow, electron density contoured at 1.5σ) 
structure superimposed on S-thiolo-FSPP (cyan), bound to UPPS (PDB code 1X06). The 
Mg2+ is from the UPPS structure. Catalytic residues in Rv3378c are shown with grey 
sticks. Y51, Y90 are built based on the F51, F90 coordinates. c) Activities of wild type 
and Rv3378c mutants in TOH production and proposed catalytic mechanism for TOH 
formation. d) Activities of wild type and Rv3378c mutants in iso-TOH production and 
proposed catalytic mechanism for iso-TOH formation. 
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Figure 6.6 Stereo-views of the structures shown in Figure 6.5. 
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Figure 6.7 Stereo-view of the Rv3378c/Y51F-TPP complex structure, with TPP electron 
densities contoured at 1.5σ. 
 
  
 
 
 
145
Figure 6.8 Isothermal titration calorimetry results for binding of bisphosphonates to 
Rv3378c, DPPS and FPPS32. a) ITC results for BPH-629 binding to Rv3378c. ∆H = -6.24 
kcal/mol, ∆S = 7.68 e.u. for site 1 and ∆H = -3.82 kcal/mol, ∆S = 8.27 e.u. for site 2. b) 
ITC results for BPH-640 binding to DPPS. ∆H = -2.71 kcal/mol, ∆S = 19.29 e.u. c) 
∆S/∆H plot for bisphosphonates binding to FPPS (blue squares) with BPH-629 binding to 
Rv3378c (red squares, indicated) and BPH-640 binding to DPPS (green square, 
indicated). Binding of BPH-629 (to Rv3378c) and BPH-640 (to DPPS) are 
overwhelmingly enthalpy driven (grouped in the blue ellipse), as found with other neutral 
aromatic side-chain bearing bisphosphonates, binding to FPPS32. 
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Figure 6.9 Inhibitor bound structures of Rv3378c and DPPS. a) Dimeric Rv3378c 
structure with two bound BPH-629 molecules (shown with spheres) in each monomer (4 
BPH-629 molecules in the dimer). Because there is only one molecule in an asymmetric 
unit, the dimer is constructed from the observed monomer structure and its symmetry 
partners. b) Front view of Rv3378c dimer. Monomer A and monomer B are shown as a 
yellow cartoon and a pink surface, respectively. c) Close-up view of the structure of 
Rv3378c bound to bisphosphonate inhibitor BPH-629 (thick orange sticks, electron 
densities contoured at 1.5σ). The BPH-629 molecules both coordinate to the catalytic 
Mg2+ (green sphere), which in turn coordinates to D34 (yellow sticks) from monomer A. 
BPH-629 (1) is buried in the substrate binding site in monomer A, formed by 
hydrophobic residues shown as orange lines. The hydrophobic moiety of BPH-629 (2) is 
stabilized by Y259, S260 and L267 from monomer B (magenta lines). d) Dimeric DPPS 
structure with one bound BPH-640 molecule (shown as spheres) in each monomer. e) 
Front view of DPPS dimer. Monomer A and monomer B are shown as a green cartoon 
and a cyan surface, respectively. f) Close-up view of the structure of DPPS bound to 
bisphosphonate inhibitor BPH-640 (thick green sticks, electron densities contoured at 
1.5σ). The hydrophobic moiety of BPH-640 is stabilized by residues from monomer A 
(green lines) and monomer B (cyan lines).  
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Figure 6.10 Stereo-views of Rv3378c structures shown in Figures 6.9a to 6.9c. 
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Figure 6.11 Stereo-views of DPPS structures shown in Figures 6.9d to 6.9f. 
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Chapter 7: Multi-Target Drug Discovery for Tuberculosis and Other 
Infectious Diseases 
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TMM, trehalose monomycolate; IC50, half maximal inhibitory concentration; MIC90, 
minimum inhibitory concentration required to inhibit the growth of 90% of organisms; 
PMF, proton motive force; Mt, M. tuberculosis; Ms, M. smegmatis; Sa, S. aureus; Bs, B. 
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chromatography; THF, tetrahydrofuran.  
 
7.2 Introduction 
Antibiotic resistance is a public health problem that, arguably, has the potential to 
destroy the efficacy of all antibiotics in the next 10-20 years 1. There is, therefore, an 
urgent need for new drugs-especially ones that might be more “resistance-resistant”. One 
possible approach to achieving this goal is to move away from targeting the direct killing 
of pathogens to inhibiting their virulence, since this might lead to a decreased “life or 
death” pressure on the organism to develop resistance2. A second approach would be to 
develop more drugs that target pathogen cell membranes. An example of this type of drug 
would be the anti-fungal amphotericin3, which functions by binding to ergosterol (which 
is not present in human cell membranes). A third and well known approach is to employ 
combination therapies4, although the problems associated with finding two new drugs 
active against two new targets are clearly significant. A fourth approach is to use “multi-
targeting” or “polypharmacology” in which a single drug has more than one target5, 6. 
This could involve “series inhibition”, in which targets would be in the same metabolic 
pathway (Figure 7.1, left); “parallel inhibition”, in which the targets would be unrelated 
but an inhibitor might mimic a common substrate or would affect e.g. a membrane 
function (Figure 7.1, middle); or “network inhibition”, in which many targets in series 
and/or in parallel could be involved (Figure 7.1, right). While challenging, many drugs 
that have been effective in mono-therapy do in fact have multiple targets5 while single-
target drugs (many of which are used in treating tuberculosis) are often only effective in 
combination therapies.  
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In this work, we consider the mechanism(s) of action of the new anti-tuberculosis 
drug SQ109 (1) (Chart 7.1), currently in Phase II clinical trials7. This drug candidate 
appeared of interest since it contains a C10 isoprenoid  (geranyl) side-chain together with 
a strongly basic (ethylenediamine) fragment-a likely cationic center-suggesting that it 
might act as a carbocation isostere for a transition state/reactive intermediate in 
isoprenoid biosynthesis8 and, as with other inhibitors of isoprenoid biosynthesis, it might 
be involved in multi-targeting. 1 was developed in a synthesis/screening program9 in 
which ~64,000 ethylenediamine analogs of the anti-tuberculosis drug ethambutol (2) 
were synthesized. 1 was ~ 4x more active than any of the other leads developed, having a 
minimum inhibitory concentration (MIC) of ~0.7-1.56 µM against M. tuberculosis 
(H37Rv, Erdman and drug-resistant strains) and insights into its mode of action recently 
became available when the target of SQ109 was proposed10 to be MmpL3, a trehalose 
monomycolate (TMM) transporter, an essential membrane protein that transports TMM 
into the cell envelope. This conclusion was based on the observation that several M. 
tuberculosis mutants produced via serial passage with several 1-like inhibitors had 
mutations in the mmpL3 gene and cross-resistance to 1, although these latter effects were 
rather small10. More intriguingly, no spontaneous resistant mutants were obtained when 
using 1, suggesting the possibility of multiple targets10-11. That idea is supported by the 
observation that 1 also has activity against other bacteria, e.g. Helicobacter pylori12 as 
well as against the yeast Candida albicans13, neither of which possess the mmpL3 gene, 
suggesting again that other 1 targets are harbored by these organisms, and potentially, by 
M. tuberculosis.   
 In this work, we synthesized a series of analogs of 1 in which we varied the 
adamantane head-group and the ethylenediamine linker (varying the possible charge 
centers), Chart 7.1. All compounds were screened against a panel of bacteria (M. 
tuberculosis, M. smegmatis, Escherichia coli, Staphylococcus aureus and Bacillus 
subtilis), two yeasts (Saccharomyces cerevisiae and Candida albicans), a malaria parasite 
(Plasmodium falciparum) and a human cell line (MCF-7), to establish anti-bacterial, anti-
fungal and anti-malarial structure-activity relationships and to assess mammalian cell 
toxicity. In addition, we investigated a subset of compounds for activity against a series 
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of putative targets, isoprenoid biosynthesis enzymes, while also investigating the effects 
of these compounds on respiration, ATP synthesis, and the proton motive force (PMF).  
 
7.3 Results and Discussions 
Only one cationic center is needed for potent activity in mycobacteria. To 
investigate which features contribute to the activity of 1 against a broad range of 
organisms we synthesized 1 and the 11 analogs (3-13) shown in Chart 7.1 in which the 
ethylenediamine linker was replaced by ethanolamine, choline, propanolamine, ethylene 
glycol or glycolic amide moieties (providing linkers with potentially, 0, 1 or 2 positive 
charges), as well several “head-group” analogs in which the adamantyl group was varied. 
The geranyl “side-chain” was kept constant. Full synthesis and characterization details 
are given in the Supporting Information.  As expected, 1 had potent activity against M. 
tuberculosis with an MIC90 of ~ 0.1-0.2 µg/mL (Table 7.1). Interestingly, the N-geranyl 
ethanolamines 3 and 13 were more potent (MIC90 values as low as 0.02-0.05 µg/mL), 
indicating that the presence of two nitrogens was not essential for activity. The O-geranyl 
ethanolamine derivative (4) had similar activity to 1 (~0.2 µg/mL), Table 7.1. With the N-
geranyl ethanolamines (3, 13), activity was about 30-fold higher than with ethambutol (2). 
The ethylene glycol (5) was far less active (50 µg/mL), as was the glycolic amide 9 (12 
µg/mL). Thus, the most active compounds all contain one strongly basic nitrogen in the 
linker region, with most activity being found with the two N-geranyl ethanolamines 3 and 
13 (Table 7.1), with 3 being ~4-5 times more active than was 1.  
We then tested all 12 compounds against M. smegmatis.  The results (Table 7.1) show 
that overall activity against M. smegmatis is less than that observed against M. 
tuberculosis, as can also be seen in the “heat-map” shown in Figure 7.2A. There is, 
however, a very high correlation coefficient (R2 = 0.9, Figure 7.2B) between the pIC50 
(=-log10IC50) values for M. tuberculosis and M. smegmatis, indicating a similar 
mechanism of action, leading to our use of M. smegmatis in several mechanism of action 
studies, described below. 
 
The cationic inhibitors exhibit broad anti-bacterial, anti-fungal, and anti-
malarial activity. All 12 compounds (1,3-13) were then tested against three other 
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bacteria: S. aureus, B. subtilis and E. coli, Table 7.1. With S. aureus (the methicillin 
resistant S. aureus (MRSA) USA300 strain), 1 itself had little activity, however, the N-
geranyl ethanolamines 3, 12, 13 and the N-geranyl propanolamine 6 all had MIC90 values 
of ~8 µg/mL, while the other analogs were much less active (MIC90 > 32 µg/mL). A 
similar pattern of activity was seen against B. subtilis, with the three ethanolamines (6, 12, 
13) exhibiting the highest levels of activity. In addition, unlike with S. aureus, 1 itself had 
activity (7.6 µg/mL, Table 7.1). With E. coli, 1, the N-geranyl ethanolamine (3) and the 
N-geranyl propanolamine (6) were all quite active with IC50 values of ~2-3 µg/mL, Table 
7.1. Moreover, there was a modest correlation (R2 = 0.5) between the M. tuberculosis (or 
M. smegmatis) pMIC90 values and those found with E. coli, Figure 7.2B. These results 
again indicate that at least one basic amine-most likely a cationic center -is required for 
best activity, plus, there must be a target or targets other than MmpL3 in E. coli since the 
mmpL3 gene is absent in this organism. Bioinformatics searches did locate 
uncharacterized mmpL3-like genes in S. aureus and B. subtilis, but it remains to be seen if 
the corresponding proteins are targeted by our compounds.        
We next tested all 12 compounds (1,3-13) for activity against S. cerevisiae and C. 
albicans. As can be seen in Table 7.1 and Figure 7.2A, 1 and the ethanolamines 3, 6, 11 
and 13 had activity in the 1-3 µg/mL range with 1 and 13 being the most potent, having 
an IC50 ~ 1 µg/mL. With C. albicans, 1 was most active, followed by the ethanolamines 3 
and 13.  Not unexpectedly, there was a high correlation between the pIC50 values seen 
between S. cerevisiae and C. albicans (R2 = 0.8; Table 7.1 and Figure 7.2B). A modest 
correlation between the pIC50 values for the yeasts and E. coli or B. subtilis is also 
apparent (R = 0.6-0.7, Figure 7.2B), suggesting the possibility of target conservation 
between fungi and bacteria. Since a recognizable mmpL3 gene is absent in the fungi, 
these results again indicate an alternate target or targets. These results also lead to the 
idea that there could be additional targets in M. tuberculosis, which would help explain 
the very low MIC values observed and the inability to induce resistance via serial passage, 
as noted by Tahlan et al10., although multiple-targeting does not necessarily guarantee 
improved potency. The results with the bacteria and fungi then suggested the possibility 
that the growth of other organisms (protozoa) might also be inhibited by 1, or its analogs. 
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To evaluate anti-protozoal activity we screened all 12 compounds (1,3-13) against the 
intra-erythrocytic form of the malaria parasite, Plasmodium falciparum. As can be seen in 
Table 7.1, 1 had a ~1 µg/mL activity against P. falciparum, and the three ethanolamines 
(3, 4 and 6) also had good activity. As viewed on the heat-map (Figure 7.2A), inhibition 
of M. tuberculosis cell growth is strongest, but is followed by P. falciparum (in the intra-
erythrocytic assay) and in each case where there is activity against P. falciparum (2, 3, 4, 
6, 7), the inhibitors (Chart 7.1) are expected to carry a +1 charge, as with the best M. 
tuberculosis growth inhibitors. When compared to growth inhibition results with a human 
cell line (MCF-7; Table 7.1), we see that activity against the human cells is much weaker 
than against P. falciparum and, of course, against M. tuberculosis. We calculate a 
therapeutic index (TI), defined as: 
TI ൌ 	 ICହ଴	ሺhuman	cell	lineሻICହ଴	ሺpathogenሻ  
 of ~18 for 1 against P. falciparum and ~40 for 3, while for M. tuberculosis we find 
TI = 120 (1) and TI = 900 (3), suggesting that these and related analogs may also be 
promising P. falciparum drug leads.  We next sought to explore what the additional 
targets for these compounds might be in cells that lack MmpL3. 
Possible protein targets for SQ109 and its analogs. The general patterns of activity 
seen with the compounds described above have some similarities across the diverse 
organisms investigated in that at least one cationic center, or perhaps more importantly a 
protonatable nitrogen, is required for activity. In M. tuberculosis, 1 is thought to act by 
inhibiting MmpL3, a TMM transporter 10, although as noted by Tahlan et al., other 
targets could also be involved. This seems quite likely since in most cases these other 
organisms lack mmpL3 or a clearly identifiable ortholog, and do not utilize TMM, as is 
also the case with H. pylori12. Given that protonated geranylamines might be good 
isosteres for transition states or reactive intermediates in enzymes involved in isoprenoid 
biosynthesis (Scheme 7.1), we investigated if 1 could inhibit any of the following 
enzymes: M. tuberculosis cis-farnesyl diphosphate synthase (Rv1086);   
M. tuberculosis cis-decaprenyl diphosphate synthase (Rv2361); P. vivax 
geranylgeranyl diphosphate synthase (GGPPS); S. aureus and E. coli undecaprenyl 
diphosphate synthases (UPPSs), S. aureus farnesyl diphosphate synthase (FPPS) and 
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human GGPPS. In essentially all cases, IC50 values were ≥ 50µM. The exception was 
human GGPPS which was inhibited by 1 (the only compound with two basic groups) 
with a 4.5 µM IC50. These enzymes are all so-called cis or trans- “head-to-tail” 
prenyltransferases14  and the presence of the two (as opposed to one) hydrophobic 
domains (in addition to the cationic center) might not be required for enzyme inhibition. 
There are, however, other prenyl transferases that might be targeted in which two 
hydrophobic domains - together  with a carbocation center - would better mimic 
transition states/reactive intermediates.  These would include the so-called “head-to-head” 
prenyl transferases, as well as some of the enzymes involved in quinone biosynthesis. 
There are demonstrated or putative head-to-head prenyl transferases in M. tuberculosis 
(Rv3397c), M. smegmatis, (Mycsm_04912), S. aureus (CrtM), B. subtilis (YisP), S. 
cerevisiae (squalene synthase, SQS) and C. albicans (SQS) and in humans (SQS), but no 
homologous proteins can be found by standard BLAST searches in P. falciparum.  The 
products (where known) of these enzymes vary and not all are essential for survival in 
vitro.  Nevertheless, we tested a subset of compounds (1, 3, 4) for activity against either 
SaCrtM or human SQS finding only weak activity (~100 µM) in all cases.  These results 
support the notion that the head-to-head prenyl transferases are unlikely cell growth 
inhibition targets of our compounds in these organisms. 
 
The other obvious candidates are the enzymes involved in quinone biosynthesis 
(Scheme 7.2) or quinone utilization. We thus next investigated the two quinone 
biosynthesis enzymes, MenA and MenG, both of which are likely to utilize cationic 
transition states/reactive intermediates during catalysis. MenA (EC 2.5.1.74, 1, 4-
dihydroxy-2-naphthoate polyprenyl transferase) catalyzes the isoprenylation of 1, 4-
dihydroxy-2-naphthoic acid by long chain isoprenoid diphosphates15, Scheme 7.2, and 
MenA is of interest as an M. tuberculosis drug target16, 17, 18. In an initial set of 
experiments we tested three potent M. tuberculosis and M. smegmatis growth inhibitors 
(1, 3 and 13) in the M. smegmatis MenA (MsMenA) membrane fragment inhibition assay 
described previously16, 17, 18 finding IC50 values of ~6 µM (Table 7.2). Typical dose 
response curves are shown in Figure 7.3A. While this assay revealed only modest activity, 
the observation that MenA activity was in fact inhibited by the three most potent 
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inhibitors is a potentially important one since this inhibition might be expected to inhibit 
electron transfer/ATP synthesis, of particular importance in non-replicating/persister 
cells18 and to contribute to cell growth inhibition beyond that seen with MmpL3 
inhibition alone. What was also of interest was that 1 had similar activity (IC50=9 M, in 　
the same assay as used here18) against MenA to that we reported previously with Ro 48-
8071, a lipophilic amine that decreases menaquinone biosynthesis and blocks M. 
tuberculosis as well as M. smegmatis cell growth. These growth inhibition effects with 
Ro 48-8071 (as well as the inhibition of respiration) were reported previously to be 
reversed in both organisms by addition of 400 μM menaquinone-4 (MK-4) or 
phylloquinone to the medium19. 
A second possible target is MenG (EC 2.1.1.163, 2-polyprenyl-1,4-naphthoquinone 
methyltransferase) which carries out the S-adenosylmethionine (SAM)-dependent 
methylation of demethylmenaquinone (the product of the MenA reaction). As with MenA, 
the MenG reaction is inhibited by 1 and the potent ethanolamine analogs 3, 13 (Table 7.2 
and Figure 7..3B and C), with IC50 in the 6-13 µM range. Unlike the C-alkylations with 
prenyl diphosphates, the MenG reaction uses SAM (as a C1 source), and Mg2+ is not 
required. With 1 binding to MenG, the cationic center in the inhibitor might mimic a 
cationic transition state/reactive intermediate, although another possibility is that the 
cationic center simply mimics the SAM S-methyl sulfonium group. Thus, both MenA and 
MenG are inhibited in vitro by 1 and its analogs, which can be expected to supplement 
MmpL3-based inhibition in the mycobacteria, as well as provide alternative targets in 
some of the organisms that lack the mmpL3 gene. Moreover, inhibition of two sequential 
targets (series inhibition) in a biosynthetic pathway can often be quite effective since the 
product of the first reaction is the substrate for the second reaction20. 
We next used an expressed E. coli MenA (hereafter EcMenA) detergent-based assay 
to obtain inhibition data for all 12 inhibitors, Table 7.2 and Figure 7.4.  Interestingly, the 
most potent inhibitor was 3 (IC50= 400 nM), and 3 was also the most potent inhibitor of 
M. tuberculosis cell growth (and, within experimental error, of E. coli cell growth, Table 
7.1). We additionally found that there was a moderate correlation between E. coli cell 
growth inhibition and EcMenA inhibition with an R2 = 0.43 (using pIC50 = -log10 IC50, 
both values in µM) values, suggesting that MenA inhibition may be involved in cell 
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growth inhibition. As described below, the experimental vs. predicted E. coli cell growth 
inhibition correlation increased to R2 = 0.77 with the incorporation of a second 
experimental parameter, pH collapse.　  
The structure of MenA is not known but it is predicted to be a trans-membrane 
protein containing ~9 -helices, as shown in Figure 7.5A21. Using modern structure 
prediction programs such as Phyre222 that are secondary-structure based, MenA is 
predicted (Figure 7.5B) to adopt basically the same all α-helical fold as found in farnesyl 
diphosphate synthase and CrtM (the S. aureus dehydrosqualene synthase), but where 1 N 
and 2 C-terminal helices (trans-membrane helices 1, 8 and 9 in Figure 7.5A) are not 
modeled, Figure 7.5B. 198 residues (68%) are, however, modeled at a predicted >90% 
accuracy, and the predicted structure has closest similarity to the crystal structure of 
farnesyl diphosphate synthase from Methylococcus capsulatus (PDB ID code # 3TS7), 
although remarkably, there is only a 10% residue identity. The 1st and 2nd aspartate-rich 
motifs essential for Mg2+ binding and catalysis in FPPS and CrtM are located in very 
similar regions in the MtMenA model, as shown in the superposition with CrtM in Figure 
7.5C (orange spheres =conserved Asps in EcMenA model; blue spheres= Asp-rich motif 
in CrtM). This then suggests, based on the 1-CrtM X-ray structure23, the binding sites for 
1 (pink) shown in Figure 7.5C. The two Asp-rich domains in MenA are also highly 
conserved, as shown by a SCORECONS24 analysis (Table 7.3). Although only a 
computational prediction, it is of interest that the highest scoring Phyre2 prediction is 
found with a prenyl transferase enzyme that is known to utilize a carbocation mechanism, 
consistent with the experimental observation that only cationic species inhibit MenA. 
Menaquinone rescue experiments. We next measured the activity of 1 against both 
actively growing (M. tuberculosis H37Rv) and non-replicating (streptomycin-starved M. 
tuberculosis 18b)25 mycobacteria, using a resazurin microplate reduction assay (REMA; 
Figure 7.6). 1 had a MIC of 0.15 µg/mL against actively replicating H37Rv in this assay, 
as expected. It also displayed activity against the non-replicating streptomycin-starved 
18b strain (where MmpL3/TMM transport is presumably not involved since there is no 
cell growth), and the effects of 1 on both strains were affected by MK-4 addition (Figure 
7.6). In the H37Rv aerobic assay, the MIC shifted from 0.15 µg/mL in the absence of 
MK-4 (Figure 7.6A) to ~1 µg/mL when the medium was supplemented with 1 mM 
 160
menaquinone, consistent with a role for 1 in inhibiting quinone biosynthesis and/or 
electron transport. As noted above, a remarkably similar effect was seen previously with 
Ro 48-8071, another lipophilic amine, at 400 μM MK-419, for both M. tuberculosis and M. 
smegmatis. The effect of 1 against non-replicating (streptomycin-starved 18b) bacteria, as 
seen by REMA as a decrease in fluorescence (lack of resazurin reduction to the highly 
fluorescent red resorufin) above a 1 concentration of 1 µg/mL was also blocked by MK-4 
addition (Figure 7.6B). The activity of 1 against non-replicating (streptomycin-starved 
18b) cells was confirmed by plating and counting CFU after 7 days of drug exposure 
(Figure 7.6C) with normal 7H9 medium or with 7H9 medium containing 1 mM MK-4. 
As can be seen in Figure 7.6C, 1 at 1 μg/mL had essentially no effect on (non-replicating) 
bacterial activity in the presence of MK-4, and only a small effect in the absence of MK-
4. However, at 10 μg/mL 1, while there was again a small effect on activity in the 
presence of MK-4, cell activity in the absence of MK-4 was reduced by ~4 log units, 
consistent with a role for 1 in blocking respiration and hence, ATP synthesis.  
Respiration, TMM and the PMF.  The results described above show that 1 has 
activity against not only the two mycobacteria (M. tuberculosis and M. smegmatis), but 
also against a range of other bacteria, fungi and a protozoan, each of which lack a 
bioinformatically- recognizable mmpL3 gene. In M. tuberculosis and M. smegmatis, 
inhibition of MenA/MenG would inhibit respiration, resulting in a decrease in ATP 
biosynthesis. This could help explain how 1 increases the level of TMM given that 
MmpL3 is a TMM transporter of the RND family of efflux pumps, many of which are 
powered by the PMF. Restated, 1 might exhibit an indirect action upon the TMM 
transporter by removing its “power source” (the proton motive force), in addition to 
directly binding to, and inhibiting, the transporter. This indirect action could be 
accomplished in one of two ways: (1) blocking respiration (by depletion of menaquinone 
by inhibition of MenA, MenG, or by directly inhibiting a component of the electron 
transport chain); or (2) a direct effect on the PMF (∆ + ∆pH, where ∆ is the membrane 
potential and ∆pH, the pH gradient). The possibility of the involvement of the PMF is 
suggested from the results of a number of studies in which lipophilic bases (e.g. 
amiodarone, local anesthetics and NSAIDS26, 27, 28) can act as uncouplers. In addition, 
there could also be multi-drug targeting affecting MmpL3, MenA, MenG and the PMF, 
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which would be expected to produce potent inhibition of cell growth/respiration/ATP 
synthesis, as well as a low rate of resistance. 
Respiration and electron transport. In earlier work17, 19, we showed that several 
MenA inhibitors, analogs of Ro 48-8071, blocked respiration in M. tuberculosis and M. 
smegmatis (as evidenced by inhibiting the reduction of methylene blue); that there was a 
correlation between cell growth inhibition and respiration inhibition19, and that the effects 
of the inhibitors could (at least in part) be reversed by adding MK-4 at the 400 M level. 　
We thus next tested all compounds for their effects on methylene blue reduction, in M. 
smegmatis (Figure 7.7), finding that there was a moderate correlation between pMIC90 
(=-log10MIC90, MIC90 in µM) for cell growth inhibition and the pIC50 (=-log10IC50, IC50 
in µM) for inhibition of whole cell respiration inhibition (R2=0.55) for all 12 compounds 
(Tables 7.1 and 7.2).  
These results suggest the possibility of a direct effect on electron transport (since the 
effects observed are rapid-10s of minutes), blocking respiration, consistent with the MK-
4 rescue experiments. The nature of the target or targets involved are beyond the scope of 
this current study, but we did carry out preliminary experiments with 1 against a series of 
dehydrogenases by monitoring the reduction of the artificial electron acceptor MTT (3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide). We used an M. 
smegmatis membrane preparation and a variety of substrates including NADH 
(measuring both Complex I and alternative NADH dehydrogenases, NDH-2); deamino-
NADH (measuring Complex I activity but not NDH-2); succinate (measuring succinate 
dehydrogenase); malate (measuring quinone-dependent malate dehydrogenase); and 
lactate (measuring lactate dehydrogenase). IC50 values for 1 were in general ~30 μg/mL, 
the exception being malate dehydrogenase (IC50 = 10 µg/mL), results that suggest that 
more than one electron-transfer protein may be involved, in cells, with the inhibitors 
mimicking quinone substrates.  
 
Uncoupler effects in membrane vesicles and in cells. The results presented above 
show that 1 and its analogs inhibit MenA, MenG, electron transfer proteins and 
respiration and that MK-4 can rescue cell growth or activity, the relatively high IC50s for 
enzyme inhibition/respiration (when compared to cell growth inhibition) being suggestive 
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of multiple targeting. What is of particular interest about all of the results described 
above is that they seem to point in one direction: respiration, offering a possible 
explanation for the previous observation that TMM accumulates (with 1), in M. 
tuberculosis, due to MmpL3 inhibition. This MmpL3 inhibition could be due to direct 
binding, or a more indirect effect on the PMF/ATP synthesis.     
 To test the hypothesis that 1 and its analogs might collapse the PMF, we first used E. 
coli inverted membrane vesicles (IMVs), essentially as described by Haagsma29. The 
results obtained with SF6847, one of the most potent uncouplers known, are shown in 
Figure 7.10A and indicate a very rapid (seconds) collapse in ΔpH, as reported by 
Haagsma et al29. The same effect was seen with 1 and analogs that have potent activity in 
cell growth inhibition, while inactive (diether/amide) analogs (e.g. 5) had no effect, 
Figures 7.10B, S4 and S5. Similar results were obtained with both E. coli and M. 
smegmatis vesicles.  The effects on the collapse in ΔpH were seen in vesicles in which 
the pH gradient was driven by either ATP hydrolysis, or by electron transport in the 
presence of succinate or NADH. Using Oxonol VI as a probe, we also found that ∆ in E. 
coli IMVs (positive inside) was collapsed (Figure 7.11A) by the same compounds, and 
there was a correlation between the collapse of the membrane potential and the collapse 
in ΔpH (using ACMA fluorescence; Table 7.2; R2=0.79, Figure 7.11B). This is consistent 
with these lipophilic cations acting as protonophores, carrying protons across the 
membrane lipid bilayer, with only compounds containing a basic nitrogen supporting the 
uncoupling activity. 
We found similar PMF effects in intact M. smegmatis cells in which there was a 
collapse in Δψ (positive outside), as measured by using DisC3(5) fluorescence, Figure 
7.12. Addition of 1 or the potent analogs to M. smegmatis cells resulted in an immediate 
increase in DisC3(5) fluorescence, indicating a collapse of Δψ. As can be seen in Figure 
7.12B, 1 collapses the membrane potential in a dose-dependent manner with an “EC50” of 
~20 µg/mL. The EC50 for one of the most potent cell growth inhibitors 13 was ~15 
µg/mL.  
In addition to these investigations of ∆ collapse in intact cells, we investigated pH 　
collapse in intact M. smegmatis cells, using 31P NMR spectroscopy. Phosphorus NMR 
chemical shifts are sensitive indicators of local pH values30. As can be seen in Figure 
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7.13A the 31P NMR chemical shift of phosphate inside M. smegmatis is ~ 0.35 ppm 
downfield from external Pi and from these chemical shifts, the internal and external pH 
values can be determined: results are shown in Figure 7.13B. There is a ∆pH=0.26 (inside 
more basic) in wild type M. smegmatis cells but this pH gradient is collapsed by the 
uncoupler CCCP (meta-chlorophenylcarbonylcyanide phenylhydrazone), the antiporter 
nigericin, as well as by 1 and 13, while as expected, the K+ ionophore valinomycin has no 
effect. The effects of 1 and the other potent analog thus leads to collapse of ∆ as well as 
∆pH in both inverted vesicles and in whole cells. This collapse in the PMF, in cells, can 
be expected to result in an inhibition of ATP synthesis, as is indeed found experimentally 
(Figure 7.10D) with the potent lead, 3. In addition, the collapse of the proton motive 
force is expected to inhibit activity of the MmpL3/TMM transporter. 
 
Quantitative models for cell growth inhibition. Any quantitative analysis of cell 
growth inhibition based on enzyme inhibition or another property (e.g. ∆pH collapse) is 
of course challenging, but it should be possible to use the multi-descriptor approach 
described previously31 with, in this case, no purely mathematical descriptors being 
required.  We thus use Equation 1: 
                                           pIC50 (cell) = a•pIC50 (A) + b•pIC50 (B) + c                      
Equation 1 
where pIC50(A) is –log10 (IC50, A) for enzyme or property A (such as MenA 
inhibition), and B is a second property, e.g. ∆pH collapse. We show by way of examples 
in Figures 7.14A,B, three-dimensional plots for E. coli cell growth inhibition: logIC50 = f 
(MenA, ∆pH), and for M. smegmatis: logMIC90 = f (respiration, ∆), where we find 
correlation coefficients of R2 = 0.82 (E. coli) and R2 = 0.72 (M. smegmatis) values for the 
experimental-versus-predicted cell growth inhibition results. In previous work we 
investigated correlations between cell and enzyme activity (pIC50) assays in 10 diverse 
systems finding31 on average an R2 = 0.32 for the 10 cell/enzyme correlations, similar to 
the R2 = 0.43 we find for the MenA alone/E. coli cell growth inhibition correlation. 
Incorporation of the second parameter (the percentage of ∆pH collapse) increases the R2 
to 0.77, suggesting the importance of multi- targeting, in E. coli. The correlation is worse 
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for M. smegmatis due, perhaps, to the omission of an MmpL3 term, expected be 
particularly important in the mycobacteria. 
 
Are there other MenA-like targets? The results presented above show that E. coli 
MenA is inhibited by 1 and its analogs and that there is a correlation between MenA 
inhibition and cell growth inhibition (in M. smegmatis) suggesting that diverse MenAs 
may be inhibited by these compounds. However, this result is perhaps surprising in that 
in E. coli, MenA is not an essential gene for aerobic growth because UbiA can be used in 
aerobic respiration. One possibility is that EcUbiA might also be inhibited by 1 (and its 
analogs). While we have not yet investigated this experimentally, what we have found is 
that MtMenA, EcMenA, as well as EcUbiA are all predicted (using the Phyre2 program) 
to have an FPPS/GGPPS-like structure. 
In all three cases the structures are predicted to contain a central FPPS/GPPS-like 
catalytic domain (comprising ~2/3  of the overall amino-acid sequence) that has close 
similarity to the same two (soluble) prenyl synthases: Methylococcus capulatus FPPS and 
Lactobacillus brevis GGPPS. Predicted sequence identity investigations have shown that 
MenA and UbiA have moderate homology32, but correlations with FPPS and GGPPS 
were not made in those studies because the actual sequence identities are very low, about 
10-16%. However, secondary-structure based algorithms do permit accurate structure 
predictions, even when residue identities are low. 
These previous bioinformatics studies also demonstrated that another class of proteins, 
protoporphyrin IX farnesyl transferases (e.g. heme o synthase) have significant sequence 
homology to the MenA/UbiA proteins – and all 3 classes of proteins are Mg2+ dependent 
prenyl transferases. Once again, the structure of heme o synthase is not known, but is 
predicted to be another 9-helix trans-membrane protein with a central FPPS/GGPPS-like 
core suggesting that MenA, UbiA, as well as protoporphyrin IX farnesyl transferases are 
all likely to be inhibited by 1 and related systems.  
 
MmpL3 and MmpL11 as targets. MmpL3 is thought to be a target for 1 (and 
diverse other inhibitors10-11, 33), blocking TMM transport. It has also been shown that 
MmpL3 together with a related protein, MmpL11, are associated with heme uptake34.  
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The X-ray structures of MmpL3 and MmpL11 have not been reported. However, both are 
membrane proteins and are predicted to have 11-12 trans-membrane helices21. Using the 
Phyre2 program22 we find with MmpL3 that 653 residues (69% coverage) are predicted 
with 100% confidence to have the structure shown in Figure 7.15A and with MmpL11, 
642 residues (66% coverage) are predicted with 100% confidence to have the structure 
shown in Figure 7.15B. Both structures are very similar to those found in cation efflux 
pumps such as CusA (PDB ID code 3ko7) and multi-drug efflux pumps such as the 
acriflavin resistance protein B (AcrB; PDB ID code 1oy8), although the C-terminus (~1/3 
of the total protein) is not modeled in either MmpL3 or MmpL11. The transmembrane 
hydrophobic domains are shown in Figures 7.15C, D (in white/light orange). 1 as well as 
several other inhibitors10-11 (Figure 7.15E) have been proposed to target MmpL3 
(detected by sequencing mutants that arose under drug pressure), but the sites of these 
mutations, shown as blue spheres in Figure 7.15F, are spread throughout the protein, 
suggesting perhaps, multi-site targeting of MmpL3/11 as an additional basis for the lack 
of resistant mutations with 1. 
 
A multi-target model for anti-infective activity. We show in Figure 7.16 a 
summary of the proposed sites of action for 1 and its analogs in M. tuberculosis and in M. 
smegmatis. Some of these targets are also present in the other pathogens investigated, but 
not in human cells. In addition to its previously proposed role in targeting MmpL3, 1 and 
its analogs also inhibit MenA and MenG and, as described above, the inhibition of M. 
tuberculosis cell growth or activity is rescued by MK-4. We also find that the PMF is 
inhibited by the most active compounds, which act as protonophores/uncouplers. This 
results in a decrease in ATP synthesis and, we propose, decreased activity of MmpL3/11, 
helping explain the accumulation10 of TMM (with 1). 
This multiple-targeting is perhaps best thought of as involving network inhibition in 
which both series and parallel paths are involved (Figure 7.1C) since at least in the 
mycobacteria, MenA, MenG, electron transport, ∆pH, ∆ and MmpL3 (and presumably 
other pumps dependent on the PMF) can all be affected. There are, of course, likely to be 
differences in the mechanisms of action of different inhibitors in different organisms (and 
in the same organisms under different growth conditions), although effects on the PMF 
 166
are expected to be quite common since they are based on more “physical” properties, 
rather than purely enzyme inhibition. The uncoupling effects we observe could also help 
explain the growth inhibition seen in human cell lines, as could inhibition of the human 
MenA, UbiA, and MenG/UbiE orthologs: UbiAD1, CoQ2 and CoQ3. 
    Also of interest are the likely differences in timescales (and concentrations) for the 
different reactions involved. The effects on the collapse in ∆ and ∆pH are very rapid-on 
the seconds to minutes timescale and are observed (in vesicle experiments) at low μM 
concentrations, for the most active species. The effects on respiration as determined by 
methylene blue reduction (in intact cells) are also rapid, typically observable in minutes, 
and may reflect the time required for inhibitors to enter the cell and accumulate (since 
they could also be being actively pumped out). Little is known about the rate of 
menaquinone turnover, but it is likely that several cell divisions are required for a large 
reduction in menaquinone levels, so while MenA/MenG inhibition may be rapid, the 
effects on cell growth may take many hours or (with M. tuberculosis) days to occur 
likewise, since MmpL3 is thought to be involved in cell wall biosynthesis, its inhibition 
would also be expected to result in observable effects on growth inhibition on a time 
scale of hours to days.  
 
 
7.4 Conclusions 
The results we have described above are of interest for drug discovery against 
tuberculosis, as well as against other bacterial, fungal and protozoan pathogens, for 
several reasons. We synthesized a series of analogs of the anti-tuberculosis drug 1 in 
which we varied the nature of the ethylenediamine linker to provide cationic, 
protonatable as well as neutral species, and in addition we varied the adamantyl 
headgroup. The most active compound against M. tuberculosis was ~5x more potent than 
was 1, and was also less toxic to an MCF-7 human cell line. We tested all compounds 
against a panel of bacteria, fungi and a protozoan parasite and the results obtained 
showed that at least one cationic (or basic) group was essential for activity. The most 
potent activity was against M. tuberculosis (MIC=0.02-0.05 µg/mL) and the intra-
erythrocytic form of the malaria parasite, P. falciparum (IC50 = 30 ng/mL). To explore 
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possible targets we tested several compounds for activity against a panel of cis- and 
trans-prenyl transferases (cis-FPPS, FPPS, DPPS, GGPPS, UPPS, CrtM and SQS) as 
well as against the menaquinone biosynthesis enzymes, MenA and MenG. Activity was 
seen against MenA and MenG and we proposed a structural model for the MenA active 
site, as well as a likely binding site for 1. In addition, we found that menaquinone (MK-4) 
rescued both aerobic H37Rv M. tuberculosis cell growth, as well as the activity of non-
replicating M. tuberculosis (streptomycin-starved 18b). We found that 1 as well as 
several analogs inhibited oxygen consumption in, M. smegmatis and there was a 
correlation between oxygen consumption and cell growth inhibition.  We tested 1 and 
each of the 11 analogs for their effects on the PMF (∆pH and ∆) in fluorescence-based 
assays, as well as in some cases in intact cells (via 31P NMR). The results obtained 
showed that 1 and the most potent cell growth inhibitors collapsed both ∆ and ∆pH and 
there were good correlations between experimental and predicted cell growth inhibition 
results based on MenA/∆pH (E.coli) and respiration/∆ (M. smegmatis). Taken together, 
the results obtained suggested a model for 1/analog activity in mycobacteria in which the 
increase in TMM levels seen on treatment with 1 have a contribution from (indirectly) 
inhibiting the TMM transporter MmpL3 by blocking the PMF/ATP biosynthesis. Overall, 
the results are of general interest since they indicate that 1 (and its analogs) can have 
diverse effects: on O2-consumption/electron transport/MenA/MenG inhibition, ∆, ∆pH, 
and ATP biosynthesis, likely helping to explain activity against non-MmpL3 containing 
pathogens such as H. pylori, C. albicans and here, P. falciparum.  Moreover, the 
possibility of developing more potent compounds that can inhibit these targets is of 
general interest in the context of developing drug leads that are “resistance resistant”, due 
to multi-targeting. 
 
7.5 Materials and Methods 
Chemical Syntheses: General methods.  
All chemicals were reagent grade and were used as received. Moisture-sensitive 
reactions were performed under an inert atmosphere (dry nitrogen) with dried solvents. 
Reactions were monitored by TLC using Merck silica gel 60 F-254 thin-layer plates. 
Flash column chromatography was carried out on Merck silica gel 60 (230-400 mesh). 1H 
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NMR and 13C NMR spectra were recorded on Varian (Palo Alto, CA) Unity 
spectrometers at 400 and 500 MHz for 1H and at 100 and 125 MHz for 13C. Coupling 
constants (J) are reported in Hz. High-resolution mass spectra (HRMS) were recorded in 
the University of Illinois Mass Spectrometry Laboratory. Elemental analyses were carried 
out in the University of Illinois Microanalysis Laboratory. HPLC/MS was performed 
using an Agilent LC/MSD Trap XCT Plus system (Agilent Technologies, Santa Clara, 
CA) with a 1100 series HPLC system including a de-gasser, an auto-sampler, a binary 
pump, and a multiple-wavelength detector. All final compounds were ≥95% pure as 
determined by elemental analysis, analytical HPLC/MS analysis or qNMR analysis. 
qNMR spectra were recorded using Varian (Palo Alto, CA) 500 MHz Unity 
spectrometers with 1,3,5-trimethoxybenzene as the internal total-spin-count quantitation 
standard; 60 degree pulse excitation, 60 s recycle delay, 1.0 Hz line-broadening due to 
exponential multiplication, and 16 accumulations. qNMR data were processed using 
Mnova NMR software (Mestrelab, Escondido, CA). All NMR spectra (including qNMR 
spectra) are provided in the Supporting Information.  
Enzyme Inhibition Assays. 
MenA and MenG Inhibition. MenA and MenG inhibition assays were carried out 
using M. smegmatis membrane fragments19. Mycobacterial MenA assays were conducted 
as previously reported19.  In addition, we used an expressed, purified E. coli MenA, as 
described below.  
MenG Assay. Vitamins K1 and K2, and kanamycin were purchased from Sigma-
Aldrich (St. Louis, MO).  Authentic MK9 was purchased from Toronto Research 
Chemicals (TRC, Canada). S-adenosyl-L-[methyl-14C] methionine (14C-SAM) obtained 
from Perkin-Elmer (47 mCi/mmol). DMK8 was prepared from an E. coli ΔubiE mutant 
(CGSC #11636), which accumulates DMK8, and was purchased from the  E.coli Genetic 
Stock Center, Yale University (http://cgsc.biology.yale. edu). 
MenG assays were conducted using the membrane fractions prepared from M. 
smegmatis grown in 7H9 medium (supplemented with oleic acid, albumin, dextrose and 
0.05% Tween 80). Washed cells were resuspended in Buffer A (50 mM MOPS pH 7.9, 5 
mM MgCl2, 5 mM DL-dithiothreitol (DTT), 10% glycerol (V/V)) and disrupted by probe 
sonication on ice with a Sanyo Soniprep 150 (10 cycles of 60 sec on and 90 sec off). The 
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whole cell lysate was centrifuged at 27,000 x g for 20 min at 4 °C. The supernatant was 
further centrifuged at 100, 000 x g (for 2 h at 4 °C) in an Optima TLX Ultracentrifuge 
(Beckman).  The membrane-enriched pellet was washed with Buffer A followed by 
ultracentrifugation at 100, 000 g. The washed pellet was resuspended in Buffer A, 
divided into aliquots and frozen at -80 °C. The membrane protein concentration was 
estimated by using a BCA protein assay kit (Pierce). 
Assay mixtures (100 µL) contained 100 mM Tris-HCL pH 8.0, 1 mM DTT, 5 mM 
MgCl2, 0.1% CHAPS, 600 ng of DMK8, 40 µM  radiolabelled SAM and varying 
concentrations of inhibitor 1 (0 to 25.0 µg/mL).  Reactions were initiated by the addition 
of 50-100 µg of M.smegmatis membrane protein and incubated at 37 °C for 1 h.  
Reactions were stopped by the addition of 0.1 M acetic acid in methanol (0.5 mL) and 
radiolabelled products were extracted with hexane (2 x 3 mL).  Pooled extracts were 
washed with 1 mL of water, evaporated to dryness under a N2 stream and dissolved in 
CHCl3/CH3OH (2:1 v/v).  An aliquot was subjected to liquid scintillation counting (LS 
6500, Beckman Coulter); an second aliquot and authentic standards (DMK8 and MK9) 
were subjected to reverse-phase TLC (Whatman KC 18F Silica gel 60 A) developed in 
acetone/water (97:3). Standards were visualized under UV light, distribution of 
radioactivity was detected by phosphorimaging (Typhoon TRIO, Amersham Biosciences) 
and quantified with ImageQuant TL v2005 software (Amersham Biosciences).  IC50 
values were calculated by using GraFit Software (Version 5.0.13). 
 
Expression and purification of EcMenA. The gene encoding EcMenA with a N-
terminal strep tag was amplified by polymerase chain reaction (PCR) with forward 
primer 5'-
GACGACGACAAGATGAGCGCGTGGAGCCATCCGCAGTTTGAAAAAGGCGGT
GGCAGCGCGGAGAATCTTTATTTTCAGGGCGCTGGTGC-3' and reverse primer 5'-
GAGGAGAAG 
CCCGGTTATTATGCTGCCCACTGGCTTAGGAATAT-3', and then cloned into 
the pET46 Ek/LIC vector. The recombinant plasmid was transformed to E. coli C43 
(DE3) and the protein induced with 1 mM isopropyl-thiogalactopyranoside (IPTG) at 
37 °C for 5 hours. The cell paste was harvested by centrifugation at 7,000 x g and re-
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suspended in buffer A containing 25 mM Tris-HCl, pH 7.5, 150 mM NaCl and 20 mM 
imidazole. A cell lysate was prepared with a JNBIO® pressure cell (JN-3000 PLUS), the 
membrane and soluble proteins being separated by ultracentrifugation at 150,000 x g for 
1.5 h. The resulting pellet was solubilized by incubation in buffer A supplemented with 1% 
(w/v) DDM detergent overnight at 4 °C. The latter solution was centrifuged (100,000 x g 
for 1 hr at 4 °C in a Beckman Ti70 rotor), and the supernatant loaded onto a Ni-NTA 
column and washed with buffer A containing 0.05% DDM. The buffer and gradient for 
the Ni-NTA column were 25 mM Tris, pH 7.5, 150 mM NaCl, 0.05% DDM and 20–500 
mM imidazole. The protein was then loaded onto a Strep-Tactin® (IBA) column 
equilibrated with washing buffer containing 100 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 
mM EDTA, and 0.05% DDM and washed with 5 column volumes of washing buffer. 
EcMenA was finally eluted with eluting buffer containing 100 mM Tris-HCl, pH 8.0, 150 
mM NaCl, 1 mM EDTA, 0.05% DDM, and 2.5 mM desthiobiotin. The purified protein 
was finally concentrated to 5 mg mL-1 in a 25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% 
DDM buffer. 
 
EcMenA Inhibition Assay. Inhibition of EcMenA was carried out using an HPLC-
based protocol. Typically, 2.5 µg EcMenA in 100 L 　 reaction buffer (25 mM Tris-HCl, 
0.1% Triton X-100, 250 µM MgCl2, 10 mM DTT, pH=7.5) was incubated with inhibitors 
for 30 min at 22 oC. 1,4-dihydroxy-2-naphthoic acid (DHNA) and farnesyl diphosphate 
(FPP) were then added to the enzyme solution to a final concentration of 150 µM each. 
The reaction was incubated at 37 oC for 3 hrs before quenching with 50 µL 0.1 M acetic 
acid in methanol containing 50 µM menaquinone-4 (MK-4, Sigma-Aldrich) as an internal 
standard. The mixture was then extracted with 600 L he　 xane by vortexing. After 
centrifugation, 500 L organic layer was collected and dried under nitrogen then 　
dissolved in 200 L methanol. 20 L of the methanol solution was then subjected 　　 　　
to HPLC analysis (0.1 % formic acid in H2O to 0.1 % formic acid in CH3CN, UV: 325 
nm, 250 µL/min). The amount of the MenA reaction product demethylmenaquinone-3 
(DMMK-3) was determined by comparison of integrated peak areas between DMMK and 
the internal standard MK-4. IC50 values were estimated by using Origin 6.1 software to 
analyze the dose-response curves.  
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Cell lines. Mycobacterium tuberculosis ATCC® 27294™, Mycobacterium smegmatis 
ATCC® 700084™, Bacillus subtilis subsp. subtilis ATCC® 6051™, E. coli ATCC® 
29425™, and Saccharomyces cerevisiae ATCC® 208352™ were purchased from the 
American Type Culture Collection. The C. albicans strain was CAI-4; the P. falciparum 
strain was 3D7 and the human cell line MCF-7 (breast adenocarcinoma), obtained from 
the National Cancer Institute. 
 
M. tuberculosis Growth Inhibition Assay. All 12 compounds (1, 3-13) were assayed 
for inhibition of M. tuberculosis cell growth as described previously35.  
 
Menaquinone Rescue Experiments With M. tuberculosis Treated With 1.  We 
measured the activity of 1 against both actively growing M. tuberculosis (H37Rv) and 
non- replicating M. tuberculosis (streptomycin-starved 18b25) using a resazurin 
microplate reduction assay. The effects of menaquinone supplementation on the dose-
response curves were investigated using medium that was supplemented with 0, 10, 100 
and 1000 M menaquinone (MK　 -4, Sigma-Aldrich) in the presence of between 10 
ng/mL and 10 µg/mL 1. The activity of 1 against non-replicating 18b was determined 
after 7 days of drug exposure by plating the culture followed 28 days later by CFU 
counting after plating serial dilutions on 7H10 agar plates (Difco) .  
 
Candida albicans Growth Inhibition Assay. C. albicans growth inhibition was 
carried out according to a reported protocol36 except that YPD media was used instead of 
RPMI 1640.  
 
E. coli Growth Inhibition Assay. IC50 values for E. coli growth inhibition were 
determined by using a broth micro-dilution method. An overnight culture of E. coli was 
diluted 50-fold into fresh Luria-Bertani (LB) broth and incubated to an OD600 of ~0.4. 
The culture was then diluted 500-fold into fresh LB medium and 100 L inoculated into 　
each well of a 96 well flat bottom culture plate (Corning Inc., Corning, NY).  The starting 
concentration of each compound was 0.3 mM and this was 2X serially diluted to 292 nM. 
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Plates were incubated for 3 h at 37 °C to mid-exponential phase. An MTT ((3-(4, 5-
dimethylthiazole-2-yl)-2, 5-diphenylthtrazolium bromide) cell proliferation assay (ATCC) 
was then carried out to obtain bacterial viability dose-response curves. Briefly, 10 L 　
MTT reagent was added into each well, followed by incubation for 2-4 hrs until a purple 
precipitate was visible. Then, 100 L detergent reagent was added and the plates 　
incubated in the dark at 22 °C for 2 hours. Absorbance was measured at 570 nm and a 
non-linear regression analysis carried out using Origin 6.1 software 
 
B. subtilis Growth Inhibition Assay. IC50 values for B. subtilis growth inhibition 
were determined by using a micro-broth dilution method. A stationary starter culture of B. 
subtilis was diluted 50-fold into fresh LB broth and grown to an OD600 of ~0.4. The 
culture was then diluted 500-fold into fresh LB medium to give a working solution, then 
100 L of working solution was transferred to each well of a 96　 -well flat bottom culture 
plate (Corning Inc., Corning, NY). Inhibitors were then added at 0.5 mM and 2x serial 
diluted to 500 nM  the volume and solvent composition constant. Plates were incubated 
for 12-16 h at 37 °C and the absorbance at 600 nm determined. A non-linear regression 
analysis was carried out using Origin 6.1 in order to obtain the IC50 values.  
 
S. cerevisiae Growth Inhibition Assay.  
The protocol was the same as for B. subtilis except that YPD instead of LB was used 
as the culture medium and the 96-well plates were incubated for 48 h instead of 12-16 h.  
 
Plasmodium falciparum Growth Inhibition Assay. We determined IC50 values for P. 
falciparum growth inhibition using the intra-erythrocytic assay described previously37.  
 
Human Cell Growth Inhibition Assay. The MCF-7 cell growth inhibition assay was 
carried out as described previously38. A broth micro-dilution method was used to 
determine the growth inhibition IC50 values. Compounds were half-log serial diluted 
using cell culture media into 96-well TC-treated round bottom plates (Corning Inc., 
Corning, NY). Cells were plated at a density of 5000 cells/well and then incubated under 
the same culture conditions for 2 days at which time an MTT ((3-(4,5-dimethylthi-azole-
 173
2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation assay (ATCC, Manassas, VA) 
was performed to obtain dose response curves.  
 
Dehydrogenase Activities. Dehydrogenase activity in M. smegmatis membranes was 
measured by using the MTT ((3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium 
bromide) reduction assay in the presence of 5 mM KCN. MTT reduction was followed at 
570 nm, after addition of the different substrates (NADH, succinate, malate or lactate).  
 
Oxygen Consumption. Oxygen concentration was monitored at 37 °C using a YSI 
model 53 oxygen electrode (Yellow Springs Instrument Co., Yellow Springs, OH) 
equipped with a temperature-controlled 1.8 mL electrode chamber. The reaction mixture 
consisted of sodium phosphate buffer, pH 7.5, 50 mM NaCl and 200-400 µg/mL 
membranes. The concentration of oxygen in the air-saturated buffer was taken to be 250 
µM, and the reaction was initiated by injecting 200 μM NADH. The electron transport 
rates are expressed as mol NADH oxidized or mol O2 (mol enzyme)-1 s-1.  Membranes 
were incubated with different concentrations of inhibitors for 5 min prior to NADH 
addition. 
 
Membrane Potential Measurements in Intact Cells.  The effects of inhibitors on 
Δψ  were determined by fluorescence quenching of the potential-sensitive probe 3,3’-
dipropylthiodicarbocyanine (DisC3(5)). M. smegmatis were grown for 8 h in 
Middlebrook 7H9-ADC-Tween 80 medium and diluted to an OD600 of 0.3 in the same 
medium plus 10 mM glucose and 1 µM nigericin. Different concentrations of 1 and its 
analogs were added to the bacterial suspension and changes in fluorescence due to the 
disruption of Δψ were continuously monitored with a fluorescence spectrophotometer 
(FLUOstar Omega, BMG LABTECH) employing an excitation wavelength of 643 nm 
and an emission wavelength of 666 nm, at 30 ºC.   
 
ATP/ADP determination. M. smegmatis were grown for 8 h in Middlebrook 7H9-
ADC-Tween 80 and diluted to an OD600 of 2. Different concentrations of 1 and its 
analogs were added and ATP/ADP ratios determined (Abcam; ADP/ATP Ratio Assay 
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Kit, catalog number: ab65313) after 10 and 60 min of incubation at 37 ºC, 200 rpm.  ATP 
and ADP were extracted from 50 µL cell suspension by adding trichloroacetic acid (TCA) 
to a final concentration of 0.5 %. After 5 min, TAE (Tris-acetic acid-EDTA) buffer was 
added to neutralize the system by diluting the sample 5-fold. The ATP and ADP cell 
concentrations were measured according to the manufacturer’s protocol.  
 
Inverted Membrane Vesicles (IMVs). E. coli IMVs were prepared by three 
passages through a pre-cooled French pressure cell at 20,000 psi. The lysate was 
centrifuged at 14,000 x g at 4 °C for 20 min to remove unbroken cells.  The supernatant 
was centrifuged at 370,000 x g at 4 °C for 1 h and the pellet, consisting of the IMVs, was 
washed with 50 mM MOPS-KOH (pH 7.5), 2 mM MgCl2.  After the second 
centrifugation step, membranes were re-suspended in 50 mM MOPS-KOH (pH 7.5), 2 
mM MgCl2, 10 % glycerol and stored at -80°C. 
 
Assay for ATP or Succinate-Driven Proton Translocation. Proton translocation 
into IMVs was measured by the decrease of ACMA fluorescence. The excitation and 
emission wavelengths were 410 nm and 480 nm, respectively. IMVs (0.1 mg/mL 
membrane protein) were pre-incubated at 37 °C in 10 mM HEPES-KOH (pH 7.5), 100 
mM KCl, 5 mM MgCl2 containing 2 µM ACMA and the baseline monitored for five 
minutes.  The reaction was then initiated by adding 1 mM ATP or 5 mM succinate. When 
the signal had stabilized, 1 or its analogs were added and proton translocation measured, 
fluorimetrically.   
 
Determination of Δψ Collapse in IMVs. The Δψ-sensitive fluorophore Oxonol VI 
(1,5-bis(5-oxo-3-propylisoxazol-4-yl)pentamethine oxonol) was used to determine if 1 
and its analogs were able to dissipate the membrane potential in IMVs. IMVs (0.1 mg/mL 
membrane protein) were added to assay buffer: 10 mM MOPS-KOH pH 7.5, 2 mM 
MgCl2, 2 µM Oxonol VI.  After a few seconds, 0.5 mM NADH was added to initiate 
respiration-dependent generation of Δψ (positive inside) and the resultant quenching of 
Oxonol VI fluorescence was monitored at 37 °C.  The emission and excitation 
wavelengths were 599 nm and 634 nm, respectively.  Uncoupling by inhibitors was 
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estimated based on their ability to dissipate the established Δψ, measured as the de-
quenching of the fluorescence signal. 
 
Determination of pH by 　 31P NMR Spectroscopy. M. smegmatis was grown to a 
cell density of 108 cells/mL in a total volume of 500 mL in a 4 L Erlenmeyer flask with 
constant shaking at 37 °C in Difco Middlebrook 7H9 media supplemented with oleic 
acid/albumin/dextrose and 0.05% Tween 80. Cells were harvested by centrifugation and 
the pellet washed twice with 5 mM phosphate buffer, pH 6.8.  The cell pellet was then re-
suspended in 200 L of the same buffer and 500 L of the resulting cell slurry 　 　
transferred to a 5 mm NMR tube. Chemical shifts were reference with respect to 85% 
phosphoric acid in D2O in a coaxial capillary.  31P NMR spectra were obtained using a 
Varian INOVA 300 (at 121.5 MHz) using 60 degree pulse excitation, proton decoupling 
and a 1 s recycle time. 1024 scans were accumulated corresponding to ~ a 60 min total 
data acquisition time  (without aeration). Spectra were analyzed as described elsewhere39. 
The peak corresponding to the 　-phosphate of ATP (at ~-10.5 ppm) and the inorganic 
phosphate peaks of interest (in the region of 0-1.5 ppm) were used to calculate the 
internal and external pH using the following equation, where d is the distance between 
the 　-phosphate of ATP and the inorganic phosphate peak, in ppm. 
                                                       pH ൌ 6.75 ൅ log ୢିଵ଴.଼ହଵଷ.ଶହିୢ  
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7.6 Schemes, Charts, Tables and Figures 
Scheme 7.1 Illustration of several reactions of interest in isoprenoid biosynthesis in the 
systems investigated here. The enzymes in red were tested for inhibition by 1. Cis-FPPS 
and trans-FPPS, UPPS and DPPS are not inhibited by 1 but CrtM is, and CrtM-1 
structures have been reported (PDB ID codes 4EA1, 4EA2) and serve as models for 
MenA inhibition. 
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Scheme 7.2 Menaquinone biosynthesis illustrated for MK-3. MK-8,9 are the abundant 
species in cells. MenA forms demethylmenaquinol (DMK) which spontaneously oxidizes 
to demethylmenaquinone.  DMK is the substrate of MenG. 
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Chart 7.1 Structures of compounds investigated. 
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Table 7.1  Inhibition by 1 and analogs of M. tuberculosis (Mt), M. smegmatis (Ms), S. 
aureus (Sa), B. subtilis (Bs), E. coli (Ec), S. cerevisiae (Sc), C. albicans (Ca), P. 
falciparum (Pf) and human (MCF-7) cell growth. 
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Table 7.2  Enzyme, respiration and PMF (∆pH, ∆ψ) inhibition results. 
Entry
Mycobacterium smegmatis Escherichia coli 
MenAa MenGa respirationb ∆collapsec MenA
d ∆pH collapsee 
1 4.8 13 58 55 3.3 0.8 
3 4 15 0.5 31 0.4 0.8 
4 N.D. N.D. 36 78 1.8 1.0 
5 N.D. N.D. 600 150 4.2 15 
6 N.D. N.D. 4.8 50 1.9 1.1 
7 N.D. N.D. 0.5 51 1.0 18 
8 N.D. N.D. 330 150 5.8 12 
9 N.D. N.D. 280 150 16 7.4 
10 N.D. N.D. 9500.0 150 4.6 4.7 
11 N.D. N.D. 2500.0 150 4.6 6.7 
12 N.D. N.D. 140.0 130 3.3 7.1 
13 8 5.7 0.3 44 3.2 0.8 
a. IC50 in µM, M. smegmatis membrane fraction (Figure 7.3); b. IC50 
in µM, from methylene blue reduction assay (Figure 7.7); c. IC50 in 
µM, from DisC3(5) assay (Figure 7.12); d. IC50 in µM, expressed E. 
coli MenA (Figure 7.4); e. IC50 in µM, measured with E. coli IMVs 
(Figures 7.8 and 7.9). N.D.: not determined 
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Table 7.3  SCORECON analysis of MtMenA. Aspartate-rich motifs are highlighted in 
bold. 
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Figure 7.1 Schematic illustrations of series (in the same metabolic pathway), parallel 
(unrelated pathways or DNA/membrane targets) or network (series and parallel target) 
inhibition. 
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Figure 7.2 Inhibition of cell growth for M. tuberculosis (Mt), M. smegmatis (Ms), S. 
aureus (Sa), B. subtilis (Bs), E. coli (Ec), S. cerevisiae (Sc), C. albicans (Ca), P. 
falciparum (Pf) and a human cell line (MCF-7) by 1, 3-13. (A)  Heat map. Red=strong 
inhibition; yellow=moderate inhibition; green=weak/no inhibition; (B) Correlation R 
values between cell growth inhibition pIC50 (-log10IC50) between all systems investigated. 
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Figure 7.3 (A) MenA inhibition using M. smegmatis membrane fragments. 3 (blue, IC50 = 
4.0 µM), 1 (black, IC50 = 4.8 µM), 13 (red, IC50 = 8.0 µM). (B) Raw data for MenG 
inhibition by 1, 3 and 13 used to generate data in (C). The assay requires the addition of 
exogenous demethylmenaquinone, which was obtained from an E. coli MenG knockout 
(KO). Inhibitors were added at the indicated concentrations.  (C) MenG inhibition results. 
3 (blue, IC50 = 14.7 µM), 1 (black, IC50 = 12.6 µM), 13 (red, IC50 = 5.7 µM). 
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Figure 7.4. E.coli MenA inhibition by 1 and its analogs. 
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Figure 7.5 (A) Transmembrane helices predictions for MtMenA. (B) Transmembrane 
helices in Phyre2 model of MtMenA (helices S1, S8 and S9 from (A) are not modeled). 
Orange: Asp rich motifs. (C) MenA model (cyan) and CrtM (green, PDB: 4EA1, N and C 
terminal helices are removed). Blue: Asp rich motifs in CrtM. CrtM structure contains 
SQ109 (2 conformers), shown as magenta spheres. 
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Figure 7.6 Menaquinone rescue experiments. (A) Aerobic M. tuberculosis H37Rv growth 
inhibition in the presence of increasing MK-4 concentrations, measured by REMA. (B) as 
(A), but with non-replicating M. tuberculosis 18b. (C) M. tuberculosis 18b cells were 
plated after 7 days of drug exposure with (grey) or without (black) MK-4. Colony 
Forming Unit counts were assessed after one month of incubation. Concentrations are in 
μg/ml. 
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Figure 7.7 Rates of oxygen depletion by M. smegmatis cells in the presence or absence of 
25 µg/mL compounds, measured by using the methylene blue reduction assay1 
monitoring at 670 nm. Data are expressed as average ± standard deviation of three 
independent experiments. 
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Figure 7.8 De-energization of E. coli inverted membrane vesicles (IMVs) by 1 and its 
analogs. Quenching of ACMA fluorescence in IMV was observed after the addition of 
ATP, which results in a decrease of fluorescence intensity (top left panel). Addition of 
inhibitors results in an increase of fluorescence intensity (I1). Data are representative of 
results of three separate experiments.  
 190
Figure 7.9 Increase of ACMA fluorescence in E. coli IMV in the presence or absence of 1 
µM compounds, expressed as an I0/I1 percentage. Data are expressed as average ± 
standard deviation of five independent experiments. 
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Figure 7.10 (A) pH collapse in E. coli IMVs by a known uncoupler SF6847. (B)  pH 
collapse in E. coli IMVs by 1 and 5. (C) Effects of 1 and analogs on ∆ in M. smegmatis 
cells. (D) Effects of 3 on ATP biosynthesis of effect in M. smegmatis cells. 
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Figure 7.11 (A) Increase of Oxonol VI fluorescence in E. coli IMVs in the presence of 1 
and its analogs. Oxonol VI fluorescence in IMVs was quenched after the addition of 
NADH.  Upon the addition of 1 µM compounds, the Oxonol VI fluorescence increased 
due to a dissipation of the membrane potential. Data are expressed as average ± standard 
deviation of three independent experiments. (B) Correlation between increase of ACMA 
fluorescence and Oxonol fluorescence. 
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Figure 7.12 ∆ dissipation in M. smegmatis cells. (A) DisC3(5) fluorescence was 
quenched in the presence of cells and after the addition of 50 µM of each compound, the 
fluorescence increased due to the dissipation of the PMF. Data are expressed as average ± 
standard deviation of three independent experiments. (B) Effect of 1 concentration on ∆ 
dissipation in M. smegmatis cells. 
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Figure 7.13 31P NMR-derived ∆pH collapse results in M. smegmatis. (A) 31P NMR 
spectrum, wt M. smegmatis. (B) ∆pH results with various inhibitors, ionophores. 1 and 13 
collapse the ∆pH. 
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Figure 7.14 Experimental (red circles) and computed (colored plane) results for cell 
growth inhibition based on Equation 1. (A) E. coli cell growth inhibition predicted using 
MenA, ∆pH collapse (IC50s in µM, R2 for the model=0.77). (B) M. smegmatis growth 
inhibition using respiration (methylene blue assay) and ∆ψ collapse (MIC90 and  IC50s in 
µM, R
2
 for the model=0.64). 
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Figure 7.15 Molecular models for MmpL3, MmpL11. (A) Phyre2 structure predictions 
for MmpL3. (B) Phyre2 structure predictions for MmpL11. (C) Phyre2 predictions 
showing hydrophobic residues (white/grey) and their proposed relation to the membrane 
for MmpL3. (D) Phyre2 predictions showing hydrophobic residues (white/grey) and their 
proposed relation to the membrane for MmpL11. (E) Structure of representative M. 
tuberculosis growth inhibitors that are thought to target MmpL3 and (F) sites of 
resistance mutations (blue spheres) in MmpL3. 
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Figure 7.16 Schematic illustration of proposed sites of action of SQ109 and its analogs. 
MenA, MenG targeting can affect respiration/electron transfer; PMF (∆pH, ∆ψ) collapse 
leads to decreased ATP biosynthesis, reduction in PMF/ATP-powered transporters (e.g. 
MmpL3), increased TMM accumulation, decreased cell wall biosynthesis. 
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